CA2643410A1 - Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs - Google Patents
Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs Download PDFInfo
- Publication number
- CA2643410A1 CA2643410A1 CA002643410A CA2643410A CA2643410A1 CA 2643410 A1 CA2643410 A1 CA 2643410A1 CA 002643410 A CA002643410 A CA 002643410A CA 2643410 A CA2643410 A CA 2643410A CA 2643410 A1 CA2643410 A1 CA 2643410A1
- Authority
- CA
- Canada
- Prior art keywords
- butyl
- group
- pentyl
- residue
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 86
- 239000003814 drug Substances 0.000 title claims abstract description 86
- UFBBWLWUIISIPW-UHFFFAOYSA-N imidazo[2,1-b][1,3]thiazole Chemical class C1=CSC2=NC=CN21 UFBBWLWUIISIPW-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 claims abstract description 157
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 557
- -1 2-pentyl Chemical group 0.000 claims description 505
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 502
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 293
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 225
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 140
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 136
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 134
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 134
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 134
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 134
- 239000000460 chlorine Substances 0.000 claims description 116
- 229910052801 chlorine Inorganic materials 0.000 claims description 116
- 229910052794 bromium Inorganic materials 0.000 claims description 109
- 125000001424 substituent group Chemical group 0.000 claims description 99
- 229910052731 fluorine Inorganic materials 0.000 claims description 93
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 93
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 89
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 89
- 125000001544 thienyl group Chemical group 0.000 claims description 88
- 125000002541 furyl group Chemical group 0.000 claims description 84
- 150000003839 salts Chemical class 0.000 claims description 79
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 70
- 229910052740 iodine Inorganic materials 0.000 claims description 69
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 68
- 208000002193 Pain Diseases 0.000 claims description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 55
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 52
- 239000012429 reaction media Substances 0.000 claims description 51
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 46
- 229910021419 crystalline silicon Inorganic materials 0.000 claims description 45
- 239000012453 solvate Substances 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 42
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 40
- 125000002950 monocyclic group Chemical group 0.000 claims description 40
- 150000007529 inorganic bases Chemical class 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 38
- 150000007530 organic bases Chemical class 0.000 claims description 38
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 38
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 37
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 36
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 35
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 34
- 150000002367 halogens Chemical group 0.000 claims description 34
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 32
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 30
- 229920006395 saturated elastomer Polymers 0.000 claims description 30
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 29
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 29
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 29
- 125000005842 heteroatom Chemical group 0.000 claims description 29
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 29
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 29
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 29
- 230000036407 pain Effects 0.000 claims description 29
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 28
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 28
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 28
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 28
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 26
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 24
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 24
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 23
- 125000004076 pyridyl group Chemical group 0.000 claims description 23
- 125000000335 thiazolyl group Chemical group 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 22
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 125000002883 imidazolyl group Chemical group 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 229960002715 nicotine Drugs 0.000 claims description 21
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 21
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000004122 cyclic group Chemical group 0.000 claims description 20
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 19
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 18
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 17
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 17
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 17
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims description 16
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims description 16
- 208000000094 Chronic Pain Diseases 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 15
- 125000002757 morpholinyl group Chemical group 0.000 claims description 15
- 125000003386 piperidinyl group Chemical group 0.000 claims description 15
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 15
- 206010013654 Drug abuse Diseases 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229960003920 cocaine Drugs 0.000 claims description 14
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 238000002483 medication Methods 0.000 claims description 14
- 208000004296 neuralgia Diseases 0.000 claims description 14
- 208000021722 neuropathic pain Diseases 0.000 claims description 14
- 229910052723 transition metal Inorganic materials 0.000 claims description 14
- 208000005298 acute pain Diseases 0.000 claims description 13
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 claims description 13
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 13
- 150000007522 mineralic acids Chemical class 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 150000007524 organic acids Chemical class 0.000 claims description 13
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 13
- 125000002971 oxazolyl group Chemical group 0.000 claims description 13
- 125000004193 piperazinyl group Chemical group 0.000 claims description 13
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 13
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 13
- 125000004306 triazinyl group Chemical group 0.000 claims description 13
- 125000001425 triazolyl group Chemical group 0.000 claims description 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- 239000005864 Sulphur Substances 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 125000001041 indolyl group Chemical group 0.000 claims description 12
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 12
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 12
- 208000019901 Anxiety disease Diseases 0.000 claims description 11
- 125000003725 azepanyl group Chemical group 0.000 claims description 11
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 11
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 11
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 11
- 208000009935 visceral pain Diseases 0.000 claims description 11
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 10
- 206010033664 Panic attack Diseases 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 150000003863 ammonium salts Chemical class 0.000 claims description 10
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 10
- 125000005959 diazepanyl group Chemical group 0.000 claims description 10
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 10
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 10
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 10
- 208000019906 panic disease Diseases 0.000 claims description 10
- 208000020016 psychiatric disease Diseases 0.000 claims description 10
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 9
- 229910052987 metal hydride Inorganic materials 0.000 claims description 9
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 9
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 208000007101 Muscle Cramp Diseases 0.000 claims description 8
- 125000005418 aryl aryl group Chemical group 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 238000011161 development Methods 0.000 claims description 8
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 claims description 8
- 229940005483 opioid analgesics Drugs 0.000 claims description 8
- 208000007848 Alcoholism Diseases 0.000 claims description 7
- 208000032841 Bulimia Diseases 0.000 claims description 7
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 7
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 7
- 206010043903 Tobacco abuse Diseases 0.000 claims description 7
- 206010001584 alcohol abuse Diseases 0.000 claims description 7
- 208000025746 alcohol use disease Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 208000022531 anorexia Diseases 0.000 claims description 7
- 201000001272 cocaine abuse Diseases 0.000 claims description 7
- 206010061428 decreased appetite Diseases 0.000 claims description 7
- 230000037406 food intake Effects 0.000 claims description 7
- 235000012631 food intake Nutrition 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 201000009032 substance abuse Diseases 0.000 claims description 7
- 208000011117 substance-related disease Diseases 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- BWQNSEMCVCACJW-UHFFFAOYSA-N 6-[5-(2-phenylethynyl)thiophen-2-yl]-n-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)CC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC=C1 BWQNSEMCVCACJW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 239000007822 coupling agent Substances 0.000 claims description 6
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 6
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 6
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 6
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 6
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 claims description 6
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 5
- GGIYIRCYHISSON-UHFFFAOYSA-N 6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(N)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 GGIYIRCYHISSON-UHFFFAOYSA-N 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 230000001149 cognitive effect Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 5
- BHCRHMMYJATVJP-UHFFFAOYSA-N n-tert-butyl-6-[5-[2-(3-fluoropyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=NC=CC=C1F BHCRHMMYJATVJP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- VYNWIZIRQLWREO-UHFFFAOYSA-N 3-[2-[5-[5-(tert-butylamino)imidazo[2,1-b][1,3]thiazol-6-yl]thiophen-2-yl]ethynyl]benzonitrile Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC(C#N)=C1 VYNWIZIRQLWREO-UHFFFAOYSA-N 0.000 claims description 4
- ITRWNLNUUPLAKD-UHFFFAOYSA-N 3-[2-[5-[5-(tert-butylamino)imidazo[2,1-b][1,3]thiazol-6-yl]thiophen-2-yl]ethynyl]phenol Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC(O)=C1 ITRWNLNUUPLAKD-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010002091 Anaesthesia Diseases 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 201000008197 Laryngitis Diseases 0.000 claims description 4
- 206010024642 Listless Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000004880 Polyuria Diseases 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 208000037003 Pseudocroup Diseases 0.000 claims description 4
- 206010067171 Regurgitation Diseases 0.000 claims description 4
- 206010041349 Somnolence Diseases 0.000 claims description 4
- 208000005392 Spasm Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 230000037005 anaesthesia Effects 0.000 claims description 4
- 238000001949 anaesthesia Methods 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 210000000748 cardiovascular system Anatomy 0.000 claims description 4
- 230000035619 diuresis Effects 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 208000017971 listlessness Diseases 0.000 claims description 4
- 230000006742 locomotor activity Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- WDCZUCRDZFXUCO-UHFFFAOYSA-N n-[6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-yl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(N1C=CSC1=N1)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 WDCZUCRDZFXUCO-UHFFFAOYSA-N 0.000 claims description 4
- WIHCQEKPUIDDFV-UHFFFAOYSA-N n-tert-butyl-2-methyl-6-[4-(2-pyridin-2-ylethynyl)phenyl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC(C)=CN2C(NC(C)(C)C)=C1C(C=C1)=CC=C1C#CC1=CC=CC=N1 WIHCQEKPUIDDFV-UHFFFAOYSA-N 0.000 claims description 4
- QMQPKKYDWPKFCR-UHFFFAOYSA-N n-tert-butyl-2-methyl-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC(C)=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 QMQPKKYDWPKFCR-UHFFFAOYSA-N 0.000 claims description 4
- UFQHMSRJMRWKAI-UHFFFAOYSA-N n-tert-butyl-3-methyl-6-[5-(2-phenylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound CC(C)(C)NC=1N2C(C)=CSC2=NC=1C(S1)=CC=C1C#CC1=CC=CC=C1 UFQHMSRJMRWKAI-UHFFFAOYSA-N 0.000 claims description 4
- MZDKAEHQIYLWRD-UHFFFAOYSA-N n-tert-butyl-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 MZDKAEHQIYLWRD-UHFFFAOYSA-N 0.000 claims description 4
- RYAOYYXIQURMFJ-UHFFFAOYSA-N n-tert-butyl-6-[5-(2-thiophen-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CS1 RYAOYYXIQURMFJ-UHFFFAOYSA-N 0.000 claims description 4
- MMOXSBRQBPXLKH-UHFFFAOYSA-N n-tert-butyl-6-[5-[2-(1,3-thiazol-2-yl)ethynyl]thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=NC=CS1 MMOXSBRQBPXLKH-UHFFFAOYSA-N 0.000 claims description 4
- YFWFTBGJJXMGRG-UHFFFAOYSA-N n-tert-butyl-6-[5-[2-(3-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound CC1=CC=CN=C1C#CC1=CC=C(C2=C(N3C=CSC3=N2)NC(C)(C)C)S1 YFWFTBGJJXMGRG-UHFFFAOYSA-N 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 4
- 208000016254 weariness Diseases 0.000 claims description 4
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- XPVCVCBHVHVXCB-UHFFFAOYSA-N n-[6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-yl]acetamide Chemical compound N1=C2SC=CN2C(NC(=O)C)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 XPVCVCBHVHVXCB-UHFFFAOYSA-N 0.000 claims description 3
- VBIHJZYSLVVNCG-UHFFFAOYSA-N n-ethyl-6-[6-(2-phenylethynyl)pyridin-3-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NCC)=C1C(C=N1)=CC=C1C#CC1=CC=CC=C1 VBIHJZYSLVVNCG-UHFFFAOYSA-N 0.000 claims description 3
- AYAOZPCTGJOFHN-UHFFFAOYSA-N n-tert-butyl-6-[5-(2-pyridin-2-ylethynyl)-1,3-thiazol-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=NC=C1C#CC1=CC=CC=N1 AYAOZPCTGJOFHN-UHFFFAOYSA-N 0.000 claims description 3
- UKULPKDAQDHHAM-UHFFFAOYSA-N n-tert-butyl-6-[5-(2-pyridin-4-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=NC=C1 UKULPKDAQDHHAM-UHFFFAOYSA-N 0.000 claims description 3
- DZHFRHJMLNLRHA-UHFFFAOYSA-N n-tert-butyl-6-[5-(2-pyrimidin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=NC=CC=N1 DZHFRHJMLNLRHA-UHFFFAOYSA-N 0.000 claims description 3
- QHKXFZHXXCHDHN-UHFFFAOYSA-N n-tert-butyl-6-[5-[2-(2-fluoropyridin-4-yl)ethynyl]thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=NC(F)=C1 QHKXFZHXXCHDHN-UHFFFAOYSA-N 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims description 2
- LWHKTTKKUHYYQL-UHFFFAOYSA-N n-tert-butyl-6-[5-(2-pyridin-2-ylethynyl)furan-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C(O1)=CC=C1C#CC1=CC=CC=N1 LWHKTTKKUHYYQL-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- QVVGVTAYHQGGSU-UHFFFAOYSA-N methyl 5-(tert-butylamino)-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazole-2-carboxylate Chemical compound N1=C2SC(C(=O)OC)=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 QVVGVTAYHQGGSU-UHFFFAOYSA-N 0.000 claims 1
- BFQVVKJHDDMRNF-UHFFFAOYSA-N n-tert-butyl-2,3-dimethyl-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound CC(C)(C)NC=1N2C(C)=C(C)SC2=NC=1C(S1)=CC=C1C#CC1=CC=CC=N1 BFQVVKJHDDMRNF-UHFFFAOYSA-N 0.000 claims 1
- XXQDQUBROITJND-UHFFFAOYSA-N n-tert-butyl-2-chloro-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC(Cl)=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 XXQDQUBROITJND-UHFFFAOYSA-N 0.000 claims 1
- TXNGUMJPIBSJHM-UHFFFAOYSA-N n-tert-butyl-3-methyl-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound CC(C)(C)NC=1N2C(C)=CSC2=NC=1C(S1)=CC=C1C#CC1=CC=CC=N1 TXNGUMJPIBSJHM-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 79
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 238000007792 addition Methods 0.000 description 44
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 18
- 239000012071 phase Substances 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- 238000010586 diagram Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 8
- 229960004132 diethyl ether Drugs 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 235000017550 sodium carbonate Nutrition 0.000 description 8
- 229910052720 vanadium Inorganic materials 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 7
- 229940043279 diisopropylamine Drugs 0.000 description 7
- 229940093499 ethyl acetate Drugs 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 235000011181 potassium carbonates Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000011877 solvent mixture Substances 0.000 description 6
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- UCYRAEIHXSVXPV-UHFFFAOYSA-K bis(trifluoromethylsulfonyloxy)indiganyl trifluoromethanesulfonate Chemical compound [In+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F UCYRAEIHXSVXPV-UHFFFAOYSA-K 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 150000002527 isonitriles Chemical class 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- DVQALMJZMANNDH-UHFFFAOYSA-N 6-(5-bromothiophen-2-yl)-n-tert-butylimidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C1=CC=C(Br)S1 DVQALMJZMANNDH-UHFFFAOYSA-N 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- FSBLVBBRXSCOKU-UHFFFAOYSA-N n-butyl isocyanide Chemical compound CCCC[N+]#[C-] FSBLVBBRXSCOKU-UHFFFAOYSA-N 0.000 description 3
- OPRPNHMETKHYCR-UHFFFAOYSA-N n-tert-butyl-3-methyl-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine;hydrochloride Chemical compound Cl.CC(C)(C)NC=1N2C(C)=CSC2=NC=1C(S1)=CC=C1C#CC1=CC=CC=N1 OPRPNHMETKHYCR-UHFFFAOYSA-N 0.000 description 3
- NGLXDFFIGAKYEB-UHFFFAOYSA-N n-tert-butyl-6-[5-(2-trimethylsilylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C1=CC=C(C#C[Si](C)(C)C)S1 NGLXDFFIGAKYEB-UHFFFAOYSA-N 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 235000003270 potassium fluoride Nutrition 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Inorganic materials [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- FAGLEPBREOXSAC-UHFFFAOYSA-N tert-butyl isocyanide Chemical compound CC(C)(C)[N+]#[C-] FAGLEPBREOXSAC-UHFFFAOYSA-N 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- HOOWCUZPEFNHDT-ZETCQYMHSA-N (S)-3,5-dihydroxyphenylglycine Chemical compound OC(=O)[C@@H](N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-ZETCQYMHSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- YVPXQMYCTGCWBE-UHFFFAOYSA-N 2-isocyano-2,4,4-trimethylpentane Chemical compound CC(C)(C)CC(C)(C)[N+]#[C-] YVPXQMYCTGCWBE-UHFFFAOYSA-N 0.000 description 2
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Inorganic materials [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- CLYFLRDSFMNDMV-UHFFFAOYSA-N n-tert-butyl-2,3-dimethyl-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine;hydrochloride Chemical compound Cl.CC(C)(C)NC=1N2C(C)=C(C)SC2=NC=1C(S1)=CC=C1C#CC1=CC=CC=N1 CLYFLRDSFMNDMV-UHFFFAOYSA-N 0.000 description 2
- CZUGBQBYXZANDZ-UHFFFAOYSA-N n-tert-butyl-2-chloro-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazol-5-amine;hydrochloride Chemical compound Cl.N1=C2SC(Cl)=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 CZUGBQBYXZANDZ-UHFFFAOYSA-N 0.000 description 2
- LWMHUSSGBUPTGR-UHFFFAOYSA-N n-tert-butyl-6-(5-ethynylthiophen-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C1=CC=C(C#C)S1 LWMHUSSGBUPTGR-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052706 scandium Inorganic materials 0.000 description 2
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 2
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- WAJIIJLJMAGUQZ-UHFFFAOYSA-N 2-(3-methoxyphenyl)-6-prop-1-ynylpyridine Chemical compound COC1=CC=CC(C=2N=C(C=CC=2)C#CC)=C1 WAJIIJLJMAGUQZ-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- NHUBNHMFXQNNMV-UHFFFAOYSA-N 2-ethynylpyridine Chemical compound C#CC1=CC=CC=N1 NHUBNHMFXQNNMV-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- FBNNFPSISPAWSO-UHFFFAOYSA-N 3-(2-pyridin-2-ylethynyl)thiophene-2-carbaldehyde Chemical compound N1=C(C=CC=C1)C#CC1=C(SC=C1)C=O FBNNFPSISPAWSO-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- ZDGZTSMMMPDJLS-UHFFFAOYSA-N 3-fluoro-2-iodopyridine Chemical compound FC1=CC=CN=C1I ZDGZTSMMMPDJLS-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- OUQMXTJYCAJLGO-UHFFFAOYSA-N 4-methyl-1,3-thiazol-2-amine Chemical compound CC1=CSC(N)=N1 OUQMXTJYCAJLGO-UHFFFAOYSA-N 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- YFMUACLZRVJOBK-UHFFFAOYSA-N 5-(2-phenylethynyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC=C1C#CC1=CC=CC=C1 YFMUACLZRVJOBK-UHFFFAOYSA-N 0.000 description 1
- YUFGCNVDLSITQG-UHFFFAOYSA-N 5-(2-pyridin-2-ylethynyl)furan-2-carbaldehyde Chemical compound O1C(C=O)=CC=C1C#CC1=CC=CC=N1 YUFGCNVDLSITQG-UHFFFAOYSA-N 0.000 description 1
- YOQVYYUNNTYTOA-UHFFFAOYSA-N 5-(2-pyridin-2-ylethynyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC=C1C#CC1=CC=CC=N1 YOQVYYUNNTYTOA-UHFFFAOYSA-N 0.000 description 1
- DYDCPFNVIPHVKC-UHFFFAOYSA-N 5-bromo-1,3-thiazole-2-carbaldehyde Chemical compound BrC1=CN=C(C=O)S1 DYDCPFNVIPHVKC-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- GUABFMPMKJGSBQ-UHFFFAOYSA-N 5-methyl-1,3-thiazol-2-amine Chemical compound CC1=CN=C(N)S1 GUABFMPMKJGSBQ-UHFFFAOYSA-N 0.000 description 1
- SQAUWBWABNLWIW-UHFFFAOYSA-N 6-(5-bromo-1,3-thiazol-2-yl)-n-tert-butylimidazo[2,1-b][1,3]thiazol-5-amine Chemical compound N1=C2SC=CN2C(NC(C)(C)C)=C1C1=NC=C(Br)S1 SQAUWBWABNLWIW-UHFFFAOYSA-N 0.000 description 1
- 241001502050 Acis Species 0.000 description 1
- 101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 240000002426 Persea americana var. drymifolia Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003574 anti-allodynic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical class CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- ATRGVCKIEFTMTO-UHFFFAOYSA-N methyl 5-(tert-butylamino)-6-[5-(2-pyridin-2-ylethynyl)thiophen-2-yl]imidazo[2,1-b][1,3]thiazole-2-carboxylate;hydrochloride Chemical compound Cl.N1=C2SC(C(=O)OC)=CN2C(NC(C)(C)C)=C1C(S1)=CC=C1C#CC1=CC=CC=N1 ATRGVCKIEFTMTO-UHFFFAOYSA-N 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- UVBXZOISXNZBLY-UHFFFAOYSA-L palladium(2+);triphenylphosphane;diacetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UVBXZOISXNZBLY-UHFFFAOYSA-L 0.000 description 1
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical compound P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 101150006137 sir gene Proteins 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
The invention relates to substituted imidazo[2,1-b]thiazole compounds of formula (I) and to methods for producing them, to drugs containing said compounds and to their use for producing drugs.
Description
Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs The present invention relates to substituted imidazo[2,1-b]thiazole compounds, methods for producing them, drugs containing said compounds and their use for producing drugs.
Pain is one of the basic symptoms in clinics. There is a worldwide need for effective pain treatments. The urgency of the requirement for providing tailored and targeted treatment of chronic and non-chronic pain, this being taken to mean pain treatment which is effective and satisfactory from the patient's standpoint, is also evident from the large number of scientific papers relating to applied analgesia and to basic nociception research which have appeared in recent times.
Traditional opioids, such as morphine, are effective in the treatment of severe to very=
severe pain, but often lead to undesired side effects such as respiratory depression, vomiting, sedation, constipation or development of tolerance. Moreover, they are often not sufficiently effective in the case of neuropathic pain, from which tumour patients in particular suffer.
One object of the present invention was therefore to provide new compounds which are particularly suitable as active pharmaceutical substances in drugs, preferably in drugs for the treatment of pain.
It was surprisingly found that the substituted imidazo[2,1-b]thiazole compounds of the general formula I indicated below are suitable for mGIuR5 receptor regulation (mGIuR5 = metabotropic glutamate receptor 5) and can therefore be used as active pharmaceutical substances in drugs for the prevention and/or treatment of disorders or illnesses connected to these receptors or processes.
One subject matter of the present invention is therefore substituted imidazo[2,1-b]thiazole compounds of the general formula I, S N
R1 x ~ M1 M2 N
in which R' and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NR6R7; -NH-C(=0)-R8; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR10; -C(=O)-NR"R'2; -C(=O)-OR'3; -(CH2)m-C(=0)-OR14 with m = 1, 2, 3, 4 or 5; -O-C(=O)-R15; -(CH2)õ-O-C(=O)-R'6 with n = 1, 2, 3, 4 or 5; -OR";
-(CH2)o O-R'$ with o = 1, 2, 3; 4 or 5; -SR19; -(CH2)P S(=O)t-R20 with p = 1, 2, 3, 4 or 5 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NR29R30; -SF5; -(CH2)õ-O-S(=O)2-with u = 1, 2, 3, 4 or 5; -(CH2),-O-S(=O)2-O-R32 with v = 1, 2, 3, 4 or 5; -(CH2)W O-P(=O)(OR33)(OR34) with w = 1, 2, 3, 4 or 5;
a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic residue optionally having at least one heteroatom as a ring member, which cycloaliphatic residue is bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system; or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22with q = 1, 2, 3, 4 or 5-1 -C(=O)-O-R23; -(CH2)r-C(=0)-O-R24with r = 1, 2, 3, 4 or 5; -C(=O)-NHR25; -(CH2)S-C(=O)-NHR26 with s = 1, 2, 3, 4 or 5; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic residue optionally having at least one heteroatom as a ring member, which cycloaliphatic residue can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system; or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, or R3 and R 4 together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated, unsubstituted or at least monosubstituted heterocycloaliphatic residue optionally having at least one further heteroatom as a ring member, which heterocycloaliphatic residue can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R5, Rs, R', R8, R'o, R", R12, R15 and R's, in each case mutually independently, denote a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
Rs R13 R14 R17 R18 R19 Rzo R21 R22 R23 R24 R25 R26 R27 R28 R29 R30, R31, R3z R33 and R34, in each case mutually independently, denote a hydrogen residue; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
Pain is one of the basic symptoms in clinics. There is a worldwide need for effective pain treatments. The urgency of the requirement for providing tailored and targeted treatment of chronic and non-chronic pain, this being taken to mean pain treatment which is effective and satisfactory from the patient's standpoint, is also evident from the large number of scientific papers relating to applied analgesia and to basic nociception research which have appeared in recent times.
Traditional opioids, such as morphine, are effective in the treatment of severe to very=
severe pain, but often lead to undesired side effects such as respiratory depression, vomiting, sedation, constipation or development of tolerance. Moreover, they are often not sufficiently effective in the case of neuropathic pain, from which tumour patients in particular suffer.
One object of the present invention was therefore to provide new compounds which are particularly suitable as active pharmaceutical substances in drugs, preferably in drugs for the treatment of pain.
It was surprisingly found that the substituted imidazo[2,1-b]thiazole compounds of the general formula I indicated below are suitable for mGIuR5 receptor regulation (mGIuR5 = metabotropic glutamate receptor 5) and can therefore be used as active pharmaceutical substances in drugs for the prevention and/or treatment of disorders or illnesses connected to these receptors or processes.
One subject matter of the present invention is therefore substituted imidazo[2,1-b]thiazole compounds of the general formula I, S N
R1 x ~ M1 M2 N
in which R' and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NR6R7; -NH-C(=0)-R8; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR10; -C(=O)-NR"R'2; -C(=O)-OR'3; -(CH2)m-C(=0)-OR14 with m = 1, 2, 3, 4 or 5; -O-C(=O)-R15; -(CH2)õ-O-C(=O)-R'6 with n = 1, 2, 3, 4 or 5; -OR";
-(CH2)o O-R'$ with o = 1, 2, 3; 4 or 5; -SR19; -(CH2)P S(=O)t-R20 with p = 1, 2, 3, 4 or 5 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NR29R30; -SF5; -(CH2)õ-O-S(=O)2-with u = 1, 2, 3, 4 or 5; -(CH2),-O-S(=O)2-O-R32 with v = 1, 2, 3, 4 or 5; -(CH2)W O-P(=O)(OR33)(OR34) with w = 1, 2, 3, 4 or 5;
a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic residue optionally having at least one heteroatom as a ring member, which cycloaliphatic residue is bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system; or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22with q = 1, 2, 3, 4 or 5-1 -C(=O)-O-R23; -(CH2)r-C(=0)-O-R24with r = 1, 2, 3, 4 or 5; -C(=O)-NHR25; -(CH2)S-C(=O)-NHR26 with s = 1, 2, 3, 4 or 5; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic residue optionally having at least one heteroatom as a ring member, which cycloaliphatic residue can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system; or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, or R3 and R 4 together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated, unsubstituted or at least monosubstituted heterocycloaliphatic residue optionally having at least one further heteroatom as a ring member, which heterocycloaliphatic residue can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R5, Rs, R', R8, R'o, R", R12, R15 and R's, in each case mutually independently, denote a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
Rs R13 R14 R17 R18 R19 Rzo R21 R22 R23 R24 R25 R26 R27 R28 R29 R30, R31, R3z R33 and R34, in each case mutually independently, denote a hydrogen residue; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
_. ...-.~. .
M' denotes an aryl or heteroaryl residue, which can be substituted with at least one further substituent and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
and M2 denotes an aryl or heteroaryl residue, which can be unsubstituted or at least monosubstituted and can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
in each case in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Provided that one or more of the above-mentioned substituents denotes a saturated or unsaturated aliphatic residue, i.e. an alkyl, alkenyl or alkynyl residue, which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -NO2, -CN, -OH, -C(=O)-OH, -C(=O)-O-(C1_5-alkyl), -SH, -NH2, -N(C1_5-alkyl)2, -N(C1_5-alkyl)(phenyl), -N(C1_5-alkyl)(CH2-phenyl), -N(C1_5-alkyl)(CH2-CH2-phenyl), -C(=S)-C1_5-alkyl, -C(=S)-phenyl and -SO3H, whereby the above-mentioned C1_5-alkyl residues can in each case be linear or branched and the above-mentioned phenyl residues can preferably be substituted with 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -O-CH3, -C2H5, -O-C3H7, -C(=0)-OH, -C(=O)-O-CH3, -C(=O)-O-C2H5, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl and tert-butyl.
An aliphatic residue, i.e. an alkyl, alkenyl or alkynyl residue, can particularly preferably be substituted with 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -NO2, -CN, -OH, -C(=O)-OH, -C(=O)-O-CH3, -SH, -NH2, -N(CH3)2, -N(C2H5)2 and -N(CH3)(C2H5).
M' denotes an aryl or heteroaryl residue, which can be substituted with at least one further substituent and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
and M2 denotes an aryl or heteroaryl residue, which can be unsubstituted or at least monosubstituted and can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
in each case in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Provided that one or more of the above-mentioned substituents denotes a saturated or unsaturated aliphatic residue, i.e. an alkyl, alkenyl or alkynyl residue, which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -NO2, -CN, -OH, -C(=O)-OH, -C(=O)-O-(C1_5-alkyl), -SH, -NH2, -N(C1_5-alkyl)2, -N(C1_5-alkyl)(phenyl), -N(C1_5-alkyl)(CH2-phenyl), -N(C1_5-alkyl)(CH2-CH2-phenyl), -C(=S)-C1_5-alkyl, -C(=S)-phenyl and -SO3H, whereby the above-mentioned C1_5-alkyl residues can in each case be linear or branched and the above-mentioned phenyl residues can preferably be substituted with 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -O-CH3, -C2H5, -O-C3H7, -C(=0)-OH, -C(=O)-O-CH3, -C(=O)-O-C2H5, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl and tert-butyl.
An aliphatic residue, i.e. an alkyl, alkenyl or alkynyl residue, can particularly preferably be substituted with 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -NO2, -CN, -OH, -C(=O)-OH, -C(=O)-O-CH3, -SH, -NH2, -N(CH3)2, -N(C2H5)2 and -N(CH3)(C2H5).
Alkenyl residues have at least one, preferably 1, 2, 3 or 4 C-C double-bonds and alkynyl residues have at least one, preferably 1, 2, 3 or 4 C-C-triple-bonds.
Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethylpent-2-yl, -C(H)(C2H5)2, -C(H)(n-C3H7)2 and -CH2-CH2-C(H)(CH3)-(CH2)3-CH3 are cited as examples of suitable Cl_lo-alkyl residues, which can be unsubstituted or monosubstituted or multiply substituted.
Multiply substituted alkyl residues should be understood as such alkyl residues which are multiply substituted either at different or at the same C-atoms, preferably twice or three times, for example, three times at the same C-atom as in the case of -CF3 or at various points as in the case of -(CHCI)-(CH2F). Multiple substitution can be performed with the same or with different substituents. -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH are cited as examples of suitable substituted alkyl residues.
Ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, pentenyl, 3-pentenyl, 4-pentenyl, hexenyl, -CH=CH-CH=CH-CH3 and -CH2-CH2-CH=CH2 are cited as examples of suitable C2_6-alkenyl residues.
Multiply substituted alkenyl residues should be understood as such alkenyl residues which are multiply substituted either at different or at the same C-atoms, preferably twice, for example, twice at the same C-atom as in the case of -CH=CCI2 or at different points as in the case of -CCI=CH-(CH2)-NH2. Multiple substitution can be performed with the same or with different substituents. -CH=CH-(CH2)-OH, -CH=CH-(CH2)-NH2 and -CH=CH-CN are cited as examples of suitable substituted alkenyl residues.
Ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, pentynyl, 3-pentynyl, 4-pentynyl and hexynyl are cited as examples of suitable C2_6-alkynyl residues.
, GRA3336PCT
Multiply substituted alkynyl residues should be understood as such alkynyl residues which are multiply substituted either at different C-atoms, for example, twice at different C-atoms as in the case of -CHCI-C=CCI. -C=C-F, -C=C-CI and -C=C-I
are cited as examples of suitable substituted alkynyl residues.
Provided that one or more of the above-mentioned substituents denotes a cycloaliphatic residue or has a cycloaliphatic residue which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3 substituents, which can be mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, -OH, -SH, -SF5, -NH2, oxo (=0), thioxo (=S), -C(=O)-OH, C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -(CH2)-O-C1_5-alkyl, -S-C1_5-alkyl, -S-phenyl, -phenyl, -O-C1_5-alkyl, -0-phenyl, -O-CH2-phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, -S(=O)2-C1_ 5-alkyl, -S(=O)-C1_5-alkyl, -NH-C1_5-alkyl, N(C1_5alkyl)(C1-5-alkyl), -C(=O)-O-C1_5-alkyl, -C(=O)-H, -C(=O)-C1_5-alkyl, -CH2-O-C(=O)-phenyl, -O-C(=0)-phenyl, -NH-S(=O)2-C1_ 5-alkyl, -NH-C(=O)-C1_5-alkyl, -C(=O)-NH2, -C(=O)-NH-C1_5-alkyl, -C(=O)-N(C1_5-alkyl)2, pyrazolyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl, whereby the above-mentioned C1_5-alkyl residues can in each case be linear or branched and the cyclic substituents or the cyclic residues of these substituents themselves can in each case be substituted with optionally 1, 2, 3, 4 or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -O-C1_5-alkyl, -0-phenyl, -0-CH2-phenyl, -(CH2)-O-C1_5-alkyl, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C(=O)-O-C1-5-alkyl and -C(=0)-CF3.
The substituents can particularly preferably be, in each case mutually independently, selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -CH2-O-CH3, -CH2-O-CZH5, -OH, -SH, -SF5, -NH2, oxo (=0), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=0)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -0-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -0-CHF2, -O-CH2F, -C(=0)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=0)-C2H5, -NH-C(=O)-CH3, -NH-C(=0)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl, whereby the cyclic substituents or the cyclic residues of these substituents themselves can be substituted with optionally 1, 2, 3, 4 or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -O-CH3, -O-C2H5, -O-C3H7, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C(=0)-O-Cj_5-alkyl and -C(=O)-CF3.
Provided that the cycloaliphatic residues have one or more heteroatoms as ring members, these can preferably have optionally 1, 2, 3, 4 or 5, particularly preferably 1, 2 or 3 heteroatom(s) as (the) ring member(s), which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur.
Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, oxiranyl, aziridinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, isothioazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, (1,2,4)-oxadiazolidinyl, (1,2,4)-thiadiazolidinyl, (1,2,4)-triazolidin-3-yl, (1,3,4)-thiadiazolidinyl, (1,3,4)-triazolidin-1-yl, (1,3,4)-triazolidin-2-yl, (2,3)-dihydrofuryl, (2,5)-dihydrofuryl, (2,3)-dihydrothienyl, (2,5)-dihydrothienyl, (2,3)-dihydropyrrolyl, (2,5)-dihydropyrrolyl, (2,3)-dihydroisoxazolyl, (4,5)-dihydroisoxazolyl, (2,5)-dihydroisothiazolyl, (2,3)-dihydropyrazolyl, (4,5)-dihydropyrazolyl, (2,5)-dihydropyrazolyl, (2,3)-dihydrooxazolyl, (4,5)-dihydrooxazolyl, (2,5)-dihydrooxazolyl, (2,3)-dihydrothiazolyl, (4,5)-dihydrothiazolyl, (2,5)-dihydrothiazolyl, (2,3)-dihydroimidazolyl, (4,5)-dihydroimidazolyl, (2,5)-dihydroimidazolyl, morpholinyl, piperidinyl, piperazinyl, azocanyl, tetrahydropyridazinyl, tetrahydropyrimidinyl, tetra hyd ro pyrazi nyl, (1,3,5)-tetrahydrotriazinyl, (1,2,4)-tetrahydrotriazin-1-yl, (1,2,4)-tetrahydrotriazin-3-yl, (1,3)-dihydrooxazinyl, (1,3)-dithian-2-yl, tetrahydropyranyl, (1,3)-dioxolan-2-yl, (3,4,5,6)-tetrahydropyridin-2-yl, (1,2,5,6)-tetrahydropyridin-1-yl, (1,2,3,4)-tetrahydropyridin-1-yl, (1,2)-dihydropyridin-1-yl, (1,4)-dihydropyridin-1-yl, 4H-1,3-thiazinyl, (1,3)-dihydrooxazin-2-yl, azepanyl, (1,4)-diazepanyl, thiomorpholinyl and dithiolanyl are cited as examples of cycloaliphatic residues which can be monosubstituted or multiply substituted.
Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetra hyd roth i ophe nyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, diazepanyl, azocanyl and dithiolanyl are particularly preferably cited as cycloaliphatic residues which can be monosubstituted or multiply substituted.
Provided that the cycloaliphatic residue is condensed with an unsubstituted or at least monosubstituted, saturated, unsaturated or aromatic mono- or polycyclic ring system, suitable unsubstituted or at least monosubstituted residues can be selected from the group comprising 2,3-dihydro-benzo[1,4]dioxinyl; 3,4-dihydro-2H-benzo[1,4]oxazinyl; benzo[1,3]dioxolyl; (1,2,3,4)-tetrahydroquinazolinyl;
indanyl;
(1,2,3,4)-tetrahydronaphthyl; 1H-indenyl; (1,2,3,4)-tetrahydroquinolinyl;
(1,2,3,4)-tetrahydroisoquinolinyl; (2,3)-dihydro-1 H-indolyl, (2,3)-dihydro-1 H-isoindolyl and decahydroisoquinolinyl.
Provided that two of the above-mentioned substituents together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated heterocycloaliphatic residue which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -SF5, -O-C1_5-alkyl, -0-phenyl, -O-CH2-phenyl, -(CH2)-O-C1_5-alkyl, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -C1_5-alkyl, -C2_5-alkenyl, -C2-5-alkynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C(=O)-O-C1-5-alkyl, -C(=O)-CF3, -S(=O)2-C1_5-alkyl, -S(=O)-C1_5-alkyl, -S(=O)2-phenyl, oxo (=0), thioxo (=S), -N(C1_5-alkyl)2, -N(H)(C1_5-alkyl), -NO2, -S-CF3, -C(=O)-OH, -NH-S(=0)2-C1_5-alkyl, -NH-C(=O)-C1_5-alkyl, -C(=O)-H, -C(=O)-C1_5-alkyl, -C(=O)-NH2, -C(=O)-N(C1_5-alkyl)2, -C(=O)-N(H)(C1_5-alkyl) and phenyl, whereby the above-mentioned C1_ 5-alkyl residues can in each case be linear or branched and the phenyl residues can in each case be unsubstituted or substituted with 1, 2, 3, 4 or 5, preferably with 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -O-C,_5-alkyl, -0-phenyl, -O-CH2-phenyl, -(CH2)-O-C1_5-alkyl, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C(=O)-O-C1_5-alkyl and -C(=O)-CF3.
The substituents can particularly preferably, in each case mutually independently, be selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C-C-SI(CH3)3, -C=C-SI(C2H5)3, -OH, oxo, thioxo, -O-CH3, -O-CZHS, -O-C3H7, -(CH2)-O-CH3, -(CH2)-O-C2H5, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NO2, -CF3, -CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -NH-S(=O)2-CH3, -C(=O)-OH, -C(=O)-H; -C(=O)-CH3, -C(=0)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3 and phenyl, whereby the phenyl residue can be substituted with 1, 2, 3, 4 or 5, preferably 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -0-CH3, -O-C2H5, -O-C3H7, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C-C-Si(C2H5)3, -C(=0)-O-Cj_5-alkyl and -C(=O)-CF3.
Provided that the heterocycloaliphatic residues have one or more further heteroatoms as ring members, these can preferably have optionally 1, 2, 3, 4 or 5, particularly preferably optionally 1, 2 or 3, further heteroatom(s) as (the) ring member(s), which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur.
Imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl are cited as examples of suitable heterocycloaliphatic residues which can be monosubstituted or multiply substituted.
Provided that the heterocycloaliphatic residue is condensed with an unsubstituted or at least monosubstituted, saturated, unsaturated or aromatic mono- or polycyclic ring system, suitable unsubstituted or at least monosubstituted residues can be selected from the group comprising (3,4)-dihydro-2H-benzo[1,4]oxazinyl; (1,2,3,4)-_ ~.
tetrahydroquinazolinyl; (1,2,3,4)-tetrahydroquinolinyl; (1,2,3,4)-tetrahydroisoquinolinyl, (2,3)-dihydro-1 H-indolyl, (2,3)-dihydro-1 H-isoindolyl and decahydroisoquinolinyl.
Provided that one or more of the above-mentioned substituents denotes an aryl or heteroaryl residue or has an aryl or heteroaryl residue, which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, -OH, -SH, -SF5, -NH2, -CH2-NH2, -C(=O)-OH, -C,_5-alkyl, -(CH2)-O-C1_5-alkyl, -CH2-OH, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-Si(CH3)3, -C-C-Si(C2H5)3, -S-Cl_5-alkyl, -S-phenyl, -S-CH2-phenyl, -O-C,_5-alkyl, -0-phenyl, -O-CH2-phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, -S(=O)2-C1_5-alkyl, -S(=O)-C1_5-alkyl, -NH-C1_5-alkyl, N(C1_5alkyl)2, -C(=O)-O-Cj_5-alkyl, -C(=O)-H; -C(=O)-C1_5-alkyl, -CH2-O-C(=O)-phenyl, -O-C(=O)-phenyl, -NH-S(=O)2-C1_5-alkyl, -NH-C(=O)-C1_5-alkyl, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, -C(=O)-NH2, -C(=O)-NH-C1_5-alkyl, -C(=O)-N(C1_5-alkyl)2, -Si(phenyl)2[C1_5-alkyl], -S(=O)2-NH2, -S(=O)2-NH-Cj_5-alkyl, -S(=O)2-N(C1_5-aIkyl)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, (1,3)-dioxolanyl, pyrazolyl, pyrrolyl, phenyl, furyl (furanyl), thiazolyl, thiadiazolyl, thiophenyl (thienyl), benzyl and phenethyl, whereby the above-mentioned C1_5-alkyl residues can in each case be linear or branched and the cyclic substituents or the cyclic residues of these substituents themselves can be substituted with optionally 1, 2, 3, 4 or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, -OH, -SH, -NH2, -C(=0)-OH, -Cl_5-alkyl, -(CH2)-O-C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C-C-Si(CH3)3, -C=C-Si(C2H5)3, -S-C,_5-alkyl, -S-phenyl, -S-CH2-phenyl, -O-C1_5-alkyl, -0-phenyl, -phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
The substituents can particularly preferably be selected in each case mutually independently from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C-C-Si(CH3)3, -C-C-Si(C2H5)3, -CH2-O-CH3, -O-C2H5, -OH, -CH2-NH2, -CH2-OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=0)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -0-CH3, -0-C2H5, -0-C3H7, -C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -0-CHF2, -0-CH2F, -C(=0)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyi, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -NH-S(=0)2-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=0)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -0-C(=0)-phenyl, -C(=0)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], -S(=O)2-NH2, -S(=O)2-NH-CH3, -S(=O)2-N(CH3)2, -NH-C(=NH)-NH2, -NH-S(=0)2-OH, (1,3)-dioxolanyl, pyrrolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyi, thiophenyl (thienyl) and benzyl, whereby the cyclic substituents or the cyclic residues of these substituents themselves can be substituted in each case with optionally 1, 2, 3, 4, or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, -OH, -SH, -NH2, -C(=O)-OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C-C-Si(CH3)3, -C=C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
A substituted aryl residue can very particularly preferably be selected from the group comprising 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 2-fluoro-phenyl, fluoro-phenyl, 4-fluoro-phenyl, 2-cyano-phenyl, 3-cyano-phenyl, 4-cyano-phenyl, 2-hydroxy-phenyl, 3-hydroxy-phenyl, 4-hydroxy-phenyl, 2-amino-phenyl, 3-amino-phenyl, 4-amino-phenyl, 2-dimethylamino-phenyl, 3-dimethylamino-phenyl, 4-dimethylamino-phenyl, 2-methylamino-phenyl, 3-methylamino-phenyl, 4-methylamino-phenyl, 2-acetyl-phenyl, 3-acetyl-phenyl, 4-acetyl-phenyl, 2-methylsulfinyl-phenyl, 3-methylsulfinyl-phenyl, 4-methylsulfinyl-phenyl, 2-methylsulfonyl-phenyl, 3-methylsulfonyl-phenyl, 4-methylsulfonyl-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2-chloro-phenyl, 3-chloro-phenyl, chloro-phenyl, 2-ethoxy-phenyl, 3-ethoxy-phenyl, 4-ethoxyphenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 2-difluoromethyl-phenyl, 3-difluoromethyl-phenyt, 4-difluoromethyl-phenyl, 2-fluoromethyl-phenyl, 3-fluoromethyl-phenyl, 4-fluoromethyl-phenyl, 2-nitro-phenyl, 3-nitro-phenyl, 4-nitro-phenyl, 2-ethyl-phenyl, 3-ethyl-phenyl, 4-ethyl-phenyl, 2-propyl-phenyl, 3-propyl-phenyl, 4-propyl-phenyl, 2-isopropyl-phenyl, 3-isopropyl-phenyl, 4-isopropyl-phenyl, 2-tert-butyl-phenyl, 3-tert-butyl-phenyl, 4-tert-butyl-phenyl, 2-carboxyphenyl, 3-carboxy-phenyl, 4-carboxyphenyl, 2-ethenyl-phenyl, 3-ethenyl-phenyl, 4-ethenyl-phenyl, 2-ethynyl-phenyl, 3-ethynyl-phenyl, 4-ethynyl-phenyl, 2-allyl-phenyl, 3-allyl-phenyl, 4-allyl-phenyl, 2-trimethylsilanylethinyl-phenyl, 3-trimethylsilanylethinyl-phenyl, 4-trimethylsilanylethinyl-phenyl, 2-formyl-phenyl, 3-formyl-phenyl, 4-formyl-phenyl, 2-acetamino-phenyl, 3-acetamino-phenyl, 4-acetamino-phenyl, 2-dimethylaminocarbonyl-phenyl, 3-dimethylaminocarbonyl-phenyl, 4-dimethylaminocarbonyl-phenyl, 2-methoxymethyl-phenyl, 3-methoxymethyl-phenyl, 4-methoxymethyl-phenyl, 2-ethoxymethyl-phenyl, 3-ethoxymethyl-phenyl, 4-ethoxymethyl-phenyl, 2-aminocarbonyl-phenyl, 3-aminocarbonyl-phenyl, 4-aminocarbonyl-phenyl, 2-methylaminocarbonyl-phenyl, 3-methylaminocarbonyl-phenyl, 4-methylaminocarbonyl-phenyl, 2-carboxymethylester-phenyl, 3-carboxymethylester-phenyl, 4-carboxymethylester-phenyl, 2-carboxyethylester-phenyl, 3-carboxyethylester-phenyl, 4-carboxyethylester-phenyl, 2-carboxy-tert-butylester-phenyl, 3-carboxy-tert-butylester-phenyl, 4-carboxy-tert-butylester-phenyl, 2-methylmercapto-phenyl, 3-methylmercapto-phenyl, 4-methylmercapto-phenyl, 2-ethylmercapto-phenyl, 3-ethylmercapto-phenyl, 4-ethylmercaptophenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodo-phenyl, 3-iodophenyl, 4-iodophenyl, 2-trifluoromethoxy-phenyl, 3-trifluoromethoxy-phenyl, 4-trifluoromethoxy-phenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-4-methyl-phenyl, (2,3)-difluorophenyl, (2,3)-dimethyl-phenyl, (2,3)-dichlorophenyl, 3-fluoro-2-trifluoromethylphenyl, (2,4)-dichloro-phenyl, (2,4)-difluorophenyl, 4-fluoro-2-trifluoromethyl-phenyl, (2,4)-dimethoxyphenyl, 2-chloro-4-fluoro-phenyl, 2-chloro-4-nitro-phenyl, 2-chloro-4-methyl-phenyl, 2-chloro-5-trifluoromethyl-phenyl, 2-chloro-5-methoxy-phenyl, 2-bromo-5-trifluoromethyl-phenyl, 2-bromo-5-methoxy-phenyl, (2,4)-dibromo-phenyl, (2,4)-dimethyl-phenyl, 2-fluoro-4-trifluoromethyl-phenyl, (2,5)-difluoro-phenyl, 2-fluoro-5-trifluoromethyl-phenyl, 5-fluoro-2-trifluoromethyl-phenyl, 5-chloro-2-trifluoromethyl-phenyl, 5-bromo-2-trifluoromethyl-phenyl, (2,5)-dimethoxy-phenyl, (2,5)-bis-trifluoromethyl-phenyl, (2,5)-dichloro-phenyl, (2,5)-dibromo-phenyl, 2-methoxy-5-nitro-phenyl, 2-fluoro-6-trifluoromethyl-phenyl, (2,6)-dimethoxy-phenyl, (2,6)-dimethyl-phenyl, (2,6)-dichloro-phenyl, 2-chloro-6-fluoro-phenyl, '2-bromo-6-chloro-phenyl, 2-bromo-6-fluor-phenyl, (2,6)-difluoro-phenyl, (2,6)-difluoro-3-methyl-phenyl, (2,6)-dibromo-phenyl, (2,6)-dichlorophenyl, 3-chloro-2-fluoro-phenyl, chloro-5-methyl-phenyl, (3,4)-dichlorophenyl, (3,4)-dimethyl-phenyl, 3-methyl-methoxy-phenyl, 4-chloro-3-nitro-phenyl, (3,4)-dimethoxy-phenyl, 4-fluoro-3-trifluoromethylphenyl, 3-fluoro-4-trifluoromethyl-phenyl, (3,4)-difluoro-phenyl, 3-cyano-4-fluoro-phenyl, 3-cyano-4-methyl-phenyl, 3-cyano-4-methoxy-phenyl, 3-bromo-4-fluoro-phenyl, 3-bromo-4-methyl-phenyl, 3-bromo-4-methoxy-phenyl, 4-chloro-2-fluoro-phenyl, 4-chloro-3-trifluoromethyl, 4-bromo-3-methyl-phenyl, 4-bromo-5-methyl-phenyl, 3-chloro-4-fluoro-phenyl, 4-fluoro-3-nitro-phenyl, 4-bromo-3-nitro-phenyl, (3,4)-dibromo-phenyl, 4-chloro-3-methyl-phenyl, 4-bromo-3-methyl-phenyl, 4-fluoro-3-methyl-phenyl, 3-fluoro-4-methyl-phenyl, 3-fluoro-5-methyl-phenyl, 2-fluoro-3-methyl-phenyl, 4-methyl-3-nitro-phenyl, (3,5)-dimethoxy-phenyl, (3,5)-dimethyl-phenyl, (3,5)-bis-trifluoromethyl-phenyl, (3,5)-difluoro-phenyl, (3,5)-dinitro-phenyl, (3,5)-dichloro-phenyl, 3-fluoro-5-trifluoromethyl-phenyl, 5-fluoro-3-trifluoromethyl-phenyl, (3,5)-dibromo-phenyl, 5-chloro-4-fluoro-phenyl, 5-chloro-4-fluoro-phenyl, 5-bromo-4-methyl-phenyl, (2,3,4)-trifluorophenyl, (2,3,4)-trichlorophenyl, (2,3,6)-trifluoro-phenyl, 5-chloro-2-methoxy-phenyl, (2,3)-difluoro-4-methyl, (2,4,5)-trifluoro-phenyl, (2,4,5)-trichloro-phenyl, (2,4)-dichloro-5-fluoro-phenyl, (2,4,6)-trichloro-phenyl, (2,4,6)-trimethylphenyl, (2,4,6)-trifluoro-phenyl, (2,4,6)-trimethoxy-phenyl, (3,4,5)-trimethoxy-phenyl, (2,3,4,5)-tetrafluoro-phenyl, 4-methoxy-(2,3,6)-trimethyl-phenyl, 4-methoxy-(2,3,6)-trimethyl-phenyl, 4-chloro-2,5-dimethyl-phenyl, 2-chloro-6-fluoro-3-methyl-phenyl, 6-chloro-2-fluoro-3-methyl, (2,4,6)-trimethylphenyl and (2,3,4,5,6)-pentafluoro-phenyl.
A substituted heteroaryl residue can very particularly preferably be selected from the group comprising 3-methyl-pyrid-2-yl, 4-methyl-pyrid-2-yl, 5-methyl-pyrid-2-yi, 6-methyl-pyrid-2-yl, 2-methyl-pyrid-3-yl, 4-methyl-pyrid-3-yl, 5-methyl-pyrid-3-yl, 6-methyl-pyrid-3-yl, 2-methyl-pyrid-4-yl, 3-methyl-pyrid-4-yi, 3-fluoro-pyrid-2-yi, 4-fluoro-pyrid-2-yl, 5-fluoro-pyrid-2-yl, 6-fluoro-pyrid-2-yl, 3-chloro-pyrid-2-yl, 4-chloro-pyrid-2-yl, 5-chloro-pyrid-2-yl, 6-chloro-pyrid-2-yl, 3-trifluoromethyl-pyrid-2-yl, 4-trifluoromethyl-pyrid-2-yl, 5-trifluoromethyl-pyrid-2-yl, 6-trifluoromethyl-pyrid-2-yl, 3-methoxy-pyrid-2-yl, 4-methoxy-pyrid-2-yl, 5-methoxy-pyrid-2-yl, 6-methoxy-pyrid-2-yl, 4-methyl-thiazole-2-yl, 5-methyl-thiazole-2-yl, 4-trifluoromethyl-thiazole-2-yl, 5-trifluoromethyl-thiazole-2-yl, 4-chloro-thiazole-2-yl, 5-chloro-thiazole-2-yl, 4-bromo-thiazole-2-yl, 5-bromo-thiazole-2-yl, 4-fluoro-thiazole-2-yl, 5-fluoro-thiazole-2-yl, 4-cyano-thiazole-2-yl, 5-cyano-thiazole-2-yi, 4-methoxy-thiazole-2-yl, 5-methoxy-thiazole-2-yl, 4-methyl-oxazole-2-yi, 5-methyl-oxazole-2-yl, 4-trifluoromethyl-oxazole-2-yl, 5-trifluoromethyl-oxazole-2-yl, 4-chloro-oxazole-2-yl, 5-chloro-oxazole-2-yl, 4-bromo-oxazole-2-yl, 5-bromo-oxazole-2-yl, 4-fluoro-oxazole-2-yl, 5-fluoro-oxazole-2-yl, 4-cyano-oxazole-2-yl, 5-cyano-oxazole-2-yl, 4-methoxy-oxazole-2-yl, 5-methoxy-oxazole-2-yl, 2-methyl-(1,2,4)-thiadiazole-5-yl, 2-trifluoromethyl-(1,2,4)-thiadiazole-5-yl, 2-chloro-(1,2,4)-thiadiazole-5-yl, 2-fluoro-(1,2,4)-thiadiazole-5-yl, 2-methoxy-(1,2,4)-thiadiazole-5-yl, 2-cyano-(1,2,4)-thiadiazole-5-yl, 2-methyl-(1,2,4)-oxadiazole-5-yl, 2-trifluoromethyl-(1,2,4)-oxadiazole-5-yl, 2-chloro-(1,2,4)-oxadiazole-5-yl, 2-fluoro-(1,2,4)-oxadiazole-5-yl, 2-methoxy-(1,2,4)-oxadiazole-5-yI and 2-cyano-(1,2,4)-oxadiazole-5-yl.
Phenyl, 1-naphthyl, 2-naphthyl and anthracenyl are cited as examples of suitable aryl residues. A suitable 6-membered aryl residue is a phenyl residue.
Provided that one or more of the above-mentioned substituents denotes a heteroaryl residue or has a heteroaryl residue, the heteroatom(s) thereof can, in each case mutually independently, preferably be selected from the group comprising oxygen, sulphur and nitrogen. A heteroaryl residue can preferably have optionally 1, 2, 3, 4 or 5, particularly preferably 1, 2 or 3 heteroatoms.
Furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl and pentazolyl are cited as examples of suitable 5- or 6-membered heteroaryl residues.
Indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl are cited as examples of suitable 9- or 10-membered heteroaryl residues.
Aryl or heteroaryl residues can, within the meaning of the present invention, be condensed (annelated) with a mono- or bicyclic ring system.
Provided that the 5- or 6-membered heteroaryl residue is condensed with an unsubstituted or at least monosubstituted aromatic mono- or polycyclic ring system, suitable unsubstituted or at least monosubstituted residues can be selected from the group comprising indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl.
(1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, (2,3)-dihydro-1 H-isoindolyl, (1,2,3,4)-tetrahydronaphthyl, (2,3)-dihydro-benzo[1.4]dioxinyl, benzo[1.3]dioxolyl and (3,4)-dihydro-2H-benzo[1.4]oxazinyl are cited as examples of 6-membered aryl residues which are condensed with an unsubstituted or at least monosubstituted saturated mono- or polycyclic ring system.
A mono- or polycyclic ring system should be understood in the context of the present invention as mono- or polycyclic hydrocarbon residues which can be saturated, unsaturated or aromatic and can optionally have one or more heteroatoms as ring members. Such a mono- or polycyclic ring system can, for example, be condensed (annelated) with a cycloaliphatic residue, a heterocycloaliphatic residue, an aryl residue or a heteroaryl residue.
Provided that a polycyclic ring system such as, for example, a bicyclic ring system is present, the various rings, in each case mutually independently, can have a different degree of saturation, i.e. be saturated, unsaturated or aromatic. The heteroatoms of each ring can, in each case mutually independently, be preferably selected from the group comprising oxygen, nitrogen and sulphur. A ring preferably contains 0, 1, 2 or 3 heteroatoms. The respective rings of the mono- or polycyclic ring system are preferably 5-, 6- or 7-membered, particularly preferably 5- or 6-membered.
Provided that one or more of the above-mentioned substituents has a saturated, unsaturated or aromatic monocyclic or polycyclic ring system which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3 substituents mutually independently selected from the group comprising oxo (=0), thioxo (=S), F, Cl, Br, I, -CN, -NO2, -OH, -CH2-OH, -SH, -SF5, -NH2, -CH2-NH2, -C(=0)-OH, -C1-alkyl, -(CH2)-O-C1-5-aIkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-Si(CH3)3, -C=C-Si(C2H5)3, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -O-C1_5-alkyl, -0-phenyl, -O-CH2-phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=0)2-phenyl, -S(=O)2-C1_5-alkyl, -S(=O)-C1_5-alkyl, -NH-C1_5-alkyl, N(C1_ 5alkyl)2, -C(=O)-O-C1_5-alkyl, -C(=0)-H; -C(=O)-C1_5-alkyl, -CH2-O-C(=0)-phenyl, -0-C(=O)-phenyl, -NH-S(=O)2-Cj_5-alkyl, -NH-C(=0)-C1_5-alkyl, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, -C(=0)-NH2, -C(=O)-NH-CI_5-alkyl, -C(=0)-N(Cj_5-alkyl)2, -Si(phenyl)2[Cl_ 5-alkyl], -S(=O)2-NH2, -S(=0)2-NH-Cj_5-alkyl, -S(=0)2-N(C1_5-alkyl)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, (1,3)-dioxolanyl, pyrazolyl, pyrrolyl, phenyl, furyl (furanyl), thiazolyl, thiadiazolyl, thiophenyl (thienyl), benzyl and phenethyl, whereby the above-mentioned C1_5-alkyl residues can in each case be linear or branched and the cyclic substituents or the cyclic residues of these substituents themselves can be substituted with optionally 1, 2, 3, 4 or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, -OH, -SH, -NH2, -C(=O)-OH, -C,_5-alkyl, -(CH2)-O-C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C-C-Si(CH3)3, -C=C-Si(C2H5)3, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -O-C,_5-alkyl, -0-phenyl, -O-CH2-phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
The substituents can particularly preferably, in each case mutually independently, be selected from the group comprising oxo (=0), thioxo (=S), F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C=C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -CH2-NH2, -CH2-OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -0-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -0-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-0-C(=O)-phenyl, -NH-S(=O)2-CH3, -NH-S(=0)2-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -0-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], -S(=O)2-NH2, -S(=O)2-NH-CH3, -S(=O)2-N(CH3)2, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, (1,3)-dioxolanyl, pyrrolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl, whereby the cyclic substituents or the cyclic residues of these substituents themselves can in each case be substituted with optionally 1, 2, 3, 4, or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the . _..~, .~.~...~ .. _ _,h..
group comprising F, Cl, Br, !, -CN, -NOZ, -OH, -SH, -NH2, -C(=O)-OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C-C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-CZH5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)Z-C2H5: -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2: -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
Provided that one of the above-mentioned substituents has a linear or branched alkylene group, the alkylene group can preferably be selected from the group comprising -(CH2)-, -(CH2)2-, -C(H)(CH3)-, -(CH2)3-, -(CH2)4-, -(CH2)5- and -C(CzHS)(H)-.
An alkylene group can particularly preferably be substituted with 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -NO2, -CN, -OH, -SH, -NH2, -N(CH3)2, -N(C2H5)2 and -N(CH3)(C2H5).
The person skilled in the art will understand that some of the substituted imidazo[2,1-b]thiazole compounds according to the invention of the general formula I can be present in the form of tautomers which are also a subject matter of the present invention and in each case can also be present as active ingredients in the drugs described below.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are preferred, in which R' and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NR6R7; -NH-C(=O)-R8; -C(=O)-R9, -C(=0)-NH2; -C(=0)-NHR10; -C(=O)-NR"R'2; -C(=0)-OR'3; -(CH2)m-C(=O)-OR14 with m = 1, 2, 3, 4 or 5; -O-C(=0)-R15; -(CH2)õ-O-C(=O)-R'6 with n = 1, 2, 3, 4 or 5; -OR";
-(CH2)0-O-R1$ with o = 1, 2, 3; 4 or 5; -SR19; -(CHZ)p S(=O)t-R20 with p = 1, 2, 3, 4 or 5 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NRZ9R30; -SF5; -(CH2)u-O-S(=O)2-with u = 1, 2, 3, 4 or 5; -(CH2)õ-O-S(=O)2-O-R32 with v 1, 2, 3, 4 or 5; -(CH2)w O-P(=O)(OR33)(OR34) with w = 1, 2, 3, 4 or 5; a linear or branched, unsubstituted or at least monosubstituted C1_10-alkyl residue, C2_6-alkenyl residue or C2_6-aikynyl residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic C3_$ residue optionally having at least one heteroatom as a ring member, which residue can be bound via a linear or branched, unsubstituted or at least monosubstituted Cy_5-alkylene group;
or an unsubstituted or at least monosubstituted 5- or 6-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1_5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=0)-R21; -(CH2)q-C(=O)-R22with q = 1, 2, 3, 4 or 5; -C(=0)-O-R23; -(CH2)r-C(=O)-O-R24with r = 1, 2, 3, 4 or 5; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2, 3, 4 or 5; a linear or branched, unsubstituted or at least monosubstituted C,_lo-alkyf residue, C2_6-alkenyl residue or C2_6-alkynyl residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic C3_$ residue optionally having at least one heteroatom as a ring member, which residue can be bound via a linear or branched, unsubstituted or at least monosubstituted Cl_5-alkylene group; or an unsubstituted or at least monosubstituted 5- or 6-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted CI_5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered, or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated, unsubstituted or at least monosubstituted heterocycloaliphatic C4_10 residue optionally having at least one further heteroatom as a ring member which can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R5, R6, R', R8, R'o, R", R12, R15 and R16, in each case mutually independently, denote a linear or branched, unsubstituted or at least monosubstituted C,_lo-alkyl residue, C2_s-alkenyl residue or C2_s-alkynyl residue; or an unsubstituted or at least monosubstituted 5- to 14-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1_5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
Rs R13 R14 R17 R18 Rls Rzo R21 R22 R23 R24 R25 R26 R27 R28 R29 Rso R31 Ra2 R33 and R34, in each case mutually independently, denote a hydrogen residue; a linear or branched, unsubstituted or at least monosubstituted Cl_lo-alkyl residue, CZ_s-alkenyl residue or CZ_s-afkynyl residue; or an unsubstituted or at least monosubstituted 5- to 14-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1_5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
Ml denotes a 5- or 6-membered aryl or heteroaryl residue, which can be substituted with at least one further substituent and can be condensed with an unsubstituted or at least monosubstituted mono- or bicyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered, and and M2 denotes a 5- or 6-membered aryl or heteroaryl residue, which can be unsubstituted or at least monosubstituted and can be condensed with an unsubstituted or at least monosubstituted mono- or bicyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
whereby the above-mentioned cycloaliphatic residues can optionally have 1, 2, 3, 4 or heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur, the above-mentioned heterocycloaliphatic residues can optionally have further 1, 2, 3, 4 or 5 heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur, the rings of the mono- or polycyclic ring system have in each case optionally 0, 1, 2 or 3 heteroatom(s) as (the) ring member(s) which are mutually independently selected from the group comprising oxygen, nitrogen and sulphur;
and the above-mentioned heteroaryl residues can optionally have 1, 2, 3, 4 or 5 heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising oxygen, sulphur and nitrogen.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula I
indicated above are furthermore preferred, in which R' and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NRsR'; -NH-C(=O)-R8; -C(=O)-R9, -C(=0)-NH2; -C(=O)-NHR10; -C(=O)-NR"R'Z; -C(=O)-OR13; -(CH2)m-C(=0)-OR'4 with m = 1, 2 or 3; -O-C(=O)-R15; -(CH2)õ-O-C(=O)-R'6 with n 1, 2 or 3; -OR"; -(CH2)o-O-R'$ with o = 1, 2 or 3; -SR19; -(CH2)P S(=O)t-R20 with p= 1, 2 or 3 and t=
0, 1 or 2;
-NH-S(=O)2-NRz7R28; -S(=O)2-NR29R30; -SF5; -(CH2)õO-S(=O)2-R31 with u= 1, 2 or 3;
-(CHZ)V-O-S(=O)2-O-R32 with v = 1, 2 or 3; -(CH2)W O-P(=O)(OR33)(OR34) with w=
1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl', isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, . _ ^ I _ ____ _ _ .
diazepanyl, azocanyl and dithiolanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, oxo (=0), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)z-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl;
or a residue selected from the group comprising phenyl, benzyl, phenethyl, (3-phenyl)-prop-1-yl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C-C-Si(CH3)3, -C=C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=0)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -0-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=0)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=0)2-CH3, -C(=0)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=0)-C2H5, -O-C(=0)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise preferred, in which R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=0)-R21; -(CH2)4-C(=0)-R22with q = 1, 2 or 3; -C(=O)-O-R23; -(CH2)rC(=O)-O-with r = 1, 2 or 3; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NHZ, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, diazepanyl, azocanyl and dithiolanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, !, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C=C-Si(C2H5)3, -C=C-Si(CH3)3, -C=C-SI(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, oxo (=0), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=0)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -0-C(=0)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl and/or can be bound via a linear or branched C1_3-alkylene group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyt, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C-C-Si(C2H5)3, -CHZ-O-CH3, -O-CZH5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=0)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=0)-NH2, -C(=0)-NH-CH3, -C(=0)-N(CH3)2, -Si(phenyl)2[C(CH3)3], (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl and/or can be bound via a linear or branched C,_3-alkylene group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C=C-Si(C2H5)3, -OH, oxo, thioxo, -0-CH3, -O-C2H5, -O-C3H7, -(CH2)-O-CH3, -(CH2)-O-C2H5, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NO2, -CF3, -O-CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=O)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -NH-S(=0)2-CH3, -C(=0)-OH, -C(=0)-H; -C(=0)-CH3, -C(=O)-C2H5, -C(=O)-N(CH3)2, -C(=0)-NH-CH3, -C(=O)-NH2, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=0)-O-C(CH3)3 and phenyl;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise preferred, in which R5, R6, R7, R8, R10, R", R'2, R'5 and R's, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butya, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-NH-CH3, -(CHZ)-N(CH3)2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3), -(CH2)-(CH2)-(CH2)-OH, -(CH2)-C(=O)-OH, -(CH2)-C(=O)-O-CH3, -(CH2)-C(=O)-O-C2H5, -(CH2)-(CH2)-C(=0)-OH, -(CH2)-(CH2)-C(=0)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -0-C3H7, -C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula I
indicated above are furthermore preferred, in which R13 R14 R17 R18 R19 R20 R21 R22 R23 R24 R25 R26 R27 Rzs R29 R30, R31, R32 R9, , R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-NH-CH3, -(CH2)-N(CH3)2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3), -(CH2)-(CH2)-(CH2)-OH, -(CH2)-C(=O)-OH, -(CH2)-C(=O)-O-CH3, -(CH2)-C(=O)-O-C2H5, -(CH2)-(CH2)-C(=O)-OH, -(CH2)-(CH2)-C(=0)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise preferred, in which M' denotes a residue selected from the group comprising phenyl, furanyl, thiophenyl (thienyl), pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxadiazolyl, triazolyl, diazinyl, triazinyl, tetrazinyl and tetrazolyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=0)-CF3, -S-CF3, -S-CHF2 and -S-CH2F;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
...... _ .__ r Substituted imidazo[2, 1 -b]thiazole compounds of the general formula I
indicated above are furthermore preferred, in which M' denotes a residue selected from the group comprising residues 1 to 38, / \ /o\ / /o\
s / ~
S S o N-N N-N
"==\ N~
N -,, N~~ N
N~~ N N
N.~ " /"~
N / ", ",%
N
/
_ N- -N
\ "
/
N
~
N N
N N
N-~ N
N N=N
N '--'\
N N~ N
N-N ~f --/N N~~
N N N-N
33 ~ 34 35 36 N-O
37 5.~V 38 which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=0)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -0-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are furthermore preferred, in which M2 denotes a residue selected from the group comprising phenyl, furanyl, thiophenyl (thienyl), pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, oxadiazolyl, triazolyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, pentazolyl, imidazolyl, quinolinyl, isoquinolinyl, naphthyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl and isobenzothiophenyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C=C-Si(CzH5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHFz, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], -CH2-NH2, pyrrolyi, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, -S(=O)2-N(CH3)2, (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise preferred, in which M2 denotes a residue selected from the group comprising residues 1 to 36, , . .... .. . _~
N - O
s O
N N-N O-N N-O
O O < ~ N
O
N- N
N N N N H
~ J I ~ ~ N i/
J~
N N ~
N N H\) -N N~ " "
C\N
\ / "J S
W
/~ "
S ~
"" ,~ N~
J~
N
y H H
N
.ss~
_...~.,. ......
.._.. ^ .~r~i^
which in each case can be linked via the position marked by a wavy line with the carbon atom of the triple bond and can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -0-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=0)-CH3, -C(=0)-C2H5, NH-S(=0)2-CH3, -NH-S(=0)2-C2H5, -S(=O)2-NH2, -S(=O)Z-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are particularly preferred, in which R' and R2, mutually independently, in each case denote a hydrogen residue; -F;
-Cl; -Br; -I; -NO2; -CN; -NH2; -NHR5; -NR6R'; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR'o; -C(=O)-NR"R12; -C(=O)-OR13; -(CH2)m-C(=0)-OR14 with m= 1, 2 or 3; -O-C(=O)-R15;
-OR"; -(CHz)o-O-R'$ with o 1, 2 or 3; -S(=0)2-NH2; -SF5; -(CH2)õ-O-S(=O)2-R31 with u = 1, 2 or 3; -(CH2),-O-S(=O)2-O-R32 with v = 1, 2 or 3; -(CH2)w O-P(=O)(OR33)(OR34) with w = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CFZ)-(CF3); a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which in each case can be ,~,.,..
unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, oxo (=0), thioxo (=S), -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F;
or a residue selected from the group comprising phenyl, benzyl, phenethyl, (3-phenyl)-prop-1-yl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -0-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22with q = 1, 2 or 3; -C(=O)-O-R23; -(CH2)r-C(=O)-O-with r = 1, 2 or 3; -C(=0)-NHR25; -(CH2)s-C(=0)-NHR26 with s = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, oxo (=0), thioxo (=S), -O-CH3, -O-C2H5, -O-and -0-C(CH3)3 and/or can be bound via a linear or branched Cl_3-alkylene group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, -OH, -SH, -SF5, -NH2, -C(=0)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHFz, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, cyclopropyl, cyclobutyl and cyclopentyl and/or can be bound via a linear or branched C1_3-alkylene group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, -OH, oxo, thioxo, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NOz, -CF3, -O-CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=O)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-N(CH3)2, -C(=0)-NH-CH3, -C(=O)-NH2, -C(=0)-O-CH3, -C(=0)-O-CZH5, -C(=0)-O-C(CH3)3 and phenyl;
R5, Rs, R', R'o, R11 R1z, R15 and R's, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFHz, -(CH2)-(CHF2), -(CH2)-(CH2F), -(CF2)-(CF3), -(CH2)-(CH2)-C(=0)-OH, -(CH2)-(CH2)-C(=0)-O-CH3 and -(CH2)-(CH2)-C(=0)-O-C2H5; or denote a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, CI, Br, I, -CN, -NOz, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, -SH, -SF5, -NH2, -C(=0)-OH, -S-CH3, -S-C2H5, -O-CH3, -C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -0-CHF2, -O-CH2F and -C(=0)-CF3;
Rs R1s' R14 R,7 R1s R21 Rzz Rza Rza Rz5 Rzs Rs' R3z, R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the .~..._.w ....... w,.
group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyi, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -0-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F and -C(=O)-CF3;
M' denotes a residue selected from the group comprising residues 1 to 9, 11, 21, 22 and 36 to 38, ~O A\--/ ~ ~ ~ ~
S ~ -O
, ~\
NS "
S ~ O ~ 0 N ~
\ /
N
~,,, N
which in each case can be unsubstituted or substituted with optionally 1 or 2 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=0)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)Z-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising residues 1 to 36, N - O
/S\ ~O~
~~
O \ ~ \N\ ~ N) O
N,N
N N N N H
~/ ~/~
N N I /N
N
N N~N ~ D
~ N
N
~
- N N~ N
~ / N ~--<\ ~N S/ (/ \
N S
s ~' H
N N N N
~
/~ VI
S ~ I
H
N NN ssr' N~ N
H
N N
\ N~ \ ~
which in each case can be linked via the position marked by a wavy line with the carbon atom of the triple bond and can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyt, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=0)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=0)2-N(CH3)2;
in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are very particularly preferred, in which R' and R 2, mutually independently, in each case denote a hydrogen residue; -F; -Cl; -Br; -I; -NO2; -CN; -NHR5; -NR6R'; -C(=O)-R9, -C(=O)-OR13; -(CH2)-O-C(=O)-R'6; -OR1'; -(CH2)-O-S(=O)2-R3'; -(CH2)-O-S(=O)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR3a); -SF5; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
or a residue selected from the group comprising phenyl, benzyl, phenethyl and (3-phenyl)-prop-1-yl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2 or 3-1 -(CH2)rC(=O)-O-R24 with r =
1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which can be bound via a-(CH2)-, -(CH2)2-, -(CH(CH3))- or -(CH2)3 group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F and/or can be bound via a-(CH2)-, -(CH2)2-, -(CH(CH3))- or -(CH2)3 group;
,. -or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, -S(=0)-CH3, -S(=O)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -C(=O)-CH3, -C(=0)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -C(=O)-O-CH3, -C(=O)-O-C2H5 and -C(=O)-O-C(CH3)3;
R5, R6, R' and R16, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CHF2), -(CH2)-(CH2F), -(CF2)-(CF3), -(CHZ)-(CH2)-C(=O)-OH; -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl and phenethyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3 and -O-CZH5;
R9, R13 R" R2, R22 R2a Rs, Rs2 R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); or a residue selected from the group comprising phenyl, benzyl and phenethyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl,-O-CH3 and -O-CZH5;
M' denotes a residue selected from the group comprising residues 1 to 6, 21, 22, 36 and 37, fs S O O
N
-<~ "
~-~S
~N
N
which in each case can be unsubstituted or substituted with optionally 1 or 2 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -SF5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl, 4-thiazolyi, 5-thiazolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl and 8-quinolinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -.. .,...~..
Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=0)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=0)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula Ia are likewise very particularly preferred, Rl S-N S 35 N% / 'X I
R3 ,N, R4 Ia, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R35 and R36, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=0)-CH3, -C(=0)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=0)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=0)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b)thiazole compounds of the general formula lb are likewise very particularly preferred S N
R' \N
S /
R 3,N, R4 Ib, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R37 and R38, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=0)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=0)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionaily in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula Ic are likewise very particularly preferred R~ S ~N S Rao XN ~
Ic, in which R', RZ, R3 and R4 have the above-mentioned meaning, and R39 and R40, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
....,. ~.
Substituted imidazo[2,1-b]thiazoie compounds of the general formula Id are likewise very particularly preferred, ~ I
R' S N S
N
\ ~
R R
Id, in which R', R2, R3 and R4 have the above-mentioned meaning, and R41 and R42, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula le are likewise very particularly preferred, R' S N S N
N
le, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R43 and R44, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3J, -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
:....-,_,...-.~.. ,....._..._.._..... _..-, Substituted imidazo[2, 1 -b]thiazole compounds of the general formula If are likewise very particularly preferred, R, S N S R46 N
R
R3 ,N_R4 If, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R45 and R46, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=0)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=0)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=0)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula Ig are likewise very particularly preferred, N~
R4s R' S 'N S N
X N 'X X I
N~Ra R
Ig, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R47 and R48, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=0)-CH3, -C(=0)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=0)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula Ih are likewise very particularly preferred, u..__..... _ ...
~N.. ..~,~.
R~ S ?NN ~ S- ~ Rso g R3'N", R4 Ih, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R49 and R50, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-CZH5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formulae Ia, Ib, Ic, Id, le, If, Ig and Ih indicated above are even further preferred, in which R' denotes a hydrogen residue; -F; -CI; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
_.4....,..- ._..-..._,__... ,....,....~..,.
R2 denotes a hydrogen residue; -F; -CI; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R3 denotes a hydrogen residue;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl;
R13 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl and (2,4,4)-trimethyl-pent-2-yl;
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl or a phenyl residue which is in each case unsubstituted;
and R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49 and R50, mutually independently in each case denote a residue selected from the group comprising F, Cl, Br, -CN, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise very particularly preferred, in which R' denotes a hydrogen residue; -F; -Cl; -Br; -CN; -O-CH3; -C(=O)-R9, -C(=O)-ORi3; -(CH2)-O-C(=O)-R16; -(CH2)-O-S(=O)2-R31; -(CH2)-O-S(=O)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR34); or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-.(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), and -(CF2)-(CF3);
R2 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -O-CH3; -C(=O)-R9, -C(=O)-OR13; -(CH2)-O-C(=O)-R16; -(CH2)-O-S(=0)2-R31; -(CH2)-O-S(=0)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR34); or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CHZ)-(CHF2), -(CH2)-(CH2F), and -(CF2)-(CF3);
R3 denotes a hydrogen residue or a residue selected from the group comprising methyl, ethyl and isopropyl;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising pyrrolidinyl, piperidinyl and morpholinyl;
R16 denotes a residue selected from the group comprising -(CH2)-(CH2)-C(=O)-OH; -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5;
R9, R13, R3', R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3);
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3) or a phenyl residue, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl,-O-CH3 and -O-C2H5;
M' denotes a residue selected from the group comprising residues 1, 3, 5, 36 and 37, :S) S O
which in each case is unsubstituted, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
M2 denotes a residue selected from the group comprising phenyl, 2-pyrimidinyl, pyrimidinyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl and 4-thiazolyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, CI, Br, -CN, -O-CH3, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula I
indicated above are likewise very particularly preferred, in which R' denotes a hydrogen residue; -F; -CI; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R2 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R3 denotes a hydrogen residue;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl;
R13 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl and (2,4,4)-tri methyl-pent-2-yl;
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl or a phenyl residue which in each case is unsubstituted;
M' denotes a residue selected from the group comprising residues 1, 3, 5 and 22, N _~
~s /
\~s V /O ~" N
which in each case is unsubstituted, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising phenyl, 2-pyrimidinyl, 5-pyrimidinyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-pyridinyl, 3-pyridinyl, M_ ~
_...w, -~._ .. _.. r -..
4-pyridinyl, 2-thiazolyl and 4-thiazolyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -O-CH3, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are still further preferably selected from the group comprising [1] 6-(5-(phenylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)-imidazo[2,1-b]thiazole-5-amine, [2] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [3] N-tert-butyl-3-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride, [4] N-tert-butyl-2-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [5] N-tert-butyl-2,3-dimethyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride, [6] N-tert-butyl-2-chloro-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride, [7] N-tert-butyl-6-(5-(pyridine-4-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [8] 5-(tert-butylamino)-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-2-carboxylic acid methylester hydrochloride and [9] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiazole-2-yl)imidazo[2,1-b]thiazole-5-amine;
Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethylpent-2-yl, -C(H)(C2H5)2, -C(H)(n-C3H7)2 and -CH2-CH2-C(H)(CH3)-(CH2)3-CH3 are cited as examples of suitable Cl_lo-alkyl residues, which can be unsubstituted or monosubstituted or multiply substituted.
Multiply substituted alkyl residues should be understood as such alkyl residues which are multiply substituted either at different or at the same C-atoms, preferably twice or three times, for example, three times at the same C-atom as in the case of -CF3 or at various points as in the case of -(CHCI)-(CH2F). Multiple substitution can be performed with the same or with different substituents. -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH are cited as examples of suitable substituted alkyl residues.
Ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, pentenyl, 3-pentenyl, 4-pentenyl, hexenyl, -CH=CH-CH=CH-CH3 and -CH2-CH2-CH=CH2 are cited as examples of suitable C2_6-alkenyl residues.
Multiply substituted alkenyl residues should be understood as such alkenyl residues which are multiply substituted either at different or at the same C-atoms, preferably twice, for example, twice at the same C-atom as in the case of -CH=CCI2 or at different points as in the case of -CCI=CH-(CH2)-NH2. Multiple substitution can be performed with the same or with different substituents. -CH=CH-(CH2)-OH, -CH=CH-(CH2)-NH2 and -CH=CH-CN are cited as examples of suitable substituted alkenyl residues.
Ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, pentynyl, 3-pentynyl, 4-pentynyl and hexynyl are cited as examples of suitable C2_6-alkynyl residues.
, GRA3336PCT
Multiply substituted alkynyl residues should be understood as such alkynyl residues which are multiply substituted either at different C-atoms, for example, twice at different C-atoms as in the case of -CHCI-C=CCI. -C=C-F, -C=C-CI and -C=C-I
are cited as examples of suitable substituted alkynyl residues.
Provided that one or more of the above-mentioned substituents denotes a cycloaliphatic residue or has a cycloaliphatic residue which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3 substituents, which can be mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, -OH, -SH, -SF5, -NH2, oxo (=0), thioxo (=S), -C(=O)-OH, C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -(CH2)-O-C1_5-alkyl, -S-C1_5-alkyl, -S-phenyl, -phenyl, -O-C1_5-alkyl, -0-phenyl, -O-CH2-phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, -S(=O)2-C1_ 5-alkyl, -S(=O)-C1_5-alkyl, -NH-C1_5-alkyl, N(C1_5alkyl)(C1-5-alkyl), -C(=O)-O-C1_5-alkyl, -C(=O)-H, -C(=O)-C1_5-alkyl, -CH2-O-C(=O)-phenyl, -O-C(=0)-phenyl, -NH-S(=O)2-C1_ 5-alkyl, -NH-C(=O)-C1_5-alkyl, -C(=O)-NH2, -C(=O)-NH-C1_5-alkyl, -C(=O)-N(C1_5-alkyl)2, pyrazolyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl, whereby the above-mentioned C1_5-alkyl residues can in each case be linear or branched and the cyclic substituents or the cyclic residues of these substituents themselves can in each case be substituted with optionally 1, 2, 3, 4 or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -O-C1_5-alkyl, -0-phenyl, -0-CH2-phenyl, -(CH2)-O-C1_5-alkyl, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C(=O)-O-C1-5-alkyl and -C(=0)-CF3.
The substituents can particularly preferably be, in each case mutually independently, selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -CH2-O-CH3, -CH2-O-CZH5, -OH, -SH, -SF5, -NH2, oxo (=0), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=0)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -0-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -0-CHF2, -O-CH2F, -C(=0)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=0)-C2H5, -NH-C(=O)-CH3, -NH-C(=0)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl, whereby the cyclic substituents or the cyclic residues of these substituents themselves can be substituted with optionally 1, 2, 3, 4 or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -O-CH3, -O-C2H5, -O-C3H7, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C(=0)-O-Cj_5-alkyl and -C(=O)-CF3.
Provided that the cycloaliphatic residues have one or more heteroatoms as ring members, these can preferably have optionally 1, 2, 3, 4 or 5, particularly preferably 1, 2 or 3 heteroatom(s) as (the) ring member(s), which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur.
Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, oxiranyl, aziridinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, isothioazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, (1,2,4)-oxadiazolidinyl, (1,2,4)-thiadiazolidinyl, (1,2,4)-triazolidin-3-yl, (1,3,4)-thiadiazolidinyl, (1,3,4)-triazolidin-1-yl, (1,3,4)-triazolidin-2-yl, (2,3)-dihydrofuryl, (2,5)-dihydrofuryl, (2,3)-dihydrothienyl, (2,5)-dihydrothienyl, (2,3)-dihydropyrrolyl, (2,5)-dihydropyrrolyl, (2,3)-dihydroisoxazolyl, (4,5)-dihydroisoxazolyl, (2,5)-dihydroisothiazolyl, (2,3)-dihydropyrazolyl, (4,5)-dihydropyrazolyl, (2,5)-dihydropyrazolyl, (2,3)-dihydrooxazolyl, (4,5)-dihydrooxazolyl, (2,5)-dihydrooxazolyl, (2,3)-dihydrothiazolyl, (4,5)-dihydrothiazolyl, (2,5)-dihydrothiazolyl, (2,3)-dihydroimidazolyl, (4,5)-dihydroimidazolyl, (2,5)-dihydroimidazolyl, morpholinyl, piperidinyl, piperazinyl, azocanyl, tetrahydropyridazinyl, tetrahydropyrimidinyl, tetra hyd ro pyrazi nyl, (1,3,5)-tetrahydrotriazinyl, (1,2,4)-tetrahydrotriazin-1-yl, (1,2,4)-tetrahydrotriazin-3-yl, (1,3)-dihydrooxazinyl, (1,3)-dithian-2-yl, tetrahydropyranyl, (1,3)-dioxolan-2-yl, (3,4,5,6)-tetrahydropyridin-2-yl, (1,2,5,6)-tetrahydropyridin-1-yl, (1,2,3,4)-tetrahydropyridin-1-yl, (1,2)-dihydropyridin-1-yl, (1,4)-dihydropyridin-1-yl, 4H-1,3-thiazinyl, (1,3)-dihydrooxazin-2-yl, azepanyl, (1,4)-diazepanyl, thiomorpholinyl and dithiolanyl are cited as examples of cycloaliphatic residues which can be monosubstituted or multiply substituted.
Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetra hyd roth i ophe nyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, diazepanyl, azocanyl and dithiolanyl are particularly preferably cited as cycloaliphatic residues which can be monosubstituted or multiply substituted.
Provided that the cycloaliphatic residue is condensed with an unsubstituted or at least monosubstituted, saturated, unsaturated or aromatic mono- or polycyclic ring system, suitable unsubstituted or at least monosubstituted residues can be selected from the group comprising 2,3-dihydro-benzo[1,4]dioxinyl; 3,4-dihydro-2H-benzo[1,4]oxazinyl; benzo[1,3]dioxolyl; (1,2,3,4)-tetrahydroquinazolinyl;
indanyl;
(1,2,3,4)-tetrahydronaphthyl; 1H-indenyl; (1,2,3,4)-tetrahydroquinolinyl;
(1,2,3,4)-tetrahydroisoquinolinyl; (2,3)-dihydro-1 H-indolyl, (2,3)-dihydro-1 H-isoindolyl and decahydroisoquinolinyl.
Provided that two of the above-mentioned substituents together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated heterocycloaliphatic residue which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -SF5, -O-C1_5-alkyl, -0-phenyl, -O-CH2-phenyl, -(CH2)-O-C1_5-alkyl, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -C1_5-alkyl, -C2_5-alkenyl, -C2-5-alkynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C(=O)-O-C1-5-alkyl, -C(=O)-CF3, -S(=O)2-C1_5-alkyl, -S(=O)-C1_5-alkyl, -S(=O)2-phenyl, oxo (=0), thioxo (=S), -N(C1_5-alkyl)2, -N(H)(C1_5-alkyl), -NO2, -S-CF3, -C(=O)-OH, -NH-S(=0)2-C1_5-alkyl, -NH-C(=O)-C1_5-alkyl, -C(=O)-H, -C(=O)-C1_5-alkyl, -C(=O)-NH2, -C(=O)-N(C1_5-alkyl)2, -C(=O)-N(H)(C1_5-alkyl) and phenyl, whereby the above-mentioned C1_ 5-alkyl residues can in each case be linear or branched and the phenyl residues can in each case be unsubstituted or substituted with 1, 2, 3, 4 or 5, preferably with 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -O-C,_5-alkyl, -0-phenyl, -O-CH2-phenyl, -(CH2)-O-C1_5-alkyl, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C(=O)-O-C1_5-alkyl and -C(=O)-CF3.
The substituents can particularly preferably, in each case mutually independently, be selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C-C-SI(CH3)3, -C=C-SI(C2H5)3, -OH, oxo, thioxo, -O-CH3, -O-CZHS, -O-C3H7, -(CH2)-O-CH3, -(CH2)-O-C2H5, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NO2, -CF3, -CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -NH-S(=O)2-CH3, -C(=O)-OH, -C(=O)-H; -C(=O)-CH3, -C(=0)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3 and phenyl, whereby the phenyl residue can be substituted with 1, 2, 3, 4 or 5, preferably 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CF3, -OH, -NH2, -O-CF3, -SH, -0-CH3, -O-C2H5, -O-C3H7, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C-C-Si(C2H5)3, -C(=0)-O-Cj_5-alkyl and -C(=O)-CF3.
Provided that the heterocycloaliphatic residues have one or more further heteroatoms as ring members, these can preferably have optionally 1, 2, 3, 4 or 5, particularly preferably optionally 1, 2 or 3, further heteroatom(s) as (the) ring member(s), which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur.
Imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl are cited as examples of suitable heterocycloaliphatic residues which can be monosubstituted or multiply substituted.
Provided that the heterocycloaliphatic residue is condensed with an unsubstituted or at least monosubstituted, saturated, unsaturated or aromatic mono- or polycyclic ring system, suitable unsubstituted or at least monosubstituted residues can be selected from the group comprising (3,4)-dihydro-2H-benzo[1,4]oxazinyl; (1,2,3,4)-_ ~.
tetrahydroquinazolinyl; (1,2,3,4)-tetrahydroquinolinyl; (1,2,3,4)-tetrahydroisoquinolinyl, (2,3)-dihydro-1 H-indolyl, (2,3)-dihydro-1 H-isoindolyl and decahydroisoquinolinyl.
Provided that one or more of the above-mentioned substituents denotes an aryl or heteroaryl residue or has an aryl or heteroaryl residue, which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, -OH, -SH, -SF5, -NH2, -CH2-NH2, -C(=O)-OH, -C,_5-alkyl, -(CH2)-O-C1_5-alkyl, -CH2-OH, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-Si(CH3)3, -C-C-Si(C2H5)3, -S-Cl_5-alkyl, -S-phenyl, -S-CH2-phenyl, -O-C,_5-alkyl, -0-phenyl, -O-CH2-phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, -S(=O)2-C1_5-alkyl, -S(=O)-C1_5-alkyl, -NH-C1_5-alkyl, N(C1_5alkyl)2, -C(=O)-O-Cj_5-alkyl, -C(=O)-H; -C(=O)-C1_5-alkyl, -CH2-O-C(=O)-phenyl, -O-C(=O)-phenyl, -NH-S(=O)2-C1_5-alkyl, -NH-C(=O)-C1_5-alkyl, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, -C(=O)-NH2, -C(=O)-NH-C1_5-alkyl, -C(=O)-N(C1_5-alkyl)2, -Si(phenyl)2[C1_5-alkyl], -S(=O)2-NH2, -S(=O)2-NH-Cj_5-alkyl, -S(=O)2-N(C1_5-aIkyl)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, (1,3)-dioxolanyl, pyrazolyl, pyrrolyl, phenyl, furyl (furanyl), thiazolyl, thiadiazolyl, thiophenyl (thienyl), benzyl and phenethyl, whereby the above-mentioned C1_5-alkyl residues can in each case be linear or branched and the cyclic substituents or the cyclic residues of these substituents themselves can be substituted with optionally 1, 2, 3, 4 or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, -OH, -SH, -NH2, -C(=0)-OH, -Cl_5-alkyl, -(CH2)-O-C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C-C-Si(CH3)3, -C=C-Si(C2H5)3, -S-C,_5-alkyl, -S-phenyl, -S-CH2-phenyl, -O-C1_5-alkyl, -0-phenyl, -phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
The substituents can particularly preferably be selected in each case mutually independently from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C-C-Si(CH3)3, -C-C-Si(C2H5)3, -CH2-O-CH3, -O-C2H5, -OH, -CH2-NH2, -CH2-OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=0)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -0-CH3, -0-C2H5, -0-C3H7, -C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -0-CHF2, -0-CH2F, -C(=0)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyi, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -NH-S(=0)2-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=0)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -0-C(=0)-phenyl, -C(=0)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], -S(=O)2-NH2, -S(=O)2-NH-CH3, -S(=O)2-N(CH3)2, -NH-C(=NH)-NH2, -NH-S(=0)2-OH, (1,3)-dioxolanyl, pyrrolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyi, thiophenyl (thienyl) and benzyl, whereby the cyclic substituents or the cyclic residues of these substituents themselves can be substituted in each case with optionally 1, 2, 3, 4, or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, -OH, -SH, -NH2, -C(=O)-OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C-C-Si(CH3)3, -C=C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
A substituted aryl residue can very particularly preferably be selected from the group comprising 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 2-fluoro-phenyl, fluoro-phenyl, 4-fluoro-phenyl, 2-cyano-phenyl, 3-cyano-phenyl, 4-cyano-phenyl, 2-hydroxy-phenyl, 3-hydroxy-phenyl, 4-hydroxy-phenyl, 2-amino-phenyl, 3-amino-phenyl, 4-amino-phenyl, 2-dimethylamino-phenyl, 3-dimethylamino-phenyl, 4-dimethylamino-phenyl, 2-methylamino-phenyl, 3-methylamino-phenyl, 4-methylamino-phenyl, 2-acetyl-phenyl, 3-acetyl-phenyl, 4-acetyl-phenyl, 2-methylsulfinyl-phenyl, 3-methylsulfinyl-phenyl, 4-methylsulfinyl-phenyl, 2-methylsulfonyl-phenyl, 3-methylsulfonyl-phenyl, 4-methylsulfonyl-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2-chloro-phenyl, 3-chloro-phenyl, chloro-phenyl, 2-ethoxy-phenyl, 3-ethoxy-phenyl, 4-ethoxyphenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 2-difluoromethyl-phenyl, 3-difluoromethyl-phenyt, 4-difluoromethyl-phenyl, 2-fluoromethyl-phenyl, 3-fluoromethyl-phenyl, 4-fluoromethyl-phenyl, 2-nitro-phenyl, 3-nitro-phenyl, 4-nitro-phenyl, 2-ethyl-phenyl, 3-ethyl-phenyl, 4-ethyl-phenyl, 2-propyl-phenyl, 3-propyl-phenyl, 4-propyl-phenyl, 2-isopropyl-phenyl, 3-isopropyl-phenyl, 4-isopropyl-phenyl, 2-tert-butyl-phenyl, 3-tert-butyl-phenyl, 4-tert-butyl-phenyl, 2-carboxyphenyl, 3-carboxy-phenyl, 4-carboxyphenyl, 2-ethenyl-phenyl, 3-ethenyl-phenyl, 4-ethenyl-phenyl, 2-ethynyl-phenyl, 3-ethynyl-phenyl, 4-ethynyl-phenyl, 2-allyl-phenyl, 3-allyl-phenyl, 4-allyl-phenyl, 2-trimethylsilanylethinyl-phenyl, 3-trimethylsilanylethinyl-phenyl, 4-trimethylsilanylethinyl-phenyl, 2-formyl-phenyl, 3-formyl-phenyl, 4-formyl-phenyl, 2-acetamino-phenyl, 3-acetamino-phenyl, 4-acetamino-phenyl, 2-dimethylaminocarbonyl-phenyl, 3-dimethylaminocarbonyl-phenyl, 4-dimethylaminocarbonyl-phenyl, 2-methoxymethyl-phenyl, 3-methoxymethyl-phenyl, 4-methoxymethyl-phenyl, 2-ethoxymethyl-phenyl, 3-ethoxymethyl-phenyl, 4-ethoxymethyl-phenyl, 2-aminocarbonyl-phenyl, 3-aminocarbonyl-phenyl, 4-aminocarbonyl-phenyl, 2-methylaminocarbonyl-phenyl, 3-methylaminocarbonyl-phenyl, 4-methylaminocarbonyl-phenyl, 2-carboxymethylester-phenyl, 3-carboxymethylester-phenyl, 4-carboxymethylester-phenyl, 2-carboxyethylester-phenyl, 3-carboxyethylester-phenyl, 4-carboxyethylester-phenyl, 2-carboxy-tert-butylester-phenyl, 3-carboxy-tert-butylester-phenyl, 4-carboxy-tert-butylester-phenyl, 2-methylmercapto-phenyl, 3-methylmercapto-phenyl, 4-methylmercapto-phenyl, 2-ethylmercapto-phenyl, 3-ethylmercapto-phenyl, 4-ethylmercaptophenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodo-phenyl, 3-iodophenyl, 4-iodophenyl, 2-trifluoromethoxy-phenyl, 3-trifluoromethoxy-phenyl, 4-trifluoromethoxy-phenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-4-methyl-phenyl, (2,3)-difluorophenyl, (2,3)-dimethyl-phenyl, (2,3)-dichlorophenyl, 3-fluoro-2-trifluoromethylphenyl, (2,4)-dichloro-phenyl, (2,4)-difluorophenyl, 4-fluoro-2-trifluoromethyl-phenyl, (2,4)-dimethoxyphenyl, 2-chloro-4-fluoro-phenyl, 2-chloro-4-nitro-phenyl, 2-chloro-4-methyl-phenyl, 2-chloro-5-trifluoromethyl-phenyl, 2-chloro-5-methoxy-phenyl, 2-bromo-5-trifluoromethyl-phenyl, 2-bromo-5-methoxy-phenyl, (2,4)-dibromo-phenyl, (2,4)-dimethyl-phenyl, 2-fluoro-4-trifluoromethyl-phenyl, (2,5)-difluoro-phenyl, 2-fluoro-5-trifluoromethyl-phenyl, 5-fluoro-2-trifluoromethyl-phenyl, 5-chloro-2-trifluoromethyl-phenyl, 5-bromo-2-trifluoromethyl-phenyl, (2,5)-dimethoxy-phenyl, (2,5)-bis-trifluoromethyl-phenyl, (2,5)-dichloro-phenyl, (2,5)-dibromo-phenyl, 2-methoxy-5-nitro-phenyl, 2-fluoro-6-trifluoromethyl-phenyl, (2,6)-dimethoxy-phenyl, (2,6)-dimethyl-phenyl, (2,6)-dichloro-phenyl, 2-chloro-6-fluoro-phenyl, '2-bromo-6-chloro-phenyl, 2-bromo-6-fluor-phenyl, (2,6)-difluoro-phenyl, (2,6)-difluoro-3-methyl-phenyl, (2,6)-dibromo-phenyl, (2,6)-dichlorophenyl, 3-chloro-2-fluoro-phenyl, chloro-5-methyl-phenyl, (3,4)-dichlorophenyl, (3,4)-dimethyl-phenyl, 3-methyl-methoxy-phenyl, 4-chloro-3-nitro-phenyl, (3,4)-dimethoxy-phenyl, 4-fluoro-3-trifluoromethylphenyl, 3-fluoro-4-trifluoromethyl-phenyl, (3,4)-difluoro-phenyl, 3-cyano-4-fluoro-phenyl, 3-cyano-4-methyl-phenyl, 3-cyano-4-methoxy-phenyl, 3-bromo-4-fluoro-phenyl, 3-bromo-4-methyl-phenyl, 3-bromo-4-methoxy-phenyl, 4-chloro-2-fluoro-phenyl, 4-chloro-3-trifluoromethyl, 4-bromo-3-methyl-phenyl, 4-bromo-5-methyl-phenyl, 3-chloro-4-fluoro-phenyl, 4-fluoro-3-nitro-phenyl, 4-bromo-3-nitro-phenyl, (3,4)-dibromo-phenyl, 4-chloro-3-methyl-phenyl, 4-bromo-3-methyl-phenyl, 4-fluoro-3-methyl-phenyl, 3-fluoro-4-methyl-phenyl, 3-fluoro-5-methyl-phenyl, 2-fluoro-3-methyl-phenyl, 4-methyl-3-nitro-phenyl, (3,5)-dimethoxy-phenyl, (3,5)-dimethyl-phenyl, (3,5)-bis-trifluoromethyl-phenyl, (3,5)-difluoro-phenyl, (3,5)-dinitro-phenyl, (3,5)-dichloro-phenyl, 3-fluoro-5-trifluoromethyl-phenyl, 5-fluoro-3-trifluoromethyl-phenyl, (3,5)-dibromo-phenyl, 5-chloro-4-fluoro-phenyl, 5-chloro-4-fluoro-phenyl, 5-bromo-4-methyl-phenyl, (2,3,4)-trifluorophenyl, (2,3,4)-trichlorophenyl, (2,3,6)-trifluoro-phenyl, 5-chloro-2-methoxy-phenyl, (2,3)-difluoro-4-methyl, (2,4,5)-trifluoro-phenyl, (2,4,5)-trichloro-phenyl, (2,4)-dichloro-5-fluoro-phenyl, (2,4,6)-trichloro-phenyl, (2,4,6)-trimethylphenyl, (2,4,6)-trifluoro-phenyl, (2,4,6)-trimethoxy-phenyl, (3,4,5)-trimethoxy-phenyl, (2,3,4,5)-tetrafluoro-phenyl, 4-methoxy-(2,3,6)-trimethyl-phenyl, 4-methoxy-(2,3,6)-trimethyl-phenyl, 4-chloro-2,5-dimethyl-phenyl, 2-chloro-6-fluoro-3-methyl-phenyl, 6-chloro-2-fluoro-3-methyl, (2,4,6)-trimethylphenyl and (2,3,4,5,6)-pentafluoro-phenyl.
A substituted heteroaryl residue can very particularly preferably be selected from the group comprising 3-methyl-pyrid-2-yl, 4-methyl-pyrid-2-yl, 5-methyl-pyrid-2-yi, 6-methyl-pyrid-2-yl, 2-methyl-pyrid-3-yl, 4-methyl-pyrid-3-yl, 5-methyl-pyrid-3-yl, 6-methyl-pyrid-3-yl, 2-methyl-pyrid-4-yl, 3-methyl-pyrid-4-yi, 3-fluoro-pyrid-2-yi, 4-fluoro-pyrid-2-yl, 5-fluoro-pyrid-2-yl, 6-fluoro-pyrid-2-yl, 3-chloro-pyrid-2-yl, 4-chloro-pyrid-2-yl, 5-chloro-pyrid-2-yl, 6-chloro-pyrid-2-yl, 3-trifluoromethyl-pyrid-2-yl, 4-trifluoromethyl-pyrid-2-yl, 5-trifluoromethyl-pyrid-2-yl, 6-trifluoromethyl-pyrid-2-yl, 3-methoxy-pyrid-2-yl, 4-methoxy-pyrid-2-yl, 5-methoxy-pyrid-2-yl, 6-methoxy-pyrid-2-yl, 4-methyl-thiazole-2-yl, 5-methyl-thiazole-2-yl, 4-trifluoromethyl-thiazole-2-yl, 5-trifluoromethyl-thiazole-2-yl, 4-chloro-thiazole-2-yl, 5-chloro-thiazole-2-yl, 4-bromo-thiazole-2-yl, 5-bromo-thiazole-2-yl, 4-fluoro-thiazole-2-yl, 5-fluoro-thiazole-2-yl, 4-cyano-thiazole-2-yl, 5-cyano-thiazole-2-yi, 4-methoxy-thiazole-2-yl, 5-methoxy-thiazole-2-yl, 4-methyl-oxazole-2-yi, 5-methyl-oxazole-2-yl, 4-trifluoromethyl-oxazole-2-yl, 5-trifluoromethyl-oxazole-2-yl, 4-chloro-oxazole-2-yl, 5-chloro-oxazole-2-yl, 4-bromo-oxazole-2-yl, 5-bromo-oxazole-2-yl, 4-fluoro-oxazole-2-yl, 5-fluoro-oxazole-2-yl, 4-cyano-oxazole-2-yl, 5-cyano-oxazole-2-yl, 4-methoxy-oxazole-2-yl, 5-methoxy-oxazole-2-yl, 2-methyl-(1,2,4)-thiadiazole-5-yl, 2-trifluoromethyl-(1,2,4)-thiadiazole-5-yl, 2-chloro-(1,2,4)-thiadiazole-5-yl, 2-fluoro-(1,2,4)-thiadiazole-5-yl, 2-methoxy-(1,2,4)-thiadiazole-5-yl, 2-cyano-(1,2,4)-thiadiazole-5-yl, 2-methyl-(1,2,4)-oxadiazole-5-yl, 2-trifluoromethyl-(1,2,4)-oxadiazole-5-yl, 2-chloro-(1,2,4)-oxadiazole-5-yl, 2-fluoro-(1,2,4)-oxadiazole-5-yl, 2-methoxy-(1,2,4)-oxadiazole-5-yI and 2-cyano-(1,2,4)-oxadiazole-5-yl.
Phenyl, 1-naphthyl, 2-naphthyl and anthracenyl are cited as examples of suitable aryl residues. A suitable 6-membered aryl residue is a phenyl residue.
Provided that one or more of the above-mentioned substituents denotes a heteroaryl residue or has a heteroaryl residue, the heteroatom(s) thereof can, in each case mutually independently, preferably be selected from the group comprising oxygen, sulphur and nitrogen. A heteroaryl residue can preferably have optionally 1, 2, 3, 4 or 5, particularly preferably 1, 2 or 3 heteroatoms.
Furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl and pentazolyl are cited as examples of suitable 5- or 6-membered heteroaryl residues.
Indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl are cited as examples of suitable 9- or 10-membered heteroaryl residues.
Aryl or heteroaryl residues can, within the meaning of the present invention, be condensed (annelated) with a mono- or bicyclic ring system.
Provided that the 5- or 6-membered heteroaryl residue is condensed with an unsubstituted or at least monosubstituted aromatic mono- or polycyclic ring system, suitable unsubstituted or at least monosubstituted residues can be selected from the group comprising indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl.
(1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, (2,3)-dihydro-1 H-isoindolyl, (1,2,3,4)-tetrahydronaphthyl, (2,3)-dihydro-benzo[1.4]dioxinyl, benzo[1.3]dioxolyl and (3,4)-dihydro-2H-benzo[1.4]oxazinyl are cited as examples of 6-membered aryl residues which are condensed with an unsubstituted or at least monosubstituted saturated mono- or polycyclic ring system.
A mono- or polycyclic ring system should be understood in the context of the present invention as mono- or polycyclic hydrocarbon residues which can be saturated, unsaturated or aromatic and can optionally have one or more heteroatoms as ring members. Such a mono- or polycyclic ring system can, for example, be condensed (annelated) with a cycloaliphatic residue, a heterocycloaliphatic residue, an aryl residue or a heteroaryl residue.
Provided that a polycyclic ring system such as, for example, a bicyclic ring system is present, the various rings, in each case mutually independently, can have a different degree of saturation, i.e. be saturated, unsaturated or aromatic. The heteroatoms of each ring can, in each case mutually independently, be preferably selected from the group comprising oxygen, nitrogen and sulphur. A ring preferably contains 0, 1, 2 or 3 heteroatoms. The respective rings of the mono- or polycyclic ring system are preferably 5-, 6- or 7-membered, particularly preferably 5- or 6-membered.
Provided that one or more of the above-mentioned substituents has a saturated, unsaturated or aromatic monocyclic or polycyclic ring system which is monosubstituted or multiply substituted, this can preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3 substituents mutually independently selected from the group comprising oxo (=0), thioxo (=S), F, Cl, Br, I, -CN, -NO2, -OH, -CH2-OH, -SH, -SF5, -NH2, -CH2-NH2, -C(=0)-OH, -C1-alkyl, -(CH2)-O-C1-5-aIkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C=C-Si(CH3)3, -C=C-Si(C2H5)3, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -O-C1_5-alkyl, -0-phenyl, -O-CH2-phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=0)2-phenyl, -S(=O)2-C1_5-alkyl, -S(=O)-C1_5-alkyl, -NH-C1_5-alkyl, N(C1_ 5alkyl)2, -C(=O)-O-C1_5-alkyl, -C(=0)-H; -C(=O)-C1_5-alkyl, -CH2-O-C(=0)-phenyl, -0-C(=O)-phenyl, -NH-S(=O)2-Cj_5-alkyl, -NH-C(=0)-C1_5-alkyl, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, -C(=0)-NH2, -C(=O)-NH-CI_5-alkyl, -C(=0)-N(Cj_5-alkyl)2, -Si(phenyl)2[Cl_ 5-alkyl], -S(=O)2-NH2, -S(=0)2-NH-Cj_5-alkyl, -S(=0)2-N(C1_5-alkyl)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, (1,3)-dioxolanyl, pyrazolyl, pyrrolyl, phenyl, furyl (furanyl), thiazolyl, thiadiazolyl, thiophenyl (thienyl), benzyl and phenethyl, whereby the above-mentioned C1_5-alkyl residues can in each case be linear or branched and the cyclic substituents or the cyclic residues of these substituents themselves can be substituted with optionally 1, 2, 3, 4 or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, -OH, -SH, -NH2, -C(=O)-OH, -C,_5-alkyl, -(CH2)-O-C1_5-alkyl, -C2_5-alkenyl, -C2_5-alkynyl, -C-C-Si(CH3)3, -C=C-Si(C2H5)3, -S-C1_5-alkyl, -S-phenyl, -S-CH2-phenyl, -O-C,_5-alkyl, -0-phenyl, -O-CH2-phenyl, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
The substituents can particularly preferably, in each case mutually independently, be selected from the group comprising oxo (=0), thioxo (=S), F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C=C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -CH2-NH2, -CH2-OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -0-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -0-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-0-C(=O)-phenyl, -NH-S(=O)2-CH3, -NH-S(=0)2-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -0-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], -S(=O)2-NH2, -S(=O)2-NH-CH3, -S(=O)2-N(CH3)2, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, (1,3)-dioxolanyl, pyrrolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl, whereby the cyclic substituents or the cyclic residues of these substituents themselves can in each case be substituted with optionally 1, 2, 3, 4, or 5, preferably with optionally 1, 2, 3 or 4 substituents mutually independently selected from the . _..~, .~.~...~ .. _ _,h..
group comprising F, Cl, Br, !, -CN, -NOZ, -OH, -SH, -NH2, -C(=O)-OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C-C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-CZH5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)Z-C2H5: -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2: -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
Provided that one of the above-mentioned substituents has a linear or branched alkylene group, the alkylene group can preferably be selected from the group comprising -(CH2)-, -(CH2)2-, -C(H)(CH3)-, -(CH2)3-, -(CH2)4-, -(CH2)5- and -C(CzHS)(H)-.
An alkylene group can particularly preferably be substituted with 1, 2 or 3 substituents mutually independently selected from the group comprising F, Cl, Br, I, -NO2, -CN, -OH, -SH, -NH2, -N(CH3)2, -N(C2H5)2 and -N(CH3)(C2H5).
The person skilled in the art will understand that some of the substituted imidazo[2,1-b]thiazole compounds according to the invention of the general formula I can be present in the form of tautomers which are also a subject matter of the present invention and in each case can also be present as active ingredients in the drugs described below.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are preferred, in which R' and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NR6R7; -NH-C(=O)-R8; -C(=O)-R9, -C(=0)-NH2; -C(=0)-NHR10; -C(=O)-NR"R'2; -C(=0)-OR'3; -(CH2)m-C(=O)-OR14 with m = 1, 2, 3, 4 or 5; -O-C(=0)-R15; -(CH2)õ-O-C(=O)-R'6 with n = 1, 2, 3, 4 or 5; -OR";
-(CH2)0-O-R1$ with o = 1, 2, 3; 4 or 5; -SR19; -(CHZ)p S(=O)t-R20 with p = 1, 2, 3, 4 or 5 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NRZ9R30; -SF5; -(CH2)u-O-S(=O)2-with u = 1, 2, 3, 4 or 5; -(CH2)õ-O-S(=O)2-O-R32 with v 1, 2, 3, 4 or 5; -(CH2)w O-P(=O)(OR33)(OR34) with w = 1, 2, 3, 4 or 5; a linear or branched, unsubstituted or at least monosubstituted C1_10-alkyl residue, C2_6-alkenyl residue or C2_6-aikynyl residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic C3_$ residue optionally having at least one heteroatom as a ring member, which residue can be bound via a linear or branched, unsubstituted or at least monosubstituted Cy_5-alkylene group;
or an unsubstituted or at least monosubstituted 5- or 6-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1_5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=0)-R21; -(CH2)q-C(=O)-R22with q = 1, 2, 3, 4 or 5; -C(=0)-O-R23; -(CH2)r-C(=O)-O-R24with r = 1, 2, 3, 4 or 5; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2, 3, 4 or 5; a linear or branched, unsubstituted or at least monosubstituted C,_lo-alkyf residue, C2_6-alkenyl residue or C2_6-alkynyl residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic C3_$ residue optionally having at least one heteroatom as a ring member, which residue can be bound via a linear or branched, unsubstituted or at least monosubstituted Cl_5-alkylene group; or an unsubstituted or at least monosubstituted 5- or 6-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted CI_5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered, or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated, unsubstituted or at least monosubstituted heterocycloaliphatic C4_10 residue optionally having at least one further heteroatom as a ring member which can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R5, R6, R', R8, R'o, R", R12, R15 and R16, in each case mutually independently, denote a linear or branched, unsubstituted or at least monosubstituted C,_lo-alkyl residue, C2_s-alkenyl residue or C2_s-alkynyl residue; or an unsubstituted or at least monosubstituted 5- to 14-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1_5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
Rs R13 R14 R17 R18 Rls Rzo R21 R22 R23 R24 R25 R26 R27 R28 R29 Rso R31 Ra2 R33 and R34, in each case mutually independently, denote a hydrogen residue; a linear or branched, unsubstituted or at least monosubstituted Cl_lo-alkyl residue, CZ_s-alkenyl residue or CZ_s-afkynyl residue; or an unsubstituted or at least monosubstituted 5- to 14-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1_5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
Ml denotes a 5- or 6-membered aryl or heteroaryl residue, which can be substituted with at least one further substituent and can be condensed with an unsubstituted or at least monosubstituted mono- or bicyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered, and and M2 denotes a 5- or 6-membered aryl or heteroaryl residue, which can be unsubstituted or at least monosubstituted and can be condensed with an unsubstituted or at least monosubstituted mono- or bicyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
whereby the above-mentioned cycloaliphatic residues can optionally have 1, 2, 3, 4 or heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur, the above-mentioned heterocycloaliphatic residues can optionally have further 1, 2, 3, 4 or 5 heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur, the rings of the mono- or polycyclic ring system have in each case optionally 0, 1, 2 or 3 heteroatom(s) as (the) ring member(s) which are mutually independently selected from the group comprising oxygen, nitrogen and sulphur;
and the above-mentioned heteroaryl residues can optionally have 1, 2, 3, 4 or 5 heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising oxygen, sulphur and nitrogen.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula I
indicated above are furthermore preferred, in which R' and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NRsR'; -NH-C(=O)-R8; -C(=O)-R9, -C(=0)-NH2; -C(=O)-NHR10; -C(=O)-NR"R'Z; -C(=O)-OR13; -(CH2)m-C(=0)-OR'4 with m = 1, 2 or 3; -O-C(=O)-R15; -(CH2)õ-O-C(=O)-R'6 with n 1, 2 or 3; -OR"; -(CH2)o-O-R'$ with o = 1, 2 or 3; -SR19; -(CH2)P S(=O)t-R20 with p= 1, 2 or 3 and t=
0, 1 or 2;
-NH-S(=O)2-NRz7R28; -S(=O)2-NR29R30; -SF5; -(CH2)õO-S(=O)2-R31 with u= 1, 2 or 3;
-(CHZ)V-O-S(=O)2-O-R32 with v = 1, 2 or 3; -(CH2)W O-P(=O)(OR33)(OR34) with w=
1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl', isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, . _ ^ I _ ____ _ _ .
diazepanyl, azocanyl and dithiolanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -C=C-SI(CH3)3, -C=C-SI(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, oxo (=0), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)z-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl;
or a residue selected from the group comprising phenyl, benzyl, phenethyl, (3-phenyl)-prop-1-yl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C-C-Si(CH3)3, -C=C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=0)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -0-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=0)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=0)2-CH3, -C(=0)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=0)-C2H5, -O-C(=0)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise preferred, in which R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=0)-R21; -(CH2)4-C(=0)-R22with q = 1, 2 or 3; -C(=O)-O-R23; -(CH2)rC(=O)-O-with r = 1, 2 or 3; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NHZ, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, diazepanyl, azocanyl and dithiolanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, !, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C=C-Si(C2H5)3, -C=C-Si(CH3)3, -C=C-SI(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, oxo (=0), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=0)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -0-C(=0)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl and/or can be bound via a linear or branched C1_3-alkylene group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyt, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C-C-Si(C2H5)3, -CHZ-O-CH3, -O-CZH5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=0)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=0)-NH2, -C(=0)-NH-CH3, -C(=0)-N(CH3)2, -Si(phenyl)2[C(CH3)3], (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl and/or can be bound via a linear or branched C,_3-alkylene group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C=C-Si(C2H5)3, -OH, oxo, thioxo, -0-CH3, -O-C2H5, -O-C3H7, -(CH2)-O-CH3, -(CH2)-O-C2H5, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NO2, -CF3, -O-CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=O)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -NH-S(=0)2-CH3, -C(=0)-OH, -C(=0)-H; -C(=0)-CH3, -C(=O)-C2H5, -C(=O)-N(CH3)2, -C(=0)-NH-CH3, -C(=O)-NH2, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=0)-O-C(CH3)3 and phenyl;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise preferred, in which R5, R6, R7, R8, R10, R", R'2, R'5 and R's, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butya, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-NH-CH3, -(CHZ)-N(CH3)2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3), -(CH2)-(CH2)-(CH2)-OH, -(CH2)-C(=O)-OH, -(CH2)-C(=O)-O-CH3, -(CH2)-C(=O)-O-C2H5, -(CH2)-(CH2)-C(=0)-OH, -(CH2)-(CH2)-C(=0)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -0-C3H7, -C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula I
indicated above are furthermore preferred, in which R13 R14 R17 R18 R19 R20 R21 R22 R23 R24 R25 R26 R27 Rzs R29 R30, R31, R32 R9, , R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-NH-CH3, -(CH2)-N(CH3)2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3), -(CH2)-(CH2)-(CH2)-OH, -(CH2)-C(=O)-OH, -(CH2)-C(=O)-O-CH3, -(CH2)-C(=O)-O-C2H5, -(CH2)-(CH2)-C(=O)-OH, -(CH2)-(CH2)-C(=0)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise preferred, in which M' denotes a residue selected from the group comprising phenyl, furanyl, thiophenyl (thienyl), pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxadiazolyl, triazolyl, diazinyl, triazinyl, tetrazinyl and tetrazolyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=0)-CF3, -S-CF3, -S-CHF2 and -S-CH2F;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
...... _ .__ r Substituted imidazo[2, 1 -b]thiazole compounds of the general formula I
indicated above are furthermore preferred, in which M' denotes a residue selected from the group comprising residues 1 to 38, / \ /o\ / /o\
s / ~
S S o N-N N-N
"==\ N~
N -,, N~~ N
N~~ N N
N.~ " /"~
N / ", ",%
N
/
_ N- -N
\ "
/
N
~
N N
N N
N-~ N
N N=N
N '--'\
N N~ N
N-N ~f --/N N~~
N N N-N
33 ~ 34 35 36 N-O
37 5.~V 38 which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=0)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -0-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are furthermore preferred, in which M2 denotes a residue selected from the group comprising phenyl, furanyl, thiophenyl (thienyl), pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, oxadiazolyl, triazolyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, pentazolyl, imidazolyl, quinolinyl, isoquinolinyl, naphthyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl and isobenzothiophenyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C=C-Si(CH3)3, -C=C-Si(CzH5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHFz, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], -CH2-NH2, pyrrolyi, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, -S(=O)2-N(CH3)2, (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise preferred, in which M2 denotes a residue selected from the group comprising residues 1 to 36, , . .... .. . _~
N - O
s O
N N-N O-N N-O
O O < ~ N
O
N- N
N N N N H
~ J I ~ ~ N i/
J~
N N ~
N N H\) -N N~ " "
C\N
\ / "J S
W
/~ "
S ~
"" ,~ N~
J~
N
y H H
N
.ss~
_...~.,. ......
.._.. ^ .~r~i^
which in each case can be linked via the position marked by a wavy line with the carbon atom of the triple bond and can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -0-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=0)-CH3, -C(=0)-C2H5, NH-S(=0)2-CH3, -NH-S(=0)2-C2H5, -S(=O)2-NH2, -S(=O)Z-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
and in each case the remaining residues have the above-mentioned meaning, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are particularly preferred, in which R' and R2, mutually independently, in each case denote a hydrogen residue; -F;
-Cl; -Br; -I; -NO2; -CN; -NH2; -NHR5; -NR6R'; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR'o; -C(=O)-NR"R12; -C(=O)-OR13; -(CH2)m-C(=0)-OR14 with m= 1, 2 or 3; -O-C(=O)-R15;
-OR"; -(CHz)o-O-R'$ with o 1, 2 or 3; -S(=0)2-NH2; -SF5; -(CH2)õ-O-S(=O)2-R31 with u = 1, 2 or 3; -(CH2),-O-S(=O)2-O-R32 with v = 1, 2 or 3; -(CH2)w O-P(=O)(OR33)(OR34) with w = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CFZ)-(CF3); a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which in each case can be ,~,.,..
unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, oxo (=0), thioxo (=S), -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F;
or a residue selected from the group comprising phenyl, benzyl, phenethyl, (3-phenyl)-prop-1-yl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -0-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22with q = 1, 2 or 3; -C(=O)-O-R23; -(CH2)r-C(=O)-O-with r = 1, 2 or 3; -C(=0)-NHR25; -(CH2)s-C(=0)-NHR26 with s = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, oxo (=0), thioxo (=S), -O-CH3, -O-C2H5, -O-and -0-C(CH3)3 and/or can be bound via a linear or branched Cl_3-alkylene group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, -OH, -SH, -SF5, -NH2, -C(=0)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHFz, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, cyclopropyl, cyclobutyl and cyclopentyl and/or can be bound via a linear or branched C1_3-alkylene group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, -OH, oxo, thioxo, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NOz, -CF3, -O-CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=0)-CH3, -S(=O)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -C(=0)-CH3, -C(=0)-C2H5, -C(=0)-N(CH3)2, -C(=0)-NH-CH3, -C(=O)-NH2, -C(=0)-O-CH3, -C(=0)-O-CZH5, -C(=0)-O-C(CH3)3 and phenyl;
R5, Rs, R', R'o, R11 R1z, R15 and R's, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFHz, -(CH2)-(CHF2), -(CH2)-(CH2F), -(CF2)-(CF3), -(CH2)-(CH2)-C(=0)-OH, -(CH2)-(CH2)-C(=0)-O-CH3 and -(CH2)-(CH2)-C(=0)-O-C2H5; or denote a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, CI, Br, I, -CN, -NOz, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, -SH, -SF5, -NH2, -C(=0)-OH, -S-CH3, -S-C2H5, -O-CH3, -C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -0-CHF2, -O-CH2F and -C(=0)-CF3;
Rs R1s' R14 R,7 R1s R21 Rzz Rza Rza Rz5 Rzs Rs' R3z, R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the .~..._.w ....... w,.
group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyi, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -0-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F and -C(=O)-CF3;
M' denotes a residue selected from the group comprising residues 1 to 9, 11, 21, 22 and 36 to 38, ~O A\--/ ~ ~ ~ ~
S ~ -O
, ~\
NS "
S ~ O ~ 0 N ~
\ /
N
~,,, N
which in each case can be unsubstituted or substituted with optionally 1 or 2 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=0)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)Z-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising residues 1 to 36, N - O
/S\ ~O~
~~
O \ ~ \N\ ~ N) O
N,N
N N N N H
~/ ~/~
N N I /N
N
N N~N ~ D
~ N
N
~
- N N~ N
~ / N ~--<\ ~N S/ (/ \
N S
s ~' H
N N N N
~
/~ VI
S ~ I
H
N NN ssr' N~ N
H
N N
\ N~ \ ~
which in each case can be linked via the position marked by a wavy line with the carbon atom of the triple bond and can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyt, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=0)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=0)2-N(CH3)2;
in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are very particularly preferred, in which R' and R 2, mutually independently, in each case denote a hydrogen residue; -F; -Cl; -Br; -I; -NO2; -CN; -NHR5; -NR6R'; -C(=O)-R9, -C(=O)-OR13; -(CH2)-O-C(=O)-R'6; -OR1'; -(CH2)-O-S(=O)2-R3'; -(CH2)-O-S(=O)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR3a); -SF5; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
or a residue selected from the group comprising phenyl, benzyl, phenethyl and (3-phenyl)-prop-1-yl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2 or 3-1 -(CH2)rC(=O)-O-R24 with r =
1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which can be bound via a-(CH2)-, -(CH2)2-, -(CH(CH3))- or -(CH2)3 group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F and/or can be bound via a-(CH2)-, -(CH2)2-, -(CH(CH3))- or -(CH2)3 group;
,. -or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, -S(=0)-CH3, -S(=O)2-CH3, -S(=0)-C2H5, -S(=0)2-C2H5, -C(=O)-CH3, -C(=0)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -C(=O)-O-CH3, -C(=O)-O-C2H5 and -C(=O)-O-C(CH3)3;
R5, R6, R' and R16, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CHF2), -(CH2)-(CH2F), -(CF2)-(CF3), -(CHZ)-(CH2)-C(=O)-OH; -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl and phenethyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3 and -O-CZH5;
R9, R13 R" R2, R22 R2a Rs, Rs2 R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); or a residue selected from the group comprising phenyl, benzyl and phenethyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl,-O-CH3 and -O-CZH5;
M' denotes a residue selected from the group comprising residues 1 to 6, 21, 22, 36 and 37, fs S O O
N
-<~ "
~-~S
~N
N
which in each case can be unsubstituted or substituted with optionally 1 or 2 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -SF5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl, 4-thiazolyi, 5-thiazolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl and 8-quinolinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -.. .,...~..
Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=0)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=0)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula Ia are likewise very particularly preferred, Rl S-N S 35 N% / 'X I
R3 ,N, R4 Ia, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R35 and R36, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=0)-CH3, -C(=0)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=0)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=0)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b)thiazole compounds of the general formula lb are likewise very particularly preferred S N
R' \N
S /
R 3,N, R4 Ib, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R37 and R38, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=0)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=0)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionaily in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula Ic are likewise very particularly preferred R~ S ~N S Rao XN ~
Ic, in which R', RZ, R3 and R4 have the above-mentioned meaning, and R39 and R40, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
....,. ~.
Substituted imidazo[2,1-b]thiazoie compounds of the general formula Id are likewise very particularly preferred, ~ I
R' S N S
N
\ ~
R R
Id, in which R', R2, R3 and R4 have the above-mentioned meaning, and R41 and R42, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula le are likewise very particularly preferred, R' S N S N
N
le, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R43 and R44, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3J, -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
:....-,_,...-.~.. ,....._..._.._..... _..-, Substituted imidazo[2, 1 -b]thiazole compounds of the general formula If are likewise very particularly preferred, R, S N S R46 N
R
R3 ,N_R4 If, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R45 and R46, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=0)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=0)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=0)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula Ig are likewise very particularly preferred, N~
R4s R' S 'N S N
X N 'X X I
N~Ra R
Ig, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R47 and R48, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=0)-CH3, -C(=0)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=0)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula Ih are likewise very particularly preferred, u..__..... _ ...
~N.. ..~,~.
R~ S ?NN ~ S- ~ Rso g R3'N", R4 Ih, in which R1, R2, R3 and R4 have the above-mentioned meaning, and R49 and R50, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-CZH5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formulae Ia, Ib, Ic, Id, le, If, Ig and Ih indicated above are even further preferred, in which R' denotes a hydrogen residue; -F; -CI; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
_.4....,..- ._..-..._,__... ,....,....~..,.
R2 denotes a hydrogen residue; -F; -CI; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R3 denotes a hydrogen residue;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl;
R13 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl and (2,4,4)-trimethyl-pent-2-yl;
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl or a phenyl residue which is in each case unsubstituted;
and R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49 and R50, mutually independently in each case denote a residue selected from the group comprising F, Cl, Br, -CN, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise very particularly preferred, in which R' denotes a hydrogen residue; -F; -Cl; -Br; -CN; -O-CH3; -C(=O)-R9, -C(=O)-ORi3; -(CH2)-O-C(=O)-R16; -(CH2)-O-S(=O)2-R31; -(CH2)-O-S(=O)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR34); or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-.(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), and -(CF2)-(CF3);
R2 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -O-CH3; -C(=O)-R9, -C(=O)-OR13; -(CH2)-O-C(=O)-R16; -(CH2)-O-S(=0)2-R31; -(CH2)-O-S(=0)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR34); or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CHZ)-(CHF2), -(CH2)-(CH2F), and -(CF2)-(CF3);
R3 denotes a hydrogen residue or a residue selected from the group comprising methyl, ethyl and isopropyl;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising pyrrolidinyl, piperidinyl and morpholinyl;
R16 denotes a residue selected from the group comprising -(CH2)-(CH2)-C(=O)-OH; -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5;
R9, R13, R3', R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3);
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3) or a phenyl residue, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl,-O-CH3 and -O-C2H5;
M' denotes a residue selected from the group comprising residues 1, 3, 5, 36 and 37, :S) S O
which in each case is unsubstituted, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
M2 denotes a residue selected from the group comprising phenyl, 2-pyrimidinyl, pyrimidinyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl and 4-thiazolyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, CI, Br, -CN, -O-CH3, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
Substituted imidazo[2, 1 -b]thiazole compounds of the general formula I
indicated above are likewise very particularly preferred, in which R' denotes a hydrogen residue; -F; -CI; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R2 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R3 denotes a hydrogen residue;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl;
R13 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl and (2,4,4)-tri methyl-pent-2-yl;
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl or a phenyl residue which in each case is unsubstituted;
M' denotes a residue selected from the group comprising residues 1, 3, 5 and 22, N _~
~s /
\~s V /O ~" N
which in each case is unsubstituted, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising phenyl, 2-pyrimidinyl, 5-pyrimidinyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-pyridinyl, 3-pyridinyl, M_ ~
_...w, -~._ .. _.. r -..
4-pyridinyl, 2-thiazolyl and 4-thiazolyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -O-CH3, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are still further preferably selected from the group comprising [1] 6-(5-(phenylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)-imidazo[2,1-b]thiazole-5-amine, [2] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [3] N-tert-butyl-3-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride, [4] N-tert-butyl-2-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [5] N-tert-butyl-2,3-dimethyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride, [6] N-tert-butyl-2-chloro-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride, [7] N-tert-butyl-6-(5-(pyridine-4-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [8] 5-(tert-butylamino)-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-2-carboxylic acid methylester hydrochloride and [9] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiazole-2-yl)imidazo[2,1-b]thiazole-5-amine;
[10] 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine, [11] N-tert-butyl-2-methyl-6-(4-(pyridine-2-ylethynyl)phenyl)imidazo[2,1-b]thiazole-5-amine, [12] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)furan-2-yl)imidazo[2,1-b]thiazole-amine, [13] N-tert-butyl-3-methyl-6-(5-(phenylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [14] 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [15] N-tert-butyl-6-(5-(pyrimidine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [16] N-tert-butyl-6-(5-((3-fluoropyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [17] N-tert-butyl-6-(5-((2-fluoropyridine-4-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [18] N-tert-butyl-6-(5-(thiophene-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [19] N-tert-butyl-6-(5-(thiazole-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [20] 3-((5-(5-(tert-butylamino)imidazo[2, 1 -b]thiazole-6-yl)thiophene-2-yl)ethynyl)phenol, [21] 3-((5-(5-(tert-butyl amino) imidazo[2,1 -b]thiazole-6-yl)thiophene-2-yl)ethynyl)benzonitrile, [22] N-ethyl-6-(6-(phenylethynyl)pyridine-3-yl)imidazo[2, 1 -b]thiazole-5-amine, [23] N-tert-butyl-6-(5-((3-methylpyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [24] N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)acetamide and [25] N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)benzamide;
in each case optionally in the form of corresponding salts, or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise particularly preferred, which, after 60 minutes of incubation in 450 pg protein from pig brain homogenate at a temperature between 20 C and 25 C
in a concentration of less than 2500 nM, preferably of less than 1000 nM, particularly preferably of less than 700 nM, very particularly preferably of less than 100 nM, even more preferably of less than 70 nM, bring about a 50-percent displacement of [3H]-2-methyl-6-(3-methoxyphenyl)-ethynytpyridine which is present in a concentration of 5 nM.
Thereby, the determination of the displacement of [3H]-2-methyl-6-(3-methoxyphenyl)-ethynylpyridine is performed as described in the section Pharmacological Methods, I. Method for determing the inhibition of [3H]-MPEP-bonding in the mGIuR5 receptor bonding assay.
A further subject matter of the present invention is a method for producing compounds of the general formula I indicated above, according to which at least one compound of the general formula II, Rl S~NH2 \
N
II, in which R' and R2 have the meaning indicated above, in a reaction medium, optionally in the presence of at least one organic or inorganic acid or at least one transition metal salt, is converted with at least one isocyanide of the general formula III, III, in which R3 has the meaning indicated above, and at least one aidehyde of the general formula IV, O
H M
IV, in which M' and M2 have the meaning indicated above, and the compound obtained in this manner of the general formula V, s N
R' \~ Ml M2 N
V, in which R1, R2, R3, M' and M2 have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, or at least one compound of the general formula II, ~ S~NH2 R \
LN
II, in which R' and R2 have the meaning indicated above, in a reaction medium, optionally in the presence of at least one organic or inorganic acid or at least one transition metal salt, is converted with at least one isocyanide of the general formula III, ..,_...,,._ ~..,~..,._ . ...._ III, in which R3 has the meaning indicated above, and at least one aldehyde of the general formula VI, A
H M -I X
VI, in which M' has the meaning indicated above and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, and the compound obtained in this manner of the general formula VII, SY N
R' \ N Ml-X
VII, in which R1, R2, R3, Ml and X have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and by conversion with at least one acetylene of the general formula XI, H SiR3 XI, in which R, mutually independently, in each case denotes a linear or branched alkyl residue or an unsubstituted phenyl residue, in a reaction medium, optionally in the presence of at least one suitable catalyst, optionally in the presence of at least one copper(I)salt, preferably in the presence of copper-(I)-iodide, and optionally in the presence of at least one inorganic and/or organic base is transformed into a correspondingly substituted compound of the general formula XII, R' \ N M1 SiR3 XII, in which R1, R2, R3 and M' have the above-mentioned meaning and R, mutually independently, in each case denotes a linear or branched alkyl residue or an unsubstituted phenyl residue, and is optionaNy purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and at least one compound of the general formula XII is transformed in a reaction medium, optionally in the presence of at least one inorganic and/or organic base, optionally in the presence of at least one inorganic salt, and optionally in the presence of at least one ammonium salt, into a correspondingly substituted compound of the general formula XIII, S N
R' \ N / Ml r XI(I, in which R', R2, R3 and M' have the above-mentioned meaning, and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and at least one compound of the general formula XIII and/or at least one compound of the general formula XII is transformed by conversion with at least one compound of the general formula M2-X, in which M2 has the above-mentioned meaning and X
denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one suitable catalyst, optionally in the presence of at least one inorganic and/or organic base, optionally in the presence of at least one inorganic salt and optionally in the presence of at least one ammonium salt into a correspondingly substituted compound of the general formula V, S N
R' M1 M2 N
V, in which R1, R2, R3, M' and M2 have the above-mentioned meaning and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, or a compound of the general formula VII is transformed by conversion with at least one acetylene of the general formula VIII, VIII, in which M2 has the meaning indicated above, in a reaction medium, optionally in the presence of at least one suitable catalyst, optionally in the presence of at least one copper(I)salt, preferably in the presence of copper-(l)-iodide and optionally in the presence of at least one inorganic and/or organic base into a correspondingly substituted compound of the general formula V, s N
R' \~ Ml M2 V, in which R', R2, R3, M' and M2 have the above-mentioned meaning and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and optionally the compound of the general formula V is transformed by conversion with at least one compound of the general formula R4-X, in which R4 has the meaning indicated above and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, in a reaction medium, in the presence of at least one organic or inorganic base, preferably in the presence of at least one metal hydride salt, or by conversion with at least one compound of the general formula R21-C(=0)-OH, in which R21 has the meaning indicated above, in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or in the presence of at least one coupling agent, or by conversion with at least one compound of the general formula R21-C(=O)-X, in which R21 has the meaning indicated above and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one organic or inorganic base, ,...__.~ .~__ . .... . ....
or by conversion with at least one compound of the general formula R21-C(=O)-H, in which R21 has the meaning indicated above, in a reaction medium, optionally in the presence of at least one reducing agent, into a compound of the general formula I, optionally in the form of a corresponding salt, S N
R1 \~ M1 M2 N
I, in which R1, R2, R3, R4, M' and M2 have the meaning indicated above, and this is optionally purified and/or isolated.
A subject matter of the present invention is also a method for producing compounds of the general formula I indicated above according to which at least one compound of the general formula V is converted, s N
R \ N ~ M M
V, in which R1, RZ, R3, M' and M2 have the above-mentioned meaning, optionally in a reaction medium in the presence of at least one organic or inorganic acid, and the compound obtained in this manner of the general formula IX, , _ .. _.._.w_~.,...~..~.
SY N
R' I Ml M2 \ N
IX, in which R1, R2, M' and M2 have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated and is transformed in a reaction medium, in the presence of at least one inorganic or organic base, preferably in the presence of at least one metal hydride salt, with at least one compound of the general formula R3-X, in which R3 has the meaning indicated above and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, or in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or optionally in the presence of at least one coupling agent with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the above-mentioned meaning, or in a reaction medium, optionally in the presence of at least one organic or inorganic base with at least one compound of the general formula R21-C(=O)-X, in which R21 has the above-mentioned meaning and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, or in a reaction medium, optionally in the presence of at least one reducing agent with at least one compound of the general formula R21-C(=O)-H, in which R21 has the above-mentioned meaning, into a corresponding compound of the general formula X, optionally in the form of a corresponding salt, S N
R' \ ~ ~e_ Ml M2 N
X, in which R1, R2, R3, M' and M2 have the above-mentioned meaning, and this is optionally purified and/or isolated, and optionally the compound of the general formula X is transformed by conversion with at least one compound of the general formula R4-X, in which R4 has the above-mentioned meaning and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, in a reaction medium, in the presence of at least one organic or inorganic base, preferably in the presence of at least one metal hydride salt, or by conversion with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the above-mentioned meaning, in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or in the presence of at least one coupling agent, or by conversion with at least one compound of the general formula R21-C(=O)-X, in which R21 has the above-mentioned meaning and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one organic or inorganic base, or by conversion with at least one compound of the general formula R21-C(=O)-H, in which R21 has the above-mentioned meaning, in a reaction medium, optionally in the presence of at least one reducing agent, _. e. .._ .,.._.~. _._ _~....~,,m~..
into a compound of the general formula I indicated above, optionally in the form of a corresponding salt, S N
R' \ M1 M2 N
in which R1, R2, R3, R4, M1 and M2 have the above-mentioned meaning, and this is optionally purified and/or isolated.
The methods according to the invention for producing substituted imidazo[2,1-b]thiazole compounds of the general formula I indicated above are also indicated in following diagrams 1 to 4.
S NH
I
R1 \
N + R3-N-C + H M1 II III IV
~
sY N
R1 \ M1 - M2 N
V
Diagram 1.
In a three-component-coupling reaction, amines of the general formula II are converted with isocyanides of the general formula III and aldehydes of the general formula IV in a reaction medium, preferably selected from the group comprising chloroform, dichloromethane, acetonitrile, methanol and ethanol, with the addition of ..... _ ... .w.k._ at least one organic or inorganic acid, preferably trifluoroacetic acid or perchloric acid, or with the addition of at least one transition metal salt, preferably with the addition of at least one transition metal triflate (transition metal trifluoromethanesulphonate), particularly preferably with the addition of at least one transition metal triflate selected from the group comprising scandium(I I I)trifluoromethanesulphonate, ytterbiumtrifluoromethanesulphonate and indium(III)trifluoromethanesulphonate, preferably at temperatures of 0 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula V.
A further method for producing substituted imidazo[2,1-b]thiazole compounds of the general formula I indicated above via compounds or the general formula V
indicated above is reproduced in Diagram 2.
S NHZ O
i A R \ N + R3-N-C + ~
Mi Step 1 II III VI
S N S N
R' \ Ml_X H- Mz R' Ml - M2 VIII
RZ N H Step 2 Rz N H
VII V
Step 5 H- SiR3 M2-X Step 5 Step 3 XI
SY N 1 S~N
R~ \ N/ SiRs Step 4 R IN' XII XIII
...,.._..__..-. ,_....__ __ n_.
Diagram 2.
In step 1, amines of the general formula II are converted in a three-component-coupling reaction with isocyanides of the general formula III and aidehydes of the general formula VI, in which X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, preferably selected from the group comprising chloroform, dichloromethane, acetonitrile, methanol and ethanol, with the addition of at least one organic or inorganic acid, preferably selected from the group comprising trifluoroacetic acid or perchloric acid, or with the addition of at least one transition metal salt, preferably with the addition of at least one transition metal triflate (transition metal trifluoromethanesulphonate), particularly preferably with the addition of at least one transition metal trifluoromethanesulphonate selected from the group comprising scandium(I I I)trifluoromethanesulphonate, ytterbiumtrifluoromethanesulphonate and indium(III) trifluoromethanesulphonate, preferably at temperatures of 0 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula VII, in which X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate.
In step 2, compounds of the general formula VII indicated above, in which X
denotes a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, are converted with acetylenes of the general formula VIII in a reaction medium, preferably selected from the group comprising methanol, ethyl acetate, ethanol, isopropanol, n-butanol, dioxane, chloroform, dichloromethane, pyridine, dimethylsulphoxide, toluol, tetrahydrofuran, dimethylformamide, acetonitrile, diethylether, water and corresponding mixtures, particularly preferably selected from the group comprising dimethylformamide, ethyl acetate, tetrahydrofuran, water and corresponding mixtures, preferably with the addition of at least one palladium catalyst, preferably selected from the group comprising palladium(II)-dichloride [PdC12], bis(triphenylphosphine)-palladium(I I)-acetate [Pd(PPh3)2(OAc)2], bis(triphenylphosphine)-palladium(II)-chloride [PdCI2(PPh3)2], palladium(II)-acetate [Pd(OAc)2; Ac = acetate], bis(acetonitrile)-palladium(II)-chloride [(CH3CN)2)PdCI2], bis(benzonitrile)-palladium(II)-chloride [(PhCN)2PdCI2] and tetrakis(triphenylphosphine)palladium [(PPh3)4Pd], particularly preferably selected from the group comprising Pd(PPh3)2(OAc)2, (PPh3)4Pd and PdCl2(PPh3)2, optionally in the presence of at least one copper(I)salt, preferably in the presence of copper(l)-iodide, optionally in the presence of at least one phosphine, preferably a phosphine selected from the group comprising triphenylphosphine, tri-(tert-butyl)-phosphine, triphenylarsine and tri-(ortho-toluyl)-phosphine, particularly preferably in the presence of triphenylphosphine, optionally with the addition of at least one inorganic salt, preferably with the addition of lithium and/or zinc chloride, optionally with the addition of at least one organic base, preferably of an organic base selected from the group comprising triethylamine, diisopropylamine, diisopropylethylamine and [1,4]-diazabicyclo-[2.2.2]octane and/or with the addition of at least one inorganic base, preferably selected from the group comprising potassium carbonate, sodium hydrogen carbonate and caesium carbonate, whereby in particular the organic base can also be the reaction medium, at temperatures of preferably -70 C to 300 C, particularly preferably of -70 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula V.
In step 3, compounds of the general formula VII indicated above are converted with compounds of the general formula XI indicated above under the conditions cited in Diagram 2, Step 2 to yield compounds of the general formula XII.
In step 4, compounds of the general formula XII indicated above are converted in a reaction medium, preferably selected from the group comprising methanol, ethyl acetate, ethanol, isopropanol, n-butanol, dioxane, chloroform, dichloromethane, pyridine, dimethylsulphoxide, toluol, tetrahydrofuran, dimethylformamide, acetonitrile, diethylether, water and corresponding mixtures, particularly preferably selected from the group comprising dimethylformamide, ethyl acetate, tetrahydrofuran, water and corresponding mixtures, optionally in the presence of at least one inorganic base, preferably in the presence of at least one inorganic base selected from the group comprising potassium carbonate, sodium hydroxide, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium hydroxide and lithium hydroxide, optionally in the presence of at least one inorganic base, preferably of at least one inorganic base selected from the group comprising triethylamine and pyridine, optionally in the presence of at least one inorganic salt, preferably in the presence of at least one .. ,.....
. ..y.. .... ...,--r.. ...M.mwwsw~..or. r.w~ . . . . . . .. .. . . .. . . .
ammonium salt or in the presence of potassium and/or sodium fluoride, particularly preferably in the presence of at least one ammonium salt selected from the group comprising tetra-n-butylammonium fluoride, tetra-n-butyl-ammonium iodide and tetrabutylammonium bromide, at temperatures of preferably -70 C to 300 C, particularly preferably of -70 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula XI I L
In step 5, compounds of the general formulae XII and XIII indicated above are converted with compounds of the general formula M2-X, in which X denotes a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesu[phonate, in a reaction medium, preferably selected from the group comprising methanol, ethyl acetate, ethanol, isopropanol, n-butanol, dioxane, chloroform, dichloromethane, pyridine, dimethylsulphoxide, toluol, tetrahydrofuran, dimethylformamide, acetonitrile, diethylether, water and corresponding mixtures, particularly preferably selected from the group comprising dimethylformamide, ethyl acetate, tetrahydrofuran, water and corresponding mixtures, preferably with the addition of at least one palladium catalyst, preferably selected from the group comprising palladium(II)-dichloride [PdCl2], bis(triphenylphosphine)-palladium(II)-acetate [Pd(PPh3)2(OAc)2], bis(triphenylphosphine)-palladium(I I)-chloride [PdCI2(PPh3)2], palladium(II)-acetate [Pd(OAc)2; Ac = acetate], bis(acetonitrile)-palladium(II)-chloride [(CH3CN)2)PdCI2], bis(benzonitrile)-palladium(II)-chloride [(PhCN)2PdCI2] and tetrakis(triphenylphosphine)palladium [(PPh3)4Pd], particularly preferably selected from the group comprising Pd(PPh3)2(OAc)Z, (PPh3)4Pd and PdCl2(PPh3)2, optionally in the presenence of at least one copper(l)salt, preferably in the presence of copper(1)-iodide, optionally in the presence of at least one phosphine, preferaby a phosphine selected from the group comprising triphenylphosphine, tri-(tert-butyl)-phosphine, triphenylarsine and tri-(ortho-toluyl)-phosphine, particularly preferaby in the presence of triphenylphosphine, optionally with the addition of at least one inorganic salt, preferably with the addition of lithium and/or zinc chloride, optionally in the presence of at least one ammonium salt or in the presence of potassium and/or sodium fluoride, preferably in the presence of at least one ammonium salt selected from the group comprising tetra-n-butylammonium fluoride, tetra-n-butyl-ammonium iodide and tetrabutylammonium bromide, optionally with the addition of at least one organic base, preferably of an organic base selected ....w.....r.p.w . . . . . . . . . . _ . . . .. . . . . . .. . .... ... . . . .
. ... .. . . . . . . . .. . _ . . . . .
from the group comprising triethylamine, diisopropylamine, diisopropylethylamine and [1,4]-diazabicyclo-[2.2.2]octane and/or with the addition of at least one inorganic base, preferably selected from the group comprising potassium carbonate, sodium hydrogen carbonate and caesium carbonate, whereby in particular the organic base can also be the reaction medium, at temperatures of preferably -70 C to 300 C, particularly preferably of -70 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula V.
The conversion of compounds of the general formula XII with compounds of the general formula M2-X is preferably performed in the presence of at least one ammonium salt or in the presence of potassium and/or sodium fluoride.
The compounds of the general formula V can be converted as shown in Diagram 3 to yield compounds of the formula X.
s N s N
~ - ~
R'~ N Ml - M2 s N
R1 \Y/ Ml MZ 2 R'~ N/ M~ = Mz 2J\` ~ I 2 R %H R2 NH2 R ~ H
v iX x Diagram 3.
In step 1, compounds of the general formula V indicated above are converted in a reaction medium, preferably selected from the group comprising ethanol, methanol and acetone, with the addition of at least one organic acid, preferably acetic acid or trifluoroacetic acid and/or with the addition of at least one inorganic acid, preferably hydochloric acid or sulphuric acid, at temperatures of preferably 0 C to 80 C, optionally in the presence of microwave radiation to yield compounds of the general formula IX.
In step 2, compounds of the general formula IX indicated above are converted with carboxylic acids of the general formula R21-(C=O)-OH, in which R21 has the above-mentioned meaning, in a reaction medium, preferably selected from the group comprising diethylether, tetrahydrofuran, acetonitrile, methanol, ethanol, dimethylformamide and dichloromethane, optionally in the presence of at least one coupling reagent, preferably selected from the group comprising 1-benzotriazolyloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), dicyclohexylcarbodiimide (DCC), N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDCI), N-[(dimethyamino)-1H-1, 2, 3-triazolo[4, 5-b]pyridino-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), O-(benzotriazol-1-yl)-N,N,N`,N`-tetramethyluroniom hexafluorophosphate (HBTU) and 1-hydroxy-7-azabenzotriazol (HOAt), optionally in the presence of at least one inorganic base, preferably selected from the group comprising potassium carbonate and caesium carbonate, or of an organic base, preferably selected from the group comprising triethylamine, pyridine, dimethylaminopyridine and diisopropylethylamine preferably at temperatures of -70 C to 100 C, optionally in the presence of microwave radiation to yield compounds of the general formula X.
Alternatively, compounds of the general formula IX are converted with carboxylic acid derivatives or carbonic acid derivatives of the general formula R21-(C=O)-X, whereby X denotes a halogen residue, preferably chlorine or bromine, in a reaction medium, preferably selected from the group comprising diethylether, tetrahydrofuran, acetonitrile, methanol, ethanol, dimethylformamide and dichloromethane, with or without addition of at least one organic or inorganic base, for example, triethylamine, dimethylaminopyridine, pyridine or diisopropylamine, optionally in the presence of at least one organic base, preferably selected from the group comprising triethylamine, dimethylaminopyridine, pyridine and diisopropylamine, or of an inorganic base at temperatures of preferably -70 C to 100 C, optionally in the presence of microwave radiation to yield compounds of the general formula X.
As a further alternative, compounds of the general formula IX are converted with aldehydes of the general formula R21-C(=O)-H in a reaction medium, preferably selected from the group comprising diethylether, tetrahydrofuran, methanol, ethanol, dichloromethane and toluol, with the addition of at least one reducing agent, preferably selected from the group comprising sodium borohydride, sodium acetoxyborohydride or sodium cyanoborohydride, at temperatures of preferably -70 C to 100 C, optionally in the presence of microwave radiation to yield compounds of the general formula X.
. ...y.,......,.õ. . . .. . . .. .. . .. . . . . . . .. ..>.d..._.,. _ ._...
,.,......-,.._ . . . .... . . .
Compounds of the general formula IX can also be converted with compounds of the general formula R3-X, in which X denotes a halogen residue, preferably chlorine, in a reaction medium, preferably selected from the group comprising toluol, tetrahydrofuran and diethylether, with the addition of at least one metal hydride salt, preferably with the addition of at least one metal hydride salt selected from the group comprising sodium hydride, potassium hydride and lithium hydride, at temperatures of preferably 0 C to 40 C to yield compounds of the general formula X.
Compounds of the general formulae X and V can furthermore be converted as indicated in Diagram 4 to yield compounds of the general formula I, whereby the same methods as described under Diagram 3, Step 2 can be used.
s N S N
R' ~ Ml - M2 R' Ml = M2 N
3 N,Ra V, X I
Diagram 4.
The compounds of the formulae II, III, IV, VI and VIII indicated above and of the general formulae R3-X, R4-X, R21-C(=O)-OH, Rz1-C(=O)-X and R21-C(=O)-H
indicated above are in each case available to purchase on the market and/or can be produced according to the normal methods known to the person skilled in the art.
The conversions described above can in each case be performed under normal conditions familiar to the person skilled in the art, for example, in terms of pressure or the sequence of the addition of components. The optimum performance of the method according to the respective conditions can optionally be determined by the person skilled in the art by simple preliminary tests.
The intermediate and end products obtained according to the conversions described above can in each case, if desired and/or necessary, be purified and/or isolated according to conventional methods known to the person skilled in the art.
Suitable purification methods are, for example, extraction methods and chromatographic methods such as column chromatography or preparative chromatography.
All of the method steps described above and in each case also the purification and/or isolation of intermediate or end products can partially or entirely be performed under an inert gas atmosphere, preferably under a nitrogen atmosphere.
The substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formulae I, Ia, Ib, Ic, Id, le, If, Ig and Ih, referred to below only as compounds of the general formula I, and corresponding stereoisomers can be isolated both in the form of the free bases thereof, the free acids thereof as well as in the form of corresponding salts, in particular physiologically acceptable salts.
The free bases of the respective substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formula I and corresponding stereoisomers can, for example, be transformed by conversion with an inorganic or organic acid, preferably with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, p-toluolsulphonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aparaginic acid, into the corresponding salts, preferably physiologically acceptable salts.
The free bases of the respective substituted imidazo[2,1-b]thiazole compounds of the above-mentioned general formula I and corresponding stereoisomers can likewise be transformed with the free acid or a salt of a sugar substitute such as e.g.
saccharin, cyclamate or acesulfam into the corresponding physiologically acceptable salts.
The free acids of the substituted imidazo[2,1-b]thiazole compounds of the above-mentioned general formula I and corresponding stereoisomers can correspondingly be transformed by conversion with a suitable base into the corresponding physiologically acceptable salts. The alkaline metal salts, alkaline earth metal salts or ammonium salts [NH,R4_1]+, in which x = 0, 1, 2, 3 or 4 and R denotes a linear or branched C1_4-alkyl residue, are cited by way of example.
The substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formula I and corresponding stereoisomers can optionally, just like the corresponding acids, the corresponding bases or salts of these compounds, be obtained according to normal methods known to the person skilled in the art also in the form of the solvates thereof, preferably in the form of the hydrates thereof.
In so far as the substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formula I can be obtained after their production in the form of a mixture of the stereoisomers thereof, preferably in the form of the racemates thereof or other mixtures of the various enantiomers and/or diastereomers thereof, these can be separated and optionally isolated according to conventional methods known to the person skilled in the art. Chromatographic separating methods, in particular liquid chromatography methods under normal pressure or under increased pressure, preferably MPLC and HPLC methods, and methods of fractionated crystallisation are cited by way of example. Therein, in particular individual enantiomers, e.g. diastereomeric salts formed by means of HPLC
on the chiral stationary phase or by means of crystallisation with chiral acids such as (+) tartaric acid, (-) tartaric acid or (+) 10-camphor sulphonic acid, can be separated from one another.
The substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formula I and corresponding stereoisomers and in each case the corresponding acids, bases, salts and solvates are toxicologically safe and are therefore suitable as active pharmaceutical ingredients in drugs.
A further subject matter of the present invention is therefore a drug containing at least one imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers ,._ _ . .,..-_.. ~. ..._. , . . .r..~
and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt, or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances.
The drug according to the invention is suitable for mGluR5 receptor regulation, in particular for inhibition of the mGluR5 receptor.
The drug according to the invention is preferably suitable for the prevention and/or treatment of disorders and/or illnesses which are at least partially mediated by mGluR5 receptors.
The drug according to the invention is therefore particularly preferably suitable for the treatment and/or prevention of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain;
migraine;
depression; neurodegenerative diseases, preferably selected from the group comprising multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's chorea; cognitive dysfunction, preferably cognitive deficiency states, particularly preferably Attention Deficit Disorder (ADD); psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks;
epilepsy; coughing; urinary incontinence; diarrhoea; pruritus; schizophrenia;
cerebral ischaemia; muscle spasms; cramps; lung illnesses, preferably selected from the group comprising asthma and pseudo-croup; regurgitation (vomiting); stroke;
dyskinesia; retinopathy; listlessness; drowsiness; weariness; laryngitis;
disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on alcohol; dependency on medicines;
dependency on drugs, preferably dependency on nicotine and/or cocaine; alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse;
withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications, preferably to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux; irritable bowel syndrome; for diuresis; for antinatriuresis; for influencing the cardiovascular system; for increasing vigilance; for increasing libido; for modulating locomotor activity or for local anaesthesia.
, ,_.y.._..,n. . . ... . .. , . . _ . . . . . ............_, .... ... .
.......w . .... ..... . .. . . . . . .
.GRA3336PCT
The drug according to the invention is very particularly preferably suitable for the prevention of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain; psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks;
dependency on alcohol; dependency on medicines; disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on drugs, preferably dependency on nicotine and/or cocaine; alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications and/or drugs, in particular to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux and irritable bowel syndrome.
The drug according to the invention is even more preferably suitable for the prevention and/or the treatment of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain.
The drug according to the invention is even more preferably suitable for the prevention and/or the treatment of psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks.
The drug according to the invention is most preferably suitable for the prevention and/or the treatment of pain, preferably of acute pain, chronic pain, neuropathic pain or visceral pain.
A further subject matter of the present invention is the use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I
indicated above, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt, or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for mGluR5 receptor regulation, preferably for inhibition of the mGluR5 receptor.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above are preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt, or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of disorders and/or illnesses which are at least partially mediated by mGluR5 receptors.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above is particularly preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt, or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain; migraine; depression;
neurodegenerative diseases, preferably selected from the group comprising multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's chorea;
cognitive dysfunction, preferably cognitive deficiency states, particularly preferably Attention Deficit Disorder (ADD); psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks; epilepsy; coughing; urinary incontinence; diarrhoea; pruritus; schizophrenia; cerebral ischaemia; muscle spasms;
cramps; lung illnesses, preferably selected from the group comprising asthma and pseudo-croup; regurgitation (vomiting); stroke; dyskinesia; retinopathy;
listlessness;
drowsiness; weariness; laryngitis; disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on alcohol; dependency on medicines; dependency on drugs, preferably dependency on _....._,._~.~.~.._ ~ ., . _ ..._ nicotine and/or cocaine; alcohol abuse; abuse of medication; drug abuse;
preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine);
development of tolerance to medications, preferably to natural or synthetic opioids;
stomach-esophagus-reflux-syndrome; gastroesophagal reflux; irritable bowel syndrome; for diuresis; for antinatriuresis; for influencing the cardiovascular system;
for increasing vigilance; for increasing libido; for modulating locomotor activity or for local anaesthesia.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above is very particularly preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain;
psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks; dependency on alcohol; dependency on medicines; disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on drugs, preferably dependency on nicotine and/or cocaine;
alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications and/or drugs, particularly to natural or synthetic opioids;
stomach-esophagus-reflux-syndrome; gastroesophagal reflux and irritable bowel syndrome.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above is even further preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired ~...._õM.. . . ~~_. _ _..
mixing ratio, or in each case in the form of a corresponding salt or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above is even further preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks.
The drug according to the invention is suitable for administration to adults and childrens including infants.
The drug according to the invention may be formulated as a liquid, semisolid or solid dosage form, for example, in the form of solutions for injection, drops, succi, syrups, sprays, suspensions, tablets, patches, capsules, dressings, suppositories, ointments, creams, lotions, gels, emulsions, aerosols or in multiparticulate form, for example, in the form of pellets or granules, optionally pressed into tablets, packaged in capsules or suspended in a liquid, and may also be administered as such.
In addition to at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above, optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemate thereof or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio, or optionally in the form of a corresponding salt or in each case in the form of a corresponding solvate, the drug according to the invention conventionally contains further physiologically acceptable pharmaceutical auxiliary substances, which can preferably be selected from the group comprising matrix materials, fillers, solvents, diluents, surface-active substances, dyes, preservatives, disintegrants, slip agents, lubricants, aromas and binders.
Selection of the physiologically acceptable auxiliary substances and the quantities thereof which are to be used depends upon whether the drug is to be administered orally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or topically, for example onto infections of the skin, mucous membranes and eyes. Preparations in the form of tablets, coated tablets, capsules, granules, pellets, drops, succi and syrups are preferred for oral administration, while solutions, suspensions, readily reconstitutible dried preparations and sprays are preferred for parenteral, topical and inhalatory administration.
The substituted imidazo[2,1-b]thiazole compounds according to the invention used in the drug according to the invention in a depot in dissolved form or in a dressing, optionally with the addition of skin penetration promoters, are suitable percutaneous administration preparations.
Orally or percutaneously administrable formulations may also release the respective substituted imidazo[2,1-b]thiazole compound according to the invention in a delayed manner.
Production of the drugs according to the invention proceeds with the assistance of conventional means, devices, methods and processes known from the prior art, such as are described for example in "Remington's Pharmaceutical Sciences", ed.
A.R.
Gennaro, 17th ed., Mack Publishing Company, Easton, Pa. (1985), in particular in part 8, chapters 76 to 93. The corresponding description is hereby introduced as a reference and is deemed to be part of the disclosure.
The quantity of the respective substituted imidazo[2, 1 -b]thiazole compounds according to the invention of the general formula I indicated above to be administered to the patient may vary and is, for example, dependent on the weight or age of the patient and on the mode of administration, the indication and the severity of the complaint. Conventionally, 0.005 to 2000 mg/kg, preferably 0.05 to 500 mg/kg, particularly preferably 0.05 to 100 mg/kg of patient body weight of at least one such compound according to the invention are administered per day.
..a . _ .__..~,, Pharmacological methods:
1. Method for determining the affinity to the mGIuR5 receptor Pig brain homogenate is produced by homogenisation (Polytron PT 3000, Kinematica AG, 10,000 rpm for 90 seconds) of pig brain halves without medulla, cerebellum and pons in buffer pH 8.0 (30mM Hepes, Sigma, order no.H3375 + 1 tablet complete to 100mI, Roche Diagnostics, order no. 1836145) in ratio 1:20 (brain weight/volume) and differential centrifugation at 900 x g and 40,000 x g. In each case, 450 pg protein from brain homogenate is incubated with 5nM 3[H]-MPEP (Tocris, order no.
R1212) (MPEP = 2-methyl-6-(3-methoxyphenyl)-ethynylpyridine) in 250 pl incubation batches in 96 well microtitration plates and the compounds to be tested (10 pM in the test) in buffer (as above) at room temperature for 60 min.
Thereafter, the batches are filtered with the help of a Brandel Cell Harvester (Brandel, TYP Robotic 9600) on unifilter plates with glass fibre filter mats (Perkin Elmer, order no. 6005177) and subsequently washed with buffer (as above) 3 times with in each case 250 pl per sample. The filter plates are subsequently dried for 60 min at 55 C. 30 pL Ultima GoIdTM scintillator is subsequently added per well (Packard BioScience, order no. 6013159) and the samples are measured after 3 hours on the 9-counter (Mikrobeta, Perkin Elmer). The unspecific bond is determined by addition of 10 pM MPEP (Tocris, order no. 1212).
2a. Formaline test in rats The formaline test (Dubuisson, D. and Dennis, S.G., 1977, Pain, 4, 161 - 174) represents a model for acute and chronic pain. A biphasic nociceptive reaction, which is recorded by observation of three clearly differentiable behavioural patterns, is induced by a single formaline injection into the dorsal side of a rear paw in freely mobile test animals. The reaction has two phases: Phase 1 = Immediate reaction (duration up to 10 min; paw shaking, licking), Phase 2 = Late reaction (after a rest phase; likewise, paw shaking, licking; duration up to 60 min). The 1st phase reflects a direct stimulation of the peripheral nocisensors with high spinal nociceptive input or glutamate release (acute pain phase); the 2nd phase reflects a spinal and peripheral _....~,..,..~, ...~.. _ _ _ _..y_ ~-~
hypersensitisation (chronic pain phase). In the investigations presented here, the chronic pain component (phase 2) was evaluated.
Formaline with a volume of 50p1 and a concentration of 5% is administered subcutaneously into the dorsal side of the right rear paw of each animal. The substances to be tested are administered 30 min before the formaline injection orally (p.o), intravenously (i.v.) or intraperitoneally (i.p.). The specific changes in behaviour such as lifting and shaking the paw, shifts in weight of the animal as well as biting and licking reactions are observed and registered in the period of observation from 21 to 27 min after formaline injection. The various forms of behaviour are summarised in the so-called pain rate (PR), which, relative to the sub-intervals of 3 min, represents the calculation of an average nociception reaction. The calculation of PR is performed on the basis of a numerical weighting (= in each case factor 1, 2, 3) of the observed forms of behaviour (corresponding behavioural score 1, 2, 3) and is calculated with the following formula:
PR = [(To x 0) + (Ti x1)+(T2x2)+(T3x3)]/180 whereby To, Tl, T2, and T3 in each case corresponds to the time in seconds in which the animal demonstrates modes of behaviour 0, 1, 2 or 3. The group size is 10 animals (n=10).
2b. Formaline test in mice Formaline with a volume of 20pl and a concentration of 1% is administered subcutaneously into the dorsal side of the right rear paw of each animal. The substances to be tested are administered 15 min before the formaline injection intraperitoneally (i.p.). The specific changes in behaviour such as lifting and shaking the paw (score 3, Dubuisson & Dennis, 1977) are observed and registered in the period of observation from 21 to 24 min after formaline injection. The group size is 10 animals (n=10).
3. Neuropathic pain in rats . _.nr,._...._ ~,....,........... . . .~. . . . . . .. . . . .. . _.... . ..
.. . . . .. . . .
The investigation of effectiveness in neuropathic pain was performed using the Bennett model (chronic constriction injury; Bennett and Xie, 1988, Pain 33: 87-107).
The corresponding parts of the literatur are hereby regarded as part of the present disclosure.
Sprague-Dawley rats with a weight of 140-160 g are provided with four loose ligatures of the right nervus ischiaticus under nembutal narcosis. The animals develop at the paw innervated by the damaged nerve an oversensitivity which is quantified after a recuperation phase of a week over approximately four weeks by means of a 4 C cold metal plate (cold allodynia). The animals are observed for a period of 2 min. on this plate and the number of retraction reactions of the damaged paw is measured. Relative to the previous value before substance administration, the substance effect is determined over a period of an hour at four points in time (15, 30, 45, 60 min. after administration) and the resultant area under the curve (AUC) and the inhibition of the cold allodynia are expressed at the individual measurement points in percent of effect to vehicle control (AUC) or to the initial value (individual measurement points). The group size is n = 10. The significance of an anti-allodynic effect is determined using the AUC values via a paired T-test (* 0.05 _ p>0.01; **
0.01 _ p> 0.001; *** p<_ 0.001; Armitage and Berry, 1987, Stat. Methods in Medical Research, London: Blackwell Scientific Publications).
4. "Elevated Plus Maze" model In the "elevated plus maze" (EPM) model, compounds are tested for possible anxiolytic effects. The tests are performed in male Sprague-Dawley rats (200-250 g) and 2 "elevated plus mazes" (Med Associates) with electronically controlled infrared light boxes are used to determine the location of the animals in the labyrinth. Each labyrinth has 2 open and 2 closed arms and a central platform. The edges of the open arms are delimited by narrow strips. The entire labyrinth is mounted on a metal stand.
At the start of a 5-min test, each animal is individually placed on the cental platform with its head in the direction of a closed arm.
The following parameters are determined or calculated and evaluated:
Number and percentage of entries into the open and closed arms, and percentage of time in the open and closed arms and on the central platform.
The data is analysed by means of a 1-factorial ANOVA (comparison of treatment groups versus vehicle group). The significance level is set at p < 0.05. All the groups have a size of N = 10.
The test is also described in Hogg, S. (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem.
Behav.
54, 21-30 and Rodgers, R.J., Cole, J.C. (1994) The elevated plus-maze:
pharmacology, methodology and ethology. In: Cooper, S.J., Hendrie, C.A. (eds.) Ethology and Psychopharmacology. Wiley & Sons; pp. 9-44. The corresponding parts of the literature are hereby regarded as part of the disclosure.
5. Description of the functional Ca2+ influx assay 20,000 CHO-hmGluR5 cells/well (Euroscreen, Gosselies, Belgium) are pipetted into 96 well plates (BD Biosciences, Heidelberg, Germany, Ref 356640, clear bottom, well, Poly-D-Lysine) and incubated overnight in HBSS buffer (Gibco No. 14025-050) with the following additions: 10% FCS (GIBCO, 10270-106) and doxycycline (BD
Biosciences Clontech 631311 600ng/ml).
For the functional investigation, the cells were loaded with 2 pM fluo-4 and 0.01 Vol%
Pluronic F127 (Molecular Probes Europe BV, Leiden Netherlands) in HBSS buffer (Hank's buffered saline solution, Gibco Invitrogen GmbH, Karlsruhe, Germany) with probenicide (Sigma P8761, 0.69 mg/ml) for 30 min at 37 C.
The cells are then washed 3 times with washing buffer (HBSS buffer, Gibco No.
14025-050, with probenicide (Sigma P8761, 0.69 mg/mI) and subsequently absorbed with the same buffer ad 100 pl. After 15 min., the plates are transferred into a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA) for the determination of Ca2+ measurements in the presence of DHPG ((S)-3,5-dihydroxyphenylglycine, Tocris Biotrend Chemikalien GmbH, Cologne, Germany, _.w....... m_.. _... . . _.r.u_ final DHPG concentration: 10 pM) and in the presence or absence of test substances.
In this case, the Ca2+-dependent fluorescence is measured before and after addition of test substances. Quantification is performed by measurement of the maximum fluorescence intensity over time.
After recording the fluorescence base line for 10 sec., 50 pl test substance solution (various test substance concentrations in HBSS buffer with 1% DMSO and 0.02%
Tween 20, Sigma) is added and the fluorescence signal is measured for 6 min.
50 pl DHPG solution ((S)-3,5-dihydroxyphenylglycine, Tocris Biotrend Chemikalien GmbH, Cologne, Germany, final DHPG concentration: 10 pM) is subsequently added and the inflow of Ca2+ is simultaneously measured for 60 sec. The final DMSO
concentration is 0.25% and the final Tween 20 content is 0.005%. The data is analysed with Microsoft Excel and GraphPad Prism. The dose-effect curves are calculated with non-linear regression and IC50 values determined. Each data point is determined 3 times and IC50 values are averaged from a minimum of 2 independent measurements.
Ki values are calculated according to the following formula: Ki =
IC50/(1 +(AGconc./EC50)).
AGcon,. = 10 pM; EC50 corresponds to the DHPG concentration which is required for half the maximum inflow of CaZ+.
General instructions for the production of exemplary substituted imidazo[2,1-b]thiazoles General synthesis diagram 1:
R7 \~ + R3-N-C + H Mi M
II III IV
R' SY
I Ml -M2 ~N
V
The conversion of amines of the general formula II with isocyanides of the general formula III and aldehydes of the general formula IV to yield compounds of the general formula V was carried out in organic solvents or solvent mixtures, for example, of chloroform, DCM, MeCN, MeOH or EtOH, with the addition of an organic or inorganic acid, for example, trifluoroacetic acid or perchloric acid, or with the addition of a transition metal triflate, for example, scandium(III)triflate, ytterbiumtriflate or indium(III)triflate, at temperatures of 0 C to 150 C.
,f , _.u.,w.__. . _..._ . . ... ,~__.
General synthesis diagram 2:
s NHz 0 ' - R ~N + R3-N-C + H~
" Ml "I Step 1 Rz X
II III VI
S Y_N S N
R' Ml-X H- Mz R' Ml Mz \ N / VIII ~N
Rz NH Step 2' Rz NH
VII V
In step 1, the conversion of amines of the general formula II with isocyanides of the general formula III and aidehydes of the general formula VI, in which X
denotes a halogen residue, to yield compounds of the general formula VII was carried out in organic solvents or solvent mixtures, for example, of chloroform, DCM, MeCN, MeOH
or EtOH, with the addition of an organic or inorganic acid, for example, trifluoroacetic acid or perchloric acid, or with the addition of a transition metal triflate, for example, scandium(III)triflate, ytterbiumtriflate or indium(III)triflate, at temperatures of 0 C to 150 C.
In step 2, the conversion of compounds of the general formula VII, in which X
denotes a halogen residue, with acetylenes of the general formula VIII to yield compounds of the general formula V is carried out in a solvent or solvent mixture, for example, of toluol, THF, DMF, MeCN, ether, NEt3 or diisopropylamine, with the addition of a palladium catalyst, for example, bis(triphenylphosphine)-palladium(II)-chloride, of copper(I)-iodide and an organic base, for example, NEt3 or diisopropylamine, and/or inorganic base, for example, potassium carbonate or caesium carbonate, at temperatures of -70 C to 150 C.
, __ ..~.~.....võ~......~ ___ . . . .
General synthesis diagram 3:
S~ S
R~ I' MI = M2 SY N R' ~ M~ = M2 N 1 R' N Ml = MZ 2 N
2 ~ RZ
R ~ H R2 NH2 NH
v lx x In step 1, compounds of the general formula V were converted to yield amines of the general formula IX in a solvent or solvent mixture, for example, of EtOH, MeOH
or acetone, with the addition of an organic or inorganic acid, for example, acetic acid, trifluoroacetic acis, hydrochloric acid or sulphuric acid, at temperatures of 0 C to 80 C.
In step 2, compounds of the general formula IX (1 equivalent) were converted with carbonic acids (1 equivalent) of the general formula RZ'-(C=O)-OH in a solvent or solvent mixture, for example, of ether, THF, MeCN, MeOH, EtOH, DMF or DCM, with or without the addition of a coupling reagent (1 equivalent), for example, DCC, BOP, HATU or EDCI and optionally in the presence of at least one inorganic or organic base, for example, NEt3 or diisopropylethylamine, at temperatures of -70 C to to yield compounds of the general formula X.
Alternatively, compounds of the general formula IX (1 equivalent) were converted with carbonic acid halogenides (1 equivalent) or carbonic acid derivatives of the . general formula RZ'-(C=0)-X, whereby X denotes a halogen residue, in a solvent or solvent mixture, for example, of ether, THF, MeCN, MeOH, EtOH, DMF or DCM, with or without the addition of an organic or inorganic base, for example, NEt3, DMAP, pyridine or diisopropylamine, at temperatures of -70 C to 100 C to yield compounds of the general formula X.
As a further alternative, compounds of the general formula IX (1 equivalent) were converted with aldehydes (1 equivalent) of the general formula R21-C(=O)-H in a solvent or solvent mixture, for example, of ether, THF, MeOH, EtOH, DCM or toluol, and subsequent addition of a reducing agent, for example, sodium borohydride, sodium acetoxyborohydride or sodium cyanoborohydride, at temperatures of -70 C
to 100 C to yield compounds of the general formula X.
Compounds of the general formula IX (1 equivalent) were likewise converted with compounds of the general formula R4-X (1.1 equivalents), in which X denotes a halogen residue, preferably chlorine, in a solvent or solvent mixture, for example, of toluol, THF, or ether, with the addition of a metal hydride salt (1.1 equivalents), preferably with the addition of sodium hydride, to yield compounds of the general formula X at temperatures of 0 C to 40 C.
General synthesis diagram 4:
S N
R' I Ml - M2 S N
R~ 8 --r ~ Mi - MZ
R2 NH R2 N, V, X I
The compounds of the general formula V or X can be converted with the same methods as described in general synthesis diagram 3, step 2 to yield compounds of the general formula I.
General synthesis diagram 5:
~... .,.r,~ ,.,_..~..~..-a........~
_.,........_ ___ _ S SY ~
R' Ml-X R' N Ml M2 VII V
H - SiR3 Step 3 Step 1 XI
SY ~N ~
R' \ I ~ M1 - SiR3 Step 2 R' \ IN/ Ml N
XII XIII
In step 1, compounds of the general formula VII indicated above (1.0 equivalent), in which X denotes a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, are converted with acetylenes of the general formula VIII (5.0 equivalents) in acetonitrile with the addition of tetrakis(triphenylphosphine)palladium [(PPh3)4Pd] (10 mol.-%) and with the addition of [1,4]-diazabicyclo-[2.2.2]octane (2.0 equivalents) under reflux to yield compounds of the general formula V.
In step 2, compounds of the general formula XII indicated above (1.0 equivalent) are converted in a reaction medium, preferably selected from the group comprising methanol and dichloromethane and corresponding mixtures in the presence of potassium carbonate (10 mol-%) at temperatures of 20 C to 30 C to yield compounds of the general formula XIII.
In step 3, compounds of the general formula XIII indicated above (1.0 equivalent) are converted with compounds of the general formula M2-X (1.25 equivalents), in which X
denotes a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in ethylacetate, with the addition of bis(triphenylphosphine)-palladium(II)-chloride [PdCI2(PPh3)2] (5 mol-%), in the presence of copper(I)-iodide (6 mol-%), with the addition of triethylamine (2.0 equivalents), at temperatures of 40 C to 60 C, to yield compounds of the general formula V.
The instructions described above for the production of substituted imidazo[2,1-b]thiazoles are explained in detail below with reference to several exemplary compounds.
The following examples serve to explain the invention in greater detail but do not restrict the general concept of the invention.
, ..~..~ ,._.
Examples The yields of the produced compounds are not optimised.
All temperatures are uncorrected.
Abbreviations:
aq. aqueous d days Brine saturated, aqueous NaCI solution DCM dichloromethane DMF N,N-dimethytformamide AE acetic acid ethylester Ether diethylether sat. saturated NEt3 triethylamine RT room temperature CC column chromatography TBME tertiary butyl-methyl-ether The chemicals and solvents used were commercially acquired from the normal suppliers (Acros, Avocado, Aldrich, Bachem, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, etc.) or synthesised according to methods known to the person skilled in the art.
Silica gel 60 (0.040 - 0.063 mm) from E. Merck, Darmstadt was used as the stationary phase for the column chromathography.
The thin layer chromatographic tests were carried out with HPTLC ready plates, silica gel 60 F 254, from E. Merck, Darmstadt.
The mixture ratios of solvents, mobile solvents or for chromatographic investigations are always indicated in volume/volume.
,_ . _,...~.~~,......~ . _ ,. _..~.~
Analysis of all the examples was performed by mass spectroscopy and NMR
spectroscopy.
Example 1: Synthesis of 6-(5-(phenylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 400 mg (4.0 mmol) 2-aminothiazole, 1018 mg (4.8 mmol) 5-phenylethynyl-thiophene-2-carbaldehyde, 557 mg (4.0 mmol) (2,4,4-trimethylpentane-2-yl)-isocyanide and 400 pl of a 20% aq. perchloric acid was stirred in DCM (8 ml) for 5 d at RT. A 1 molar aq. Na2CO3 sol. was subsequently added.
The phases were separated and the aqueous phase was extracted with DCM. The collected organic phases were washed with brine and dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC (AE/hexane 1:4) was performed with the residue, whereby 637 mg (1.47 mmol, 37%) 6-(5-(phenylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained.
Example 2: Synthesis of N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 400 mg (4.0 mmol) 2-aminothiazole, 938 mg (4.4 mmol) 5-(pyridine-2-yl-ethynyl)-thiophene-2-carbatdehyde, 332 mg (4.0 mmol) tert.butyl-isocyanide and pl of a 20% aq. perchloric acid in chloroform (10 ml) was stirred for 10 d at RT. A 1 molar aq. Na2CO3 sol. was subsequently added. The phases were separated and the aqueous phase was extracted with chloroform. The collected organic phases were washed with brine and dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC (AE/DCM 15:85) was performed with the residue, whereby 223 mg impure raw product was obtained. 156 mg (0.41 mmol, 10%) N-tert-butyl-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained from this by crystallisation from AE.
Example 3: Synthesis of N-tert-butyl-3-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine hydrochloride A solution of 256 mg (2.25 mmol) 2-amino-4-methyl-thiazole, 527 mg (2.48 mmol) (pyridine-2-yl-ethinyl)-thiophene-2-carbaldehyde, 205 mg (2.48 mmol) tert.butyl-isocyanide and 58 lal of a 70% aq. perchloric acid was stirred in chloroform (2 ml) for 16 h at RT. Dilution with DCM (20 ml) was subsequently performed and a 1 molar aq.
Na2CO3 sol. (10 ml) added. After 10 min stirring at RT, the phases were separated.
The aqueous phase was extracted with DCM. The collected organic phases were dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC
(AE/DCM 25:75) was performed with the residue, whereby 41 mg impure raw product was obtained. This was dissolved in acetone (1 ml) and 1{al water and 11 NI
trimethylchlorosilane were subsequently added. The resultant precipitate was sucked up and washed with ether. Thereby, 18 mg (0.04 mmol, 2%) N-tert-butyl-3-methyl-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine hydrochloride was obtained.
Example 4: Synthesis of N-tert-butyl-2-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 256 mg (2.25 mmol) 2-amino-5-methyl-thiazole, 527 mg (2.48 mmol) (pyridine-2-yl-ethynyl)-thiophene-2-carbaldehyde, 205 mg (2.48 mmol) tert.butyl-isocyanide and 58 pl of a 70%n aq. perchloric acid was stirred in chloroform (2 ml) for 16 h at RT. Dilution with DCM (20 ml) was subsequently performed and a 1 molar aq.
Na2CO3 sol. (10 ml) added. After 10 min stirring at RT, the phases were separated.
The aqueous phase was extracted with DCM. The collected organic phases were dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC
(AE/DCM 25:75) was performed with the residue, whereby 367 mg impure raw product was obtained. 48 mg (0.12 mmol, 5%) N-tert-butyl-2-methyl-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained from this by crystallisation from AE.
Example 5: Synthesis of N-tert-butyl-2,3-dimethyl-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride Example 6: Synthesis von N-tert-butyl-2-chloro-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride The synthesis of Examples 5 and 6 was performed in accordance with the method described for Example 3.
Example 7: N-tert-butyl-6-(5-(pyridine-4-ylethinyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine Example 8: 5-(tert-butylamino)-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-2-carbonic acid methylester hydrochloride The synthesis of Examples 7 and 8 was performed in accordance with the method described for Example 4.
Example 9: N-tert-butyl-6-(5-(pyridine-2-ylethynyi)thiazole-2-yl)imidazo[2,1-b]thiazole-5-amine a) Synthesis of 6-(5-bromothiazole-2-yi)-N-tert-butylimidazo[2,1-b]thiazole-5-amine 1 molar perchloric acid (10 pl) in ethanol (4 ml) was added to a solution of 100 mg (1.0 mmol) 2-amino-thiazole, 191 mg (1.0 mmol) 5-bromo-thiazole-2-carbaldehyde and 97 mg (1.17 mmol) tert.butylisonitrile and the mixture was heated for 5 min in the microwave (Biotage initiator). The reaction solution was subsequently concentrated in a vacuum. A CC (TBME/hexane 1:1) was performed with the residue, whereby 71 mg (0.2 mmol, 20%) 6-(5-bromothiazole-2-yl)-N-tert-butylimidazo[2,1-b]thiazole-amine [MH+] 357.0 was obtained.
b) Synthesis of N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiazole-2-yl)imidazo[2,1-b]thiazole-5-amine A mixture of 235 mg (0.66 mmol) 6-(5-bromothiazole-2-yl)-N-tert-butylimidazo[2,1-b]thiazole-5-amine, 22 mg (0.033 mmol) bis(triphenylphosphine)-palladium-(II)-chloride, 12 mg (0.066mmol) copper-(I)-iodide, 80 NI (0.79 mmol) 2-ethynylpyridine and 731 pI (5.28 mmol) NEt3 in DMF (2 ml) was heated in the microwave (Biotage Initiator) for 10 min to 120 C. The reaction solution was diluted with water and extracted several times with AE. The collected organic phases were washed with brine and dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC (1.TBME, 2.MeOH) was performed with the residue, whereby 43 mg (0.11 mmol, 17%) N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiazote-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained.
Example 10: Synthesis of 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yi)imidazo[2,1-b]thiazole-5-amine A solution of 5.0 g (50.0 mmol) 2-amino-thiazole, 10.7 g (50.0 mmol) 5-(pyridine-2-yl-ethynyl)-thiophene-2-carbaldehyde, 7.0 g (50.0 mmol) (2,4,4-trimethylpentane-2-yl)-isocyanide and 1.0 ml of a 70% aq. perchloric acid in chloroform (25 ml) was heated to 50 C while being stirred for 5 d. Dilution with DCM was subsequently performed and a 1 molar aq. Na2CO3 sol. was added. After 10 min of stirring at RT, the phases were separated. The aqueous phase was extracted with DCM. The collected organic phases were dried over Na2SO4, filtered and concentrated in a vacuum. 11.86 g (27.3 mmol, 55%) 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained by multiple crystallisation of the residue from AE.
Example 11: N-tert-butyl-2-methyl-6-(4-(pyridine-2-ylethynyl)phenyl)imidazo[2,1-b]thiazole-5-amine The synthesis of Example 11 was performed in accordance with the method described for Example 10.
Example 12: Synthesis of N-tert-butyi-6-(5-(pyridine-2-ylethynyl)furan-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 380 mg (3.8 mmol) 2-amino-thiazole, 749 mg (3.8 mmol) 5-(pyridine-2-yl-ethynyl)-furan-2-carbaldehyde, 378 mg (3.8 mmol) tert.butyl-isonitril and 73 pl of a 70% aq. perchloric acid in chloroform (2 ml) was heated to 45 C while being stirred for 16 h. Dilution with DCM was subsequently performed and a 1 molar aq.
Na2CO3 sol. was added. After 10 min of stirring at RT, the phases were separated. The aqueous phase was extracted with DCM. The collected organic phases were dried over Na2SO4, filtered and concentrated in a vacuum. 472 mg (1.3 mmol, 34%) N-tert-butyl-6-(5-(pyridine-2-ylethynyl)furan-2-yl)imidazo[2, 1 -b]thiazole-5-amine was obtained by CC (AE) with the residue.
Example 13: N-tert-butyl-3-methyl-6-(5-(phenylethynyl)thiophene-2-yl)im idazo[2,1-b]thiazole-5-amine The synthesis of Example 13 was performed in accordance with the method described for Example 12.
Example 14: Synthesis of 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine Trifluoroacetic acid (30 ml) was added to a solution of 2.5 g (5.75 mmol) 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine (Example 10) in DCM (30 ml) and the mixture was stirred for min at RT. Basification (pH > 12) was subsequently performed under cooling (ice bath) with a 12 molar aq. NaOH sol. The resultant residue was filtered off and dissolved in a mixture of AE (200 ml) and DCM (50 ml) and washed with water (15 ml) and dried over Na2SO4. After removal of the solvent in a vacuum, 773 mg (2.40 mmol, 42%) 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained.
Example 16: N-tert-butyl-6-(5-((3-fluoropyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine a) Synthesis of 6-(5-bromothiophene-2-yl)-N-tert-butylimidazo[2,1-b]thiazole-5-amine 22.9 g(119.9 mmol) 5-bromo-thiophene-2-carbaldehyde and 11.0 g (131.9 mmol) tert.-butyl-isonitrile were added to a solution of 12.0 g (119.9 mmol) 2-amino-thiazole in chloroform (60 ml). A 1 molar perchloric acid (2.3 ml) was added to the reaction solution and heated to 50 C while being stirred for 5 d. After cooling to RT, dilution ,,...._~.. ... _. . __.._.. .
with DCM was performed and a 1 molar aq. Na2CO3 sol. added. After 10 min of stirring at RT, the phases were separated. The organic phase was dried over Na2SO4, filtered and concentrated in a vacuum. 6.6 g (18.5 mmol, 15%) 6-(5-bromothiophene-2-yl)-N-tert-butylimidazo[2,1-b]thiazole-5-amine ([MH+] 356.0) was obtained by crystallisation of the residue from AE.
b) Synthesis of N-tert-butyl-6-(5-((trimethylsilyl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine 4.1 g (3.5 mmol) tetrakis(triphenyl)phosphine-palladium(0), 17.2 g (175.4 mmol) trimethyl-silylacetylene and 7.9 g (70.2 mmol) 1,4-diazabicyclo[2.2.2]octane were consecutively added to a suspension of 12.5 g (35.1 mmol) 6-(5-bromothiophene-yl)-N-tert-butylimidazo[2,1-b]thiazole-5-amine in acetonitrile (150 ml). The reaction solution was heated for 72 h under reflux and subsequently concentated in a vacuum. 3.0 g (7.9 mmol, 23%) N-tert-butyl-6-(5-((trimethylsilyl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine ([MH+] 374.1) was obtained by CC (DCM/AE
95:5).
c) Synthesis of N-tert-butyl-6-(5-ethynylthiophene-2-yl)imidazo[2,1-b]thiazole-amine A suspension of 3.0 g (7.9 mmol) N-tert-butyl-6-(5-((trimethylsilyl)-ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine in a mixture of DCM (12 ml) and methanol (58 ml) was heated to 35 C and 108 mg (0.79 mmol) potassium carbonate was added.
After 100 min of stirring at RT, water and DCM were added. The phases were separated and the aqueous phase was extracted with DCM. The collected organic phases were washed with water, dried over Na2SO4, filtered and concentrated in a vacuum. The obtained 2.17 g (7.2 mmol, 91%) of raw product of N-tert-butyl-6-(5-ethynylthiophene-2-yl)imidazo[2,1-b]thiazole-5-amine ([MH+] 302.1) was converted in the next step without further purification.
d) Synthesis of N-tert-butyl-6-(5-((3-fluoropyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 450 mg (1.49 mmol) N-tert-butyl-6-(5-ethynylthiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, 333 mg (1.90 mmol) 3-fluoro-2-iodo-pyridine, 38 mg (0.06 mmol) bis(triphenylphosphine)-palladium-(II)-chloride, 19 mg (0.07 mmol) copper-(I)-iodide and 389 pI (2.80 mmol) NEt3 in AE (21 ml) was heated to 50 C while being stirred for ,.._.. . _ . ..
...,., ._~._~_ 20 h. Concentration in a vacuum was subsequently performed and a CC (AE) carried out with the residue, whereby 456 mg (1.15 mmol, 77%) N-tert-butyl-6-(5-((3-fl uoropyridi ne-2-yl)ethynyl)thiophene-2-yl)i mid azo[2, 1 -b]thiazole-5-amine was obtained.
Example 15: N-tert-butyl-6-(5-(pyrimidine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazoie-5-amine Example 17: N-tert-butyl-6-(5-((2-fluoropyridine-4-yl)ethynyl)thiophene-2-yl)im idazo[2,1-b]thiazole-5-amine Example 18: N-tert-butyl-6-(5-(thiophene-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine Example 19: N-tert-butyl-6-(5-(thiazole-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine Example 20: 3-((5-(5-(tert-butylamino)imidazo[2,1-b]thiazole-6-yl)thiophene-2-yl)ethynyl)phenol Example 21: 3-((5-(5-(tert-butylamino)imidazo[2,1-b]thiazole-6-yl)thiophene-2-yl)ethynyl)benzonitrile Example 23 N-tert-butyl-6-(5-((3-methylpyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine The synthesis of Examples 15, 17, 18, 19, 20, 21 and 23 was performed in accordance with the method described for Example 16.
Example 25: Synthesis of N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)benzamide . r_.._ .._.._.~r.... _,. _ _ _ _ 59 pI (0.52 mmol) benzoylchloride was dropped into a solution of 185 mg (0.57 mmol) 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine (Example 14) and 174 NI (1.26 mmol) NEt3 in DCM (3 ml) under cooling (ice bath).
After 16 h of stirring at RT, dilution with AE was performed. Washing was subsequently carried out consecutively with a saturated, aqueous sodium carbonate solution and with a saturated, aqueous sodium chloride solution. The organic phase was dried over Na2SO4, filtered and concentrated in a vacuum. A CC (AE) was performed with the residue, whereby 10 mg (0.02 mmol, 4%) N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)benzamide was obtained.
Example 22: N-ethyl-6-(6-(phenylethynyl)pyridine-3-yl)imidazo[2,1-b]thiazole-5-amine The synthesis of Example 22 was performed in accordance with the method described for Example 4.
Example 24: N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)acetamide The synthesis of Example 24 was performed in accordance with the method described for Example 25.
w_....,. __._. .
...~. ._...~~.,.,.~...~
The values obtained by means of mass spectrometry are listed in the following table.
Example Mass [MH+]
1 434.2 2 379.1 3 393.1 4 393.1 407.1 6 413.1 7 379.1 8 437.1 9 380.1 435.2 11 387.2 12 363.1 13 392.1 14 323.0 380.1 16 397.1 17 397.1 18 384.1 19 385.1 394.1 21 403.1 22 345.1 23 393.1 24 365.0 427.1 Pharmacological data:
1. The affinity of the substituted imidazo[2,1-b]thiazole compounds according to the invention of the general formula I to the mGluR5 receptor was determined as described above.
The substituted imidazo[2,1-b]thiazole compounds according to the invention exhibit an outstanding affinity to the mGluR5 receptor.
The pharmacological data for the substituted imidazo[2,1-b]thiazole compounds according to Examples 1 to 4 is reproduced in the following table 1:
Table 1:
Ex. ICso ['H]-MPEP bond mGIuR5 receptor (pig) ED50 formaline test mGIuR5 receptor (pig) (10 NM) (rat) i.v.
INMI inhibition (%) Img/kgl 1 2.1800 2 0.0063 0.47 3 0.0120 4 0.0055 0.0170 6 0.0099 7 0.0030 8 0.1600 0.1000 11 0.0200 12 0.0870 14 0.1400 0.0100 16 0.0130 17 0.0180 18 0.0450 19 0.0240 0.1700 21 0.0260 23 0.2300 2. The substituted imidazo[2,1-b]thiazole compounds according to the invention also exhibit an outstanding effect in the formaline test on rats as is reproduced in the following table 2.
Table 2:
Ex. ED50 formaline test Formaline test (rat) i.v. (rat) p.o.
[mg/kg] Reduction in the nociceptive behaviour over controls at 10 mg/kg [%]
2 0.47 66 3. The substituted imidazo[2,1-b]thiazole compounds according to the invention exhibit an outstanding affinity to the human mGluR5 receptor (Table 3.) Table 3.
Ex. K; mGluR5 receptor (human) CaZ+-influx [pM]
4 0.00031 7 0.00026 .., .w ~.......~..,.... _,-. . ... .. _.... .~...,...,_....~.-..
in each case optionally in the form of corresponding salts, or in each case in the form of corresponding solvates.
Substituted imidazo[2,1-b]thiazole compounds of the general formula I
indicated above are likewise particularly preferred, which, after 60 minutes of incubation in 450 pg protein from pig brain homogenate at a temperature between 20 C and 25 C
in a concentration of less than 2500 nM, preferably of less than 1000 nM, particularly preferably of less than 700 nM, very particularly preferably of less than 100 nM, even more preferably of less than 70 nM, bring about a 50-percent displacement of [3H]-2-methyl-6-(3-methoxyphenyl)-ethynytpyridine which is present in a concentration of 5 nM.
Thereby, the determination of the displacement of [3H]-2-methyl-6-(3-methoxyphenyl)-ethynylpyridine is performed as described in the section Pharmacological Methods, I. Method for determing the inhibition of [3H]-MPEP-bonding in the mGIuR5 receptor bonding assay.
A further subject matter of the present invention is a method for producing compounds of the general formula I indicated above, according to which at least one compound of the general formula II, Rl S~NH2 \
N
II, in which R' and R2 have the meaning indicated above, in a reaction medium, optionally in the presence of at least one organic or inorganic acid or at least one transition metal salt, is converted with at least one isocyanide of the general formula III, III, in which R3 has the meaning indicated above, and at least one aidehyde of the general formula IV, O
H M
IV, in which M' and M2 have the meaning indicated above, and the compound obtained in this manner of the general formula V, s N
R' \~ Ml M2 N
V, in which R1, R2, R3, M' and M2 have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, or at least one compound of the general formula II, ~ S~NH2 R \
LN
II, in which R' and R2 have the meaning indicated above, in a reaction medium, optionally in the presence of at least one organic or inorganic acid or at least one transition metal salt, is converted with at least one isocyanide of the general formula III, ..,_...,,._ ~..,~..,._ . ...._ III, in which R3 has the meaning indicated above, and at least one aldehyde of the general formula VI, A
H M -I X
VI, in which M' has the meaning indicated above and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, and the compound obtained in this manner of the general formula VII, SY N
R' \ N Ml-X
VII, in which R1, R2, R3, Ml and X have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and by conversion with at least one acetylene of the general formula XI, H SiR3 XI, in which R, mutually independently, in each case denotes a linear or branched alkyl residue or an unsubstituted phenyl residue, in a reaction medium, optionally in the presence of at least one suitable catalyst, optionally in the presence of at least one copper(I)salt, preferably in the presence of copper-(I)-iodide, and optionally in the presence of at least one inorganic and/or organic base is transformed into a correspondingly substituted compound of the general formula XII, R' \ N M1 SiR3 XII, in which R1, R2, R3 and M' have the above-mentioned meaning and R, mutually independently, in each case denotes a linear or branched alkyl residue or an unsubstituted phenyl residue, and is optionaNy purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and at least one compound of the general formula XII is transformed in a reaction medium, optionally in the presence of at least one inorganic and/or organic base, optionally in the presence of at least one inorganic salt, and optionally in the presence of at least one ammonium salt, into a correspondingly substituted compound of the general formula XIII, S N
R' \ N / Ml r XI(I, in which R', R2, R3 and M' have the above-mentioned meaning, and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and at least one compound of the general formula XIII and/or at least one compound of the general formula XII is transformed by conversion with at least one compound of the general formula M2-X, in which M2 has the above-mentioned meaning and X
denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one suitable catalyst, optionally in the presence of at least one inorganic and/or organic base, optionally in the presence of at least one inorganic salt and optionally in the presence of at least one ammonium salt into a correspondingly substituted compound of the general formula V, S N
R' M1 M2 N
V, in which R1, R2, R3, M' and M2 have the above-mentioned meaning and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, or a compound of the general formula VII is transformed by conversion with at least one acetylene of the general formula VIII, VIII, in which M2 has the meaning indicated above, in a reaction medium, optionally in the presence of at least one suitable catalyst, optionally in the presence of at least one copper(I)salt, preferably in the presence of copper-(l)-iodide and optionally in the presence of at least one inorganic and/or organic base into a correspondingly substituted compound of the general formula V, s N
R' \~ Ml M2 V, in which R', R2, R3, M' and M2 have the above-mentioned meaning and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and optionally the compound of the general formula V is transformed by conversion with at least one compound of the general formula R4-X, in which R4 has the meaning indicated above and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, in a reaction medium, in the presence of at least one organic or inorganic base, preferably in the presence of at least one metal hydride salt, or by conversion with at least one compound of the general formula R21-C(=0)-OH, in which R21 has the meaning indicated above, in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or in the presence of at least one coupling agent, or by conversion with at least one compound of the general formula R21-C(=O)-X, in which R21 has the meaning indicated above and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one organic or inorganic base, ,...__.~ .~__ . .... . ....
or by conversion with at least one compound of the general formula R21-C(=O)-H, in which R21 has the meaning indicated above, in a reaction medium, optionally in the presence of at least one reducing agent, into a compound of the general formula I, optionally in the form of a corresponding salt, S N
R1 \~ M1 M2 N
I, in which R1, R2, R3, R4, M' and M2 have the meaning indicated above, and this is optionally purified and/or isolated.
A subject matter of the present invention is also a method for producing compounds of the general formula I indicated above according to which at least one compound of the general formula V is converted, s N
R \ N ~ M M
V, in which R1, RZ, R3, M' and M2 have the above-mentioned meaning, optionally in a reaction medium in the presence of at least one organic or inorganic acid, and the compound obtained in this manner of the general formula IX, , _ .. _.._.w_~.,...~..~.
SY N
R' I Ml M2 \ N
IX, in which R1, R2, M' and M2 have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated and is transformed in a reaction medium, in the presence of at least one inorganic or organic base, preferably in the presence of at least one metal hydride salt, with at least one compound of the general formula R3-X, in which R3 has the meaning indicated above and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, or in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or optionally in the presence of at least one coupling agent with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the above-mentioned meaning, or in a reaction medium, optionally in the presence of at least one organic or inorganic base with at least one compound of the general formula R21-C(=O)-X, in which R21 has the above-mentioned meaning and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, or in a reaction medium, optionally in the presence of at least one reducing agent with at least one compound of the general formula R21-C(=O)-H, in which R21 has the above-mentioned meaning, into a corresponding compound of the general formula X, optionally in the form of a corresponding salt, S N
R' \ ~ ~e_ Ml M2 N
X, in which R1, R2, R3, M' and M2 have the above-mentioned meaning, and this is optionally purified and/or isolated, and optionally the compound of the general formula X is transformed by conversion with at least one compound of the general formula R4-X, in which R4 has the above-mentioned meaning and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, in a reaction medium, in the presence of at least one organic or inorganic base, preferably in the presence of at least one metal hydride salt, or by conversion with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the above-mentioned meaning, in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or in the presence of at least one coupling agent, or by conversion with at least one compound of the general formula R21-C(=O)-X, in which R21 has the above-mentioned meaning and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one organic or inorganic base, or by conversion with at least one compound of the general formula R21-C(=O)-H, in which R21 has the above-mentioned meaning, in a reaction medium, optionally in the presence of at least one reducing agent, _. e. .._ .,.._.~. _._ _~....~,,m~..
into a compound of the general formula I indicated above, optionally in the form of a corresponding salt, S N
R' \ M1 M2 N
in which R1, R2, R3, R4, M1 and M2 have the above-mentioned meaning, and this is optionally purified and/or isolated.
The methods according to the invention for producing substituted imidazo[2,1-b]thiazole compounds of the general formula I indicated above are also indicated in following diagrams 1 to 4.
S NH
I
R1 \
N + R3-N-C + H M1 II III IV
~
sY N
R1 \ M1 - M2 N
V
Diagram 1.
In a three-component-coupling reaction, amines of the general formula II are converted with isocyanides of the general formula III and aldehydes of the general formula IV in a reaction medium, preferably selected from the group comprising chloroform, dichloromethane, acetonitrile, methanol and ethanol, with the addition of ..... _ ... .w.k._ at least one organic or inorganic acid, preferably trifluoroacetic acid or perchloric acid, or with the addition of at least one transition metal salt, preferably with the addition of at least one transition metal triflate (transition metal trifluoromethanesulphonate), particularly preferably with the addition of at least one transition metal triflate selected from the group comprising scandium(I I I)trifluoromethanesulphonate, ytterbiumtrifluoromethanesulphonate and indium(III)trifluoromethanesulphonate, preferably at temperatures of 0 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula V.
A further method for producing substituted imidazo[2,1-b]thiazole compounds of the general formula I indicated above via compounds or the general formula V
indicated above is reproduced in Diagram 2.
S NHZ O
i A R \ N + R3-N-C + ~
Mi Step 1 II III VI
S N S N
R' \ Ml_X H- Mz R' Ml - M2 VIII
RZ N H Step 2 Rz N H
VII V
Step 5 H- SiR3 M2-X Step 5 Step 3 XI
SY N 1 S~N
R~ \ N/ SiRs Step 4 R IN' XII XIII
...,.._..__..-. ,_....__ __ n_.
Diagram 2.
In step 1, amines of the general formula II are converted in a three-component-coupling reaction with isocyanides of the general formula III and aidehydes of the general formula VI, in which X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, preferably selected from the group comprising chloroform, dichloromethane, acetonitrile, methanol and ethanol, with the addition of at least one organic or inorganic acid, preferably selected from the group comprising trifluoroacetic acid or perchloric acid, or with the addition of at least one transition metal salt, preferably with the addition of at least one transition metal triflate (transition metal trifluoromethanesulphonate), particularly preferably with the addition of at least one transition metal trifluoromethanesulphonate selected from the group comprising scandium(I I I)trifluoromethanesulphonate, ytterbiumtrifluoromethanesulphonate and indium(III) trifluoromethanesulphonate, preferably at temperatures of 0 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula VII, in which X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate.
In step 2, compounds of the general formula VII indicated above, in which X
denotes a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, are converted with acetylenes of the general formula VIII in a reaction medium, preferably selected from the group comprising methanol, ethyl acetate, ethanol, isopropanol, n-butanol, dioxane, chloroform, dichloromethane, pyridine, dimethylsulphoxide, toluol, tetrahydrofuran, dimethylformamide, acetonitrile, diethylether, water and corresponding mixtures, particularly preferably selected from the group comprising dimethylformamide, ethyl acetate, tetrahydrofuran, water and corresponding mixtures, preferably with the addition of at least one palladium catalyst, preferably selected from the group comprising palladium(II)-dichloride [PdC12], bis(triphenylphosphine)-palladium(I I)-acetate [Pd(PPh3)2(OAc)2], bis(triphenylphosphine)-palladium(II)-chloride [PdCI2(PPh3)2], palladium(II)-acetate [Pd(OAc)2; Ac = acetate], bis(acetonitrile)-palladium(II)-chloride [(CH3CN)2)PdCI2], bis(benzonitrile)-palladium(II)-chloride [(PhCN)2PdCI2] and tetrakis(triphenylphosphine)palladium [(PPh3)4Pd], particularly preferably selected from the group comprising Pd(PPh3)2(OAc)2, (PPh3)4Pd and PdCl2(PPh3)2, optionally in the presence of at least one copper(I)salt, preferably in the presence of copper(l)-iodide, optionally in the presence of at least one phosphine, preferably a phosphine selected from the group comprising triphenylphosphine, tri-(tert-butyl)-phosphine, triphenylarsine and tri-(ortho-toluyl)-phosphine, particularly preferably in the presence of triphenylphosphine, optionally with the addition of at least one inorganic salt, preferably with the addition of lithium and/or zinc chloride, optionally with the addition of at least one organic base, preferably of an organic base selected from the group comprising triethylamine, diisopropylamine, diisopropylethylamine and [1,4]-diazabicyclo-[2.2.2]octane and/or with the addition of at least one inorganic base, preferably selected from the group comprising potassium carbonate, sodium hydrogen carbonate and caesium carbonate, whereby in particular the organic base can also be the reaction medium, at temperatures of preferably -70 C to 300 C, particularly preferably of -70 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula V.
In step 3, compounds of the general formula VII indicated above are converted with compounds of the general formula XI indicated above under the conditions cited in Diagram 2, Step 2 to yield compounds of the general formula XII.
In step 4, compounds of the general formula XII indicated above are converted in a reaction medium, preferably selected from the group comprising methanol, ethyl acetate, ethanol, isopropanol, n-butanol, dioxane, chloroform, dichloromethane, pyridine, dimethylsulphoxide, toluol, tetrahydrofuran, dimethylformamide, acetonitrile, diethylether, water and corresponding mixtures, particularly preferably selected from the group comprising dimethylformamide, ethyl acetate, tetrahydrofuran, water and corresponding mixtures, optionally in the presence of at least one inorganic base, preferably in the presence of at least one inorganic base selected from the group comprising potassium carbonate, sodium hydroxide, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium hydroxide and lithium hydroxide, optionally in the presence of at least one inorganic base, preferably of at least one inorganic base selected from the group comprising triethylamine and pyridine, optionally in the presence of at least one inorganic salt, preferably in the presence of at least one .. ,.....
. ..y.. .... ...,--r.. ...M.mwwsw~..or. r.w~ . . . . . . .. .. . . .. . . .
ammonium salt or in the presence of potassium and/or sodium fluoride, particularly preferably in the presence of at least one ammonium salt selected from the group comprising tetra-n-butylammonium fluoride, tetra-n-butyl-ammonium iodide and tetrabutylammonium bromide, at temperatures of preferably -70 C to 300 C, particularly preferably of -70 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula XI I L
In step 5, compounds of the general formulae XII and XIII indicated above are converted with compounds of the general formula M2-X, in which X denotes a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesu[phonate, in a reaction medium, preferably selected from the group comprising methanol, ethyl acetate, ethanol, isopropanol, n-butanol, dioxane, chloroform, dichloromethane, pyridine, dimethylsulphoxide, toluol, tetrahydrofuran, dimethylformamide, acetonitrile, diethylether, water and corresponding mixtures, particularly preferably selected from the group comprising dimethylformamide, ethyl acetate, tetrahydrofuran, water and corresponding mixtures, preferably with the addition of at least one palladium catalyst, preferably selected from the group comprising palladium(II)-dichloride [PdCl2], bis(triphenylphosphine)-palladium(II)-acetate [Pd(PPh3)2(OAc)2], bis(triphenylphosphine)-palladium(I I)-chloride [PdCI2(PPh3)2], palladium(II)-acetate [Pd(OAc)2; Ac = acetate], bis(acetonitrile)-palladium(II)-chloride [(CH3CN)2)PdCI2], bis(benzonitrile)-palladium(II)-chloride [(PhCN)2PdCI2] and tetrakis(triphenylphosphine)palladium [(PPh3)4Pd], particularly preferably selected from the group comprising Pd(PPh3)2(OAc)Z, (PPh3)4Pd and PdCl2(PPh3)2, optionally in the presenence of at least one copper(l)salt, preferably in the presence of copper(1)-iodide, optionally in the presence of at least one phosphine, preferaby a phosphine selected from the group comprising triphenylphosphine, tri-(tert-butyl)-phosphine, triphenylarsine and tri-(ortho-toluyl)-phosphine, particularly preferaby in the presence of triphenylphosphine, optionally with the addition of at least one inorganic salt, preferably with the addition of lithium and/or zinc chloride, optionally in the presence of at least one ammonium salt or in the presence of potassium and/or sodium fluoride, preferably in the presence of at least one ammonium salt selected from the group comprising tetra-n-butylammonium fluoride, tetra-n-butyl-ammonium iodide and tetrabutylammonium bromide, optionally with the addition of at least one organic base, preferably of an organic base selected ....w.....r.p.w . . . . . . . . . . _ . . . .. . . . . . .. . .... ... . . . .
. ... .. . . . . . . . .. . _ . . . . .
from the group comprising triethylamine, diisopropylamine, diisopropylethylamine and [1,4]-diazabicyclo-[2.2.2]octane and/or with the addition of at least one inorganic base, preferably selected from the group comprising potassium carbonate, sodium hydrogen carbonate and caesium carbonate, whereby in particular the organic base can also be the reaction medium, at temperatures of preferably -70 C to 300 C, particularly preferably of -70 C to 150 C, optionally in the presence of microwave radiation to yield compounds of the general formula V.
The conversion of compounds of the general formula XII with compounds of the general formula M2-X is preferably performed in the presence of at least one ammonium salt or in the presence of potassium and/or sodium fluoride.
The compounds of the general formula V can be converted as shown in Diagram 3 to yield compounds of the formula X.
s N s N
~ - ~
R'~ N Ml - M2 s N
R1 \Y/ Ml MZ 2 R'~ N/ M~ = Mz 2J\` ~ I 2 R %H R2 NH2 R ~ H
v iX x Diagram 3.
In step 1, compounds of the general formula V indicated above are converted in a reaction medium, preferably selected from the group comprising ethanol, methanol and acetone, with the addition of at least one organic acid, preferably acetic acid or trifluoroacetic acid and/or with the addition of at least one inorganic acid, preferably hydochloric acid or sulphuric acid, at temperatures of preferably 0 C to 80 C, optionally in the presence of microwave radiation to yield compounds of the general formula IX.
In step 2, compounds of the general formula IX indicated above are converted with carboxylic acids of the general formula R21-(C=O)-OH, in which R21 has the above-mentioned meaning, in a reaction medium, preferably selected from the group comprising diethylether, tetrahydrofuran, acetonitrile, methanol, ethanol, dimethylformamide and dichloromethane, optionally in the presence of at least one coupling reagent, preferably selected from the group comprising 1-benzotriazolyloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), dicyclohexylcarbodiimide (DCC), N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDCI), N-[(dimethyamino)-1H-1, 2, 3-triazolo[4, 5-b]pyridino-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), O-(benzotriazol-1-yl)-N,N,N`,N`-tetramethyluroniom hexafluorophosphate (HBTU) and 1-hydroxy-7-azabenzotriazol (HOAt), optionally in the presence of at least one inorganic base, preferably selected from the group comprising potassium carbonate and caesium carbonate, or of an organic base, preferably selected from the group comprising triethylamine, pyridine, dimethylaminopyridine and diisopropylethylamine preferably at temperatures of -70 C to 100 C, optionally in the presence of microwave radiation to yield compounds of the general formula X.
Alternatively, compounds of the general formula IX are converted with carboxylic acid derivatives or carbonic acid derivatives of the general formula R21-(C=O)-X, whereby X denotes a halogen residue, preferably chlorine or bromine, in a reaction medium, preferably selected from the group comprising diethylether, tetrahydrofuran, acetonitrile, methanol, ethanol, dimethylformamide and dichloromethane, with or without addition of at least one organic or inorganic base, for example, triethylamine, dimethylaminopyridine, pyridine or diisopropylamine, optionally in the presence of at least one organic base, preferably selected from the group comprising triethylamine, dimethylaminopyridine, pyridine and diisopropylamine, or of an inorganic base at temperatures of preferably -70 C to 100 C, optionally in the presence of microwave radiation to yield compounds of the general formula X.
As a further alternative, compounds of the general formula IX are converted with aldehydes of the general formula R21-C(=O)-H in a reaction medium, preferably selected from the group comprising diethylether, tetrahydrofuran, methanol, ethanol, dichloromethane and toluol, with the addition of at least one reducing agent, preferably selected from the group comprising sodium borohydride, sodium acetoxyborohydride or sodium cyanoborohydride, at temperatures of preferably -70 C to 100 C, optionally in the presence of microwave radiation to yield compounds of the general formula X.
. ...y.,......,.õ. . . .. . . .. .. . .. . . . . . . .. ..>.d..._.,. _ ._...
,.,......-,.._ . . . .... . . .
Compounds of the general formula IX can also be converted with compounds of the general formula R3-X, in which X denotes a halogen residue, preferably chlorine, in a reaction medium, preferably selected from the group comprising toluol, tetrahydrofuran and diethylether, with the addition of at least one metal hydride salt, preferably with the addition of at least one metal hydride salt selected from the group comprising sodium hydride, potassium hydride and lithium hydride, at temperatures of preferably 0 C to 40 C to yield compounds of the general formula X.
Compounds of the general formulae X and V can furthermore be converted as indicated in Diagram 4 to yield compounds of the general formula I, whereby the same methods as described under Diagram 3, Step 2 can be used.
s N S N
R' ~ Ml - M2 R' Ml = M2 N
3 N,Ra V, X I
Diagram 4.
The compounds of the formulae II, III, IV, VI and VIII indicated above and of the general formulae R3-X, R4-X, R21-C(=O)-OH, Rz1-C(=O)-X and R21-C(=O)-H
indicated above are in each case available to purchase on the market and/or can be produced according to the normal methods known to the person skilled in the art.
The conversions described above can in each case be performed under normal conditions familiar to the person skilled in the art, for example, in terms of pressure or the sequence of the addition of components. The optimum performance of the method according to the respective conditions can optionally be determined by the person skilled in the art by simple preliminary tests.
The intermediate and end products obtained according to the conversions described above can in each case, if desired and/or necessary, be purified and/or isolated according to conventional methods known to the person skilled in the art.
Suitable purification methods are, for example, extraction methods and chromatographic methods such as column chromatography or preparative chromatography.
All of the method steps described above and in each case also the purification and/or isolation of intermediate or end products can partially or entirely be performed under an inert gas atmosphere, preferably under a nitrogen atmosphere.
The substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formulae I, Ia, Ib, Ic, Id, le, If, Ig and Ih, referred to below only as compounds of the general formula I, and corresponding stereoisomers can be isolated both in the form of the free bases thereof, the free acids thereof as well as in the form of corresponding salts, in particular physiologically acceptable salts.
The free bases of the respective substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formula I and corresponding stereoisomers can, for example, be transformed by conversion with an inorganic or organic acid, preferably with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, p-toluolsulphonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aparaginic acid, into the corresponding salts, preferably physiologically acceptable salts.
The free bases of the respective substituted imidazo[2,1-b]thiazole compounds of the above-mentioned general formula I and corresponding stereoisomers can likewise be transformed with the free acid or a salt of a sugar substitute such as e.g.
saccharin, cyclamate or acesulfam into the corresponding physiologically acceptable salts.
The free acids of the substituted imidazo[2,1-b]thiazole compounds of the above-mentioned general formula I and corresponding stereoisomers can correspondingly be transformed by conversion with a suitable base into the corresponding physiologically acceptable salts. The alkaline metal salts, alkaline earth metal salts or ammonium salts [NH,R4_1]+, in which x = 0, 1, 2, 3 or 4 and R denotes a linear or branched C1_4-alkyl residue, are cited by way of example.
The substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formula I and corresponding stereoisomers can optionally, just like the corresponding acids, the corresponding bases or salts of these compounds, be obtained according to normal methods known to the person skilled in the art also in the form of the solvates thereof, preferably in the form of the hydrates thereof.
In so far as the substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formula I can be obtained after their production in the form of a mixture of the stereoisomers thereof, preferably in the form of the racemates thereof or other mixtures of the various enantiomers and/or diastereomers thereof, these can be separated and optionally isolated according to conventional methods known to the person skilled in the art. Chromatographic separating methods, in particular liquid chromatography methods under normal pressure or under increased pressure, preferably MPLC and HPLC methods, and methods of fractionated crystallisation are cited by way of example. Therein, in particular individual enantiomers, e.g. diastereomeric salts formed by means of HPLC
on the chiral stationary phase or by means of crystallisation with chiral acids such as (+) tartaric acid, (-) tartaric acid or (+) 10-camphor sulphonic acid, can be separated from one another.
The substituted imidazo[2,1-b]thiazole compounds according to the invention of the above-mentioned general formula I and corresponding stereoisomers and in each case the corresponding acids, bases, salts and solvates are toxicologically safe and are therefore suitable as active pharmaceutical ingredients in drugs.
A further subject matter of the present invention is therefore a drug containing at least one imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers ,._ _ . .,..-_.. ~. ..._. , . . .r..~
and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt, or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances.
The drug according to the invention is suitable for mGluR5 receptor regulation, in particular for inhibition of the mGluR5 receptor.
The drug according to the invention is preferably suitable for the prevention and/or treatment of disorders and/or illnesses which are at least partially mediated by mGluR5 receptors.
The drug according to the invention is therefore particularly preferably suitable for the treatment and/or prevention of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain;
migraine;
depression; neurodegenerative diseases, preferably selected from the group comprising multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's chorea; cognitive dysfunction, preferably cognitive deficiency states, particularly preferably Attention Deficit Disorder (ADD); psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks;
epilepsy; coughing; urinary incontinence; diarrhoea; pruritus; schizophrenia;
cerebral ischaemia; muscle spasms; cramps; lung illnesses, preferably selected from the group comprising asthma and pseudo-croup; regurgitation (vomiting); stroke;
dyskinesia; retinopathy; listlessness; drowsiness; weariness; laryngitis;
disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on alcohol; dependency on medicines;
dependency on drugs, preferably dependency on nicotine and/or cocaine; alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse;
withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications, preferably to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux; irritable bowel syndrome; for diuresis; for antinatriuresis; for influencing the cardiovascular system; for increasing vigilance; for increasing libido; for modulating locomotor activity or for local anaesthesia.
, ,_.y.._..,n. . . ... . .. , . . _ . . . . . ............_, .... ... .
.......w . .... ..... . .. . . . . . .
.GRA3336PCT
The drug according to the invention is very particularly preferably suitable for the prevention of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain; psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks;
dependency on alcohol; dependency on medicines; disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on drugs, preferably dependency on nicotine and/or cocaine; alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications and/or drugs, in particular to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux and irritable bowel syndrome.
The drug according to the invention is even more preferably suitable for the prevention and/or the treatment of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain.
The drug according to the invention is even more preferably suitable for the prevention and/or the treatment of psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks.
The drug according to the invention is most preferably suitable for the prevention and/or the treatment of pain, preferably of acute pain, chronic pain, neuropathic pain or visceral pain.
A further subject matter of the present invention is the use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I
indicated above, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt, or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for mGluR5 receptor regulation, preferably for inhibition of the mGluR5 receptor.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above are preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt, or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of disorders and/or illnesses which are at least partially mediated by mGluR5 receptors.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above is particularly preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt, or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain; migraine; depression;
neurodegenerative diseases, preferably selected from the group comprising multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's chorea;
cognitive dysfunction, preferably cognitive deficiency states, particularly preferably Attention Deficit Disorder (ADD); psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks; epilepsy; coughing; urinary incontinence; diarrhoea; pruritus; schizophrenia; cerebral ischaemia; muscle spasms;
cramps; lung illnesses, preferably selected from the group comprising asthma and pseudo-croup; regurgitation (vomiting); stroke; dyskinesia; retinopathy;
listlessness;
drowsiness; weariness; laryngitis; disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on alcohol; dependency on medicines; dependency on drugs, preferably dependency on _....._,._~.~.~.._ ~ ., . _ ..._ nicotine and/or cocaine; alcohol abuse; abuse of medication; drug abuse;
preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine);
development of tolerance to medications, preferably to natural or synthetic opioids;
stomach-esophagus-reflux-syndrome; gastroesophagal reflux; irritable bowel syndrome; for diuresis; for antinatriuresis; for influencing the cardiovascular system;
for increasing vigilance; for increasing libido; for modulating locomotor activity or for local anaesthesia.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above is very particularly preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain;
psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks; dependency on alcohol; dependency on medicines; disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on drugs, preferably dependency on nicotine and/or cocaine;
alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications and/or drugs, particularly to natural or synthetic opioids;
stomach-esophagus-reflux-syndrome; gastroesophagal reflux and irritable bowel syndrome.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above is even further preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired ~...._õM.. . . ~~_. _ _..
mixing ratio, or in each case in the form of a corresponding salt or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain.
The use of at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above is even further preferred, in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of a corresponding salt or in each case in the form of a corresponding solvate, and optionally one or more pharmaceutically acceptable auxiliary substances for the production of a drug for the prevention and/or treatment of psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks.
The drug according to the invention is suitable for administration to adults and childrens including infants.
The drug according to the invention may be formulated as a liquid, semisolid or solid dosage form, for example, in the form of solutions for injection, drops, succi, syrups, sprays, suspensions, tablets, patches, capsules, dressings, suppositories, ointments, creams, lotions, gels, emulsions, aerosols or in multiparticulate form, for example, in the form of pellets or granules, optionally pressed into tablets, packaged in capsules or suspended in a liquid, and may also be administered as such.
In addition to at least one substituted imidazo[2,1-b]thiazole compound according to the invention of the general formula I indicated above, optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemate thereof or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio, or optionally in the form of a corresponding salt or in each case in the form of a corresponding solvate, the drug according to the invention conventionally contains further physiologically acceptable pharmaceutical auxiliary substances, which can preferably be selected from the group comprising matrix materials, fillers, solvents, diluents, surface-active substances, dyes, preservatives, disintegrants, slip agents, lubricants, aromas and binders.
Selection of the physiologically acceptable auxiliary substances and the quantities thereof which are to be used depends upon whether the drug is to be administered orally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or topically, for example onto infections of the skin, mucous membranes and eyes. Preparations in the form of tablets, coated tablets, capsules, granules, pellets, drops, succi and syrups are preferred for oral administration, while solutions, suspensions, readily reconstitutible dried preparations and sprays are preferred for parenteral, topical and inhalatory administration.
The substituted imidazo[2,1-b]thiazole compounds according to the invention used in the drug according to the invention in a depot in dissolved form or in a dressing, optionally with the addition of skin penetration promoters, are suitable percutaneous administration preparations.
Orally or percutaneously administrable formulations may also release the respective substituted imidazo[2,1-b]thiazole compound according to the invention in a delayed manner.
Production of the drugs according to the invention proceeds with the assistance of conventional means, devices, methods and processes known from the prior art, such as are described for example in "Remington's Pharmaceutical Sciences", ed.
A.R.
Gennaro, 17th ed., Mack Publishing Company, Easton, Pa. (1985), in particular in part 8, chapters 76 to 93. The corresponding description is hereby introduced as a reference and is deemed to be part of the disclosure.
The quantity of the respective substituted imidazo[2, 1 -b]thiazole compounds according to the invention of the general formula I indicated above to be administered to the patient may vary and is, for example, dependent on the weight or age of the patient and on the mode of administration, the indication and the severity of the complaint. Conventionally, 0.005 to 2000 mg/kg, preferably 0.05 to 500 mg/kg, particularly preferably 0.05 to 100 mg/kg of patient body weight of at least one such compound according to the invention are administered per day.
..a . _ .__..~,, Pharmacological methods:
1. Method for determining the affinity to the mGIuR5 receptor Pig brain homogenate is produced by homogenisation (Polytron PT 3000, Kinematica AG, 10,000 rpm for 90 seconds) of pig brain halves without medulla, cerebellum and pons in buffer pH 8.0 (30mM Hepes, Sigma, order no.H3375 + 1 tablet complete to 100mI, Roche Diagnostics, order no. 1836145) in ratio 1:20 (brain weight/volume) and differential centrifugation at 900 x g and 40,000 x g. In each case, 450 pg protein from brain homogenate is incubated with 5nM 3[H]-MPEP (Tocris, order no.
R1212) (MPEP = 2-methyl-6-(3-methoxyphenyl)-ethynylpyridine) in 250 pl incubation batches in 96 well microtitration plates and the compounds to be tested (10 pM in the test) in buffer (as above) at room temperature for 60 min.
Thereafter, the batches are filtered with the help of a Brandel Cell Harvester (Brandel, TYP Robotic 9600) on unifilter plates with glass fibre filter mats (Perkin Elmer, order no. 6005177) and subsequently washed with buffer (as above) 3 times with in each case 250 pl per sample. The filter plates are subsequently dried for 60 min at 55 C. 30 pL Ultima GoIdTM scintillator is subsequently added per well (Packard BioScience, order no. 6013159) and the samples are measured after 3 hours on the 9-counter (Mikrobeta, Perkin Elmer). The unspecific bond is determined by addition of 10 pM MPEP (Tocris, order no. 1212).
2a. Formaline test in rats The formaline test (Dubuisson, D. and Dennis, S.G., 1977, Pain, 4, 161 - 174) represents a model for acute and chronic pain. A biphasic nociceptive reaction, which is recorded by observation of three clearly differentiable behavioural patterns, is induced by a single formaline injection into the dorsal side of a rear paw in freely mobile test animals. The reaction has two phases: Phase 1 = Immediate reaction (duration up to 10 min; paw shaking, licking), Phase 2 = Late reaction (after a rest phase; likewise, paw shaking, licking; duration up to 60 min). The 1st phase reflects a direct stimulation of the peripheral nocisensors with high spinal nociceptive input or glutamate release (acute pain phase); the 2nd phase reflects a spinal and peripheral _....~,..,..~, ...~.. _ _ _ _..y_ ~-~
hypersensitisation (chronic pain phase). In the investigations presented here, the chronic pain component (phase 2) was evaluated.
Formaline with a volume of 50p1 and a concentration of 5% is administered subcutaneously into the dorsal side of the right rear paw of each animal. The substances to be tested are administered 30 min before the formaline injection orally (p.o), intravenously (i.v.) or intraperitoneally (i.p.). The specific changes in behaviour such as lifting and shaking the paw, shifts in weight of the animal as well as biting and licking reactions are observed and registered in the period of observation from 21 to 27 min after formaline injection. The various forms of behaviour are summarised in the so-called pain rate (PR), which, relative to the sub-intervals of 3 min, represents the calculation of an average nociception reaction. The calculation of PR is performed on the basis of a numerical weighting (= in each case factor 1, 2, 3) of the observed forms of behaviour (corresponding behavioural score 1, 2, 3) and is calculated with the following formula:
PR = [(To x 0) + (Ti x1)+(T2x2)+(T3x3)]/180 whereby To, Tl, T2, and T3 in each case corresponds to the time in seconds in which the animal demonstrates modes of behaviour 0, 1, 2 or 3. The group size is 10 animals (n=10).
2b. Formaline test in mice Formaline with a volume of 20pl and a concentration of 1% is administered subcutaneously into the dorsal side of the right rear paw of each animal. The substances to be tested are administered 15 min before the formaline injection intraperitoneally (i.p.). The specific changes in behaviour such as lifting and shaking the paw (score 3, Dubuisson & Dennis, 1977) are observed and registered in the period of observation from 21 to 24 min after formaline injection. The group size is 10 animals (n=10).
3. Neuropathic pain in rats . _.nr,._...._ ~,....,........... . . .~. . . . . . .. . . . .. . _.... . ..
.. . . . .. . . .
The investigation of effectiveness in neuropathic pain was performed using the Bennett model (chronic constriction injury; Bennett and Xie, 1988, Pain 33: 87-107).
The corresponding parts of the literatur are hereby regarded as part of the present disclosure.
Sprague-Dawley rats with a weight of 140-160 g are provided with four loose ligatures of the right nervus ischiaticus under nembutal narcosis. The animals develop at the paw innervated by the damaged nerve an oversensitivity which is quantified after a recuperation phase of a week over approximately four weeks by means of a 4 C cold metal plate (cold allodynia). The animals are observed for a period of 2 min. on this plate and the number of retraction reactions of the damaged paw is measured. Relative to the previous value before substance administration, the substance effect is determined over a period of an hour at four points in time (15, 30, 45, 60 min. after administration) and the resultant area under the curve (AUC) and the inhibition of the cold allodynia are expressed at the individual measurement points in percent of effect to vehicle control (AUC) or to the initial value (individual measurement points). The group size is n = 10. The significance of an anti-allodynic effect is determined using the AUC values via a paired T-test (* 0.05 _ p>0.01; **
0.01 _ p> 0.001; *** p<_ 0.001; Armitage and Berry, 1987, Stat. Methods in Medical Research, London: Blackwell Scientific Publications).
4. "Elevated Plus Maze" model In the "elevated plus maze" (EPM) model, compounds are tested for possible anxiolytic effects. The tests are performed in male Sprague-Dawley rats (200-250 g) and 2 "elevated plus mazes" (Med Associates) with electronically controlled infrared light boxes are used to determine the location of the animals in the labyrinth. Each labyrinth has 2 open and 2 closed arms and a central platform. The edges of the open arms are delimited by narrow strips. The entire labyrinth is mounted on a metal stand.
At the start of a 5-min test, each animal is individually placed on the cental platform with its head in the direction of a closed arm.
The following parameters are determined or calculated and evaluated:
Number and percentage of entries into the open and closed arms, and percentage of time in the open and closed arms and on the central platform.
The data is analysed by means of a 1-factorial ANOVA (comparison of treatment groups versus vehicle group). The significance level is set at p < 0.05. All the groups have a size of N = 10.
The test is also described in Hogg, S. (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem.
Behav.
54, 21-30 and Rodgers, R.J., Cole, J.C. (1994) The elevated plus-maze:
pharmacology, methodology and ethology. In: Cooper, S.J., Hendrie, C.A. (eds.) Ethology and Psychopharmacology. Wiley & Sons; pp. 9-44. The corresponding parts of the literature are hereby regarded as part of the disclosure.
5. Description of the functional Ca2+ influx assay 20,000 CHO-hmGluR5 cells/well (Euroscreen, Gosselies, Belgium) are pipetted into 96 well plates (BD Biosciences, Heidelberg, Germany, Ref 356640, clear bottom, well, Poly-D-Lysine) and incubated overnight in HBSS buffer (Gibco No. 14025-050) with the following additions: 10% FCS (GIBCO, 10270-106) and doxycycline (BD
Biosciences Clontech 631311 600ng/ml).
For the functional investigation, the cells were loaded with 2 pM fluo-4 and 0.01 Vol%
Pluronic F127 (Molecular Probes Europe BV, Leiden Netherlands) in HBSS buffer (Hank's buffered saline solution, Gibco Invitrogen GmbH, Karlsruhe, Germany) with probenicide (Sigma P8761, 0.69 mg/ml) for 30 min at 37 C.
The cells are then washed 3 times with washing buffer (HBSS buffer, Gibco No.
14025-050, with probenicide (Sigma P8761, 0.69 mg/mI) and subsequently absorbed with the same buffer ad 100 pl. After 15 min., the plates are transferred into a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA) for the determination of Ca2+ measurements in the presence of DHPG ((S)-3,5-dihydroxyphenylglycine, Tocris Biotrend Chemikalien GmbH, Cologne, Germany, _.w....... m_.. _... . . _.r.u_ final DHPG concentration: 10 pM) and in the presence or absence of test substances.
In this case, the Ca2+-dependent fluorescence is measured before and after addition of test substances. Quantification is performed by measurement of the maximum fluorescence intensity over time.
After recording the fluorescence base line for 10 sec., 50 pl test substance solution (various test substance concentrations in HBSS buffer with 1% DMSO and 0.02%
Tween 20, Sigma) is added and the fluorescence signal is measured for 6 min.
50 pl DHPG solution ((S)-3,5-dihydroxyphenylglycine, Tocris Biotrend Chemikalien GmbH, Cologne, Germany, final DHPG concentration: 10 pM) is subsequently added and the inflow of Ca2+ is simultaneously measured for 60 sec. The final DMSO
concentration is 0.25% and the final Tween 20 content is 0.005%. The data is analysed with Microsoft Excel and GraphPad Prism. The dose-effect curves are calculated with non-linear regression and IC50 values determined. Each data point is determined 3 times and IC50 values are averaged from a minimum of 2 independent measurements.
Ki values are calculated according to the following formula: Ki =
IC50/(1 +(AGconc./EC50)).
AGcon,. = 10 pM; EC50 corresponds to the DHPG concentration which is required for half the maximum inflow of CaZ+.
General instructions for the production of exemplary substituted imidazo[2,1-b]thiazoles General synthesis diagram 1:
R7 \~ + R3-N-C + H Mi M
II III IV
R' SY
I Ml -M2 ~N
V
The conversion of amines of the general formula II with isocyanides of the general formula III and aldehydes of the general formula IV to yield compounds of the general formula V was carried out in organic solvents or solvent mixtures, for example, of chloroform, DCM, MeCN, MeOH or EtOH, with the addition of an organic or inorganic acid, for example, trifluoroacetic acid or perchloric acid, or with the addition of a transition metal triflate, for example, scandium(III)triflate, ytterbiumtriflate or indium(III)triflate, at temperatures of 0 C to 150 C.
,f , _.u.,w.__. . _..._ . . ... ,~__.
General synthesis diagram 2:
s NHz 0 ' - R ~N + R3-N-C + H~
" Ml "I Step 1 Rz X
II III VI
S Y_N S N
R' Ml-X H- Mz R' Ml Mz \ N / VIII ~N
Rz NH Step 2' Rz NH
VII V
In step 1, the conversion of amines of the general formula II with isocyanides of the general formula III and aidehydes of the general formula VI, in which X
denotes a halogen residue, to yield compounds of the general formula VII was carried out in organic solvents or solvent mixtures, for example, of chloroform, DCM, MeCN, MeOH
or EtOH, with the addition of an organic or inorganic acid, for example, trifluoroacetic acid or perchloric acid, or with the addition of a transition metal triflate, for example, scandium(III)triflate, ytterbiumtriflate or indium(III)triflate, at temperatures of 0 C to 150 C.
In step 2, the conversion of compounds of the general formula VII, in which X
denotes a halogen residue, with acetylenes of the general formula VIII to yield compounds of the general formula V is carried out in a solvent or solvent mixture, for example, of toluol, THF, DMF, MeCN, ether, NEt3 or diisopropylamine, with the addition of a palladium catalyst, for example, bis(triphenylphosphine)-palladium(II)-chloride, of copper(I)-iodide and an organic base, for example, NEt3 or diisopropylamine, and/or inorganic base, for example, potassium carbonate or caesium carbonate, at temperatures of -70 C to 150 C.
, __ ..~.~.....võ~......~ ___ . . . .
General synthesis diagram 3:
S~ S
R~ I' MI = M2 SY N R' ~ M~ = M2 N 1 R' N Ml = MZ 2 N
2 ~ RZ
R ~ H R2 NH2 NH
v lx x In step 1, compounds of the general formula V were converted to yield amines of the general formula IX in a solvent or solvent mixture, for example, of EtOH, MeOH
or acetone, with the addition of an organic or inorganic acid, for example, acetic acid, trifluoroacetic acis, hydrochloric acid or sulphuric acid, at temperatures of 0 C to 80 C.
In step 2, compounds of the general formula IX (1 equivalent) were converted with carbonic acids (1 equivalent) of the general formula RZ'-(C=O)-OH in a solvent or solvent mixture, for example, of ether, THF, MeCN, MeOH, EtOH, DMF or DCM, with or without the addition of a coupling reagent (1 equivalent), for example, DCC, BOP, HATU or EDCI and optionally in the presence of at least one inorganic or organic base, for example, NEt3 or diisopropylethylamine, at temperatures of -70 C to to yield compounds of the general formula X.
Alternatively, compounds of the general formula IX (1 equivalent) were converted with carbonic acid halogenides (1 equivalent) or carbonic acid derivatives of the . general formula RZ'-(C=0)-X, whereby X denotes a halogen residue, in a solvent or solvent mixture, for example, of ether, THF, MeCN, MeOH, EtOH, DMF or DCM, with or without the addition of an organic or inorganic base, for example, NEt3, DMAP, pyridine or diisopropylamine, at temperatures of -70 C to 100 C to yield compounds of the general formula X.
As a further alternative, compounds of the general formula IX (1 equivalent) were converted with aldehydes (1 equivalent) of the general formula R21-C(=O)-H in a solvent or solvent mixture, for example, of ether, THF, MeOH, EtOH, DCM or toluol, and subsequent addition of a reducing agent, for example, sodium borohydride, sodium acetoxyborohydride or sodium cyanoborohydride, at temperatures of -70 C
to 100 C to yield compounds of the general formula X.
Compounds of the general formula IX (1 equivalent) were likewise converted with compounds of the general formula R4-X (1.1 equivalents), in which X denotes a halogen residue, preferably chlorine, in a solvent or solvent mixture, for example, of toluol, THF, or ether, with the addition of a metal hydride salt (1.1 equivalents), preferably with the addition of sodium hydride, to yield compounds of the general formula X at temperatures of 0 C to 40 C.
General synthesis diagram 4:
S N
R' I Ml - M2 S N
R~ 8 --r ~ Mi - MZ
R2 NH R2 N, V, X I
The compounds of the general formula V or X can be converted with the same methods as described in general synthesis diagram 3, step 2 to yield compounds of the general formula I.
General synthesis diagram 5:
~... .,.r,~ ,.,_..~..~..-a........~
_.,........_ ___ _ S SY ~
R' Ml-X R' N Ml M2 VII V
H - SiR3 Step 3 Step 1 XI
SY ~N ~
R' \ I ~ M1 - SiR3 Step 2 R' \ IN/ Ml N
XII XIII
In step 1, compounds of the general formula VII indicated above (1.0 equivalent), in which X denotes a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, are converted with acetylenes of the general formula VIII (5.0 equivalents) in acetonitrile with the addition of tetrakis(triphenylphosphine)palladium [(PPh3)4Pd] (10 mol.-%) and with the addition of [1,4]-diazabicyclo-[2.2.2]octane (2.0 equivalents) under reflux to yield compounds of the general formula V.
In step 2, compounds of the general formula XII indicated above (1.0 equivalent) are converted in a reaction medium, preferably selected from the group comprising methanol and dichloromethane and corresponding mixtures in the presence of potassium carbonate (10 mol-%) at temperatures of 20 C to 30 C to yield compounds of the general formula XIII.
In step 3, compounds of the general formula XIII indicated above (1.0 equivalent) are converted with compounds of the general formula M2-X (1.25 equivalents), in which X
denotes a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in ethylacetate, with the addition of bis(triphenylphosphine)-palladium(II)-chloride [PdCI2(PPh3)2] (5 mol-%), in the presence of copper(I)-iodide (6 mol-%), with the addition of triethylamine (2.0 equivalents), at temperatures of 40 C to 60 C, to yield compounds of the general formula V.
The instructions described above for the production of substituted imidazo[2,1-b]thiazoles are explained in detail below with reference to several exemplary compounds.
The following examples serve to explain the invention in greater detail but do not restrict the general concept of the invention.
, ..~..~ ,._.
Examples The yields of the produced compounds are not optimised.
All temperatures are uncorrected.
Abbreviations:
aq. aqueous d days Brine saturated, aqueous NaCI solution DCM dichloromethane DMF N,N-dimethytformamide AE acetic acid ethylester Ether diethylether sat. saturated NEt3 triethylamine RT room temperature CC column chromatography TBME tertiary butyl-methyl-ether The chemicals and solvents used were commercially acquired from the normal suppliers (Acros, Avocado, Aldrich, Bachem, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, etc.) or synthesised according to methods known to the person skilled in the art.
Silica gel 60 (0.040 - 0.063 mm) from E. Merck, Darmstadt was used as the stationary phase for the column chromathography.
The thin layer chromatographic tests were carried out with HPTLC ready plates, silica gel 60 F 254, from E. Merck, Darmstadt.
The mixture ratios of solvents, mobile solvents or for chromatographic investigations are always indicated in volume/volume.
,_ . _,...~.~~,......~ . _ ,. _..~.~
Analysis of all the examples was performed by mass spectroscopy and NMR
spectroscopy.
Example 1: Synthesis of 6-(5-(phenylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 400 mg (4.0 mmol) 2-aminothiazole, 1018 mg (4.8 mmol) 5-phenylethynyl-thiophene-2-carbaldehyde, 557 mg (4.0 mmol) (2,4,4-trimethylpentane-2-yl)-isocyanide and 400 pl of a 20% aq. perchloric acid was stirred in DCM (8 ml) for 5 d at RT. A 1 molar aq. Na2CO3 sol. was subsequently added.
The phases were separated and the aqueous phase was extracted with DCM. The collected organic phases were washed with brine and dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC (AE/hexane 1:4) was performed with the residue, whereby 637 mg (1.47 mmol, 37%) 6-(5-(phenylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained.
Example 2: Synthesis of N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 400 mg (4.0 mmol) 2-aminothiazole, 938 mg (4.4 mmol) 5-(pyridine-2-yl-ethynyl)-thiophene-2-carbatdehyde, 332 mg (4.0 mmol) tert.butyl-isocyanide and pl of a 20% aq. perchloric acid in chloroform (10 ml) was stirred for 10 d at RT. A 1 molar aq. Na2CO3 sol. was subsequently added. The phases were separated and the aqueous phase was extracted with chloroform. The collected organic phases were washed with brine and dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC (AE/DCM 15:85) was performed with the residue, whereby 223 mg impure raw product was obtained. 156 mg (0.41 mmol, 10%) N-tert-butyl-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained from this by crystallisation from AE.
Example 3: Synthesis of N-tert-butyl-3-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine hydrochloride A solution of 256 mg (2.25 mmol) 2-amino-4-methyl-thiazole, 527 mg (2.48 mmol) (pyridine-2-yl-ethinyl)-thiophene-2-carbaldehyde, 205 mg (2.48 mmol) tert.butyl-isocyanide and 58 lal of a 70% aq. perchloric acid was stirred in chloroform (2 ml) for 16 h at RT. Dilution with DCM (20 ml) was subsequently performed and a 1 molar aq.
Na2CO3 sol. (10 ml) added. After 10 min stirring at RT, the phases were separated.
The aqueous phase was extracted with DCM. The collected organic phases were dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC
(AE/DCM 25:75) was performed with the residue, whereby 41 mg impure raw product was obtained. This was dissolved in acetone (1 ml) and 1{al water and 11 NI
trimethylchlorosilane were subsequently added. The resultant precipitate was sucked up and washed with ether. Thereby, 18 mg (0.04 mmol, 2%) N-tert-butyl-3-methyl-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine hydrochloride was obtained.
Example 4: Synthesis of N-tert-butyl-2-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 256 mg (2.25 mmol) 2-amino-5-methyl-thiazole, 527 mg (2.48 mmol) (pyridine-2-yl-ethynyl)-thiophene-2-carbaldehyde, 205 mg (2.48 mmol) tert.butyl-isocyanide and 58 pl of a 70%n aq. perchloric acid was stirred in chloroform (2 ml) for 16 h at RT. Dilution with DCM (20 ml) was subsequently performed and a 1 molar aq.
Na2CO3 sol. (10 ml) added. After 10 min stirring at RT, the phases were separated.
The aqueous phase was extracted with DCM. The collected organic phases were dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC
(AE/DCM 25:75) was performed with the residue, whereby 367 mg impure raw product was obtained. 48 mg (0.12 mmol, 5%) N-tert-butyl-2-methyl-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained from this by crystallisation from AE.
Example 5: Synthesis of N-tert-butyl-2,3-dimethyl-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride Example 6: Synthesis von N-tert-butyl-2-chloro-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine hydrochloride The synthesis of Examples 5 and 6 was performed in accordance with the method described for Example 3.
Example 7: N-tert-butyl-6-(5-(pyridine-4-ylethinyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine Example 8: 5-(tert-butylamino)-6-(5-(pyridine-2-ylethinyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-2-carbonic acid methylester hydrochloride The synthesis of Examples 7 and 8 was performed in accordance with the method described for Example 4.
Example 9: N-tert-butyl-6-(5-(pyridine-2-ylethynyi)thiazole-2-yl)imidazo[2,1-b]thiazole-5-amine a) Synthesis of 6-(5-bromothiazole-2-yi)-N-tert-butylimidazo[2,1-b]thiazole-5-amine 1 molar perchloric acid (10 pl) in ethanol (4 ml) was added to a solution of 100 mg (1.0 mmol) 2-amino-thiazole, 191 mg (1.0 mmol) 5-bromo-thiazole-2-carbaldehyde and 97 mg (1.17 mmol) tert.butylisonitrile and the mixture was heated for 5 min in the microwave (Biotage initiator). The reaction solution was subsequently concentrated in a vacuum. A CC (TBME/hexane 1:1) was performed with the residue, whereby 71 mg (0.2 mmol, 20%) 6-(5-bromothiazole-2-yl)-N-tert-butylimidazo[2,1-b]thiazole-amine [MH+] 357.0 was obtained.
b) Synthesis of N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiazole-2-yl)imidazo[2,1-b]thiazole-5-amine A mixture of 235 mg (0.66 mmol) 6-(5-bromothiazole-2-yl)-N-tert-butylimidazo[2,1-b]thiazole-5-amine, 22 mg (0.033 mmol) bis(triphenylphosphine)-palladium-(II)-chloride, 12 mg (0.066mmol) copper-(I)-iodide, 80 NI (0.79 mmol) 2-ethynylpyridine and 731 pI (5.28 mmol) NEt3 in DMF (2 ml) was heated in the microwave (Biotage Initiator) for 10 min to 120 C. The reaction solution was diluted with water and extracted several times with AE. The collected organic phases were washed with brine and dried over MgSO4. After filtering and removal of the solvent in a vacuum, a CC (1.TBME, 2.MeOH) was performed with the residue, whereby 43 mg (0.11 mmol, 17%) N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiazote-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained.
Example 10: Synthesis of 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yi)imidazo[2,1-b]thiazole-5-amine A solution of 5.0 g (50.0 mmol) 2-amino-thiazole, 10.7 g (50.0 mmol) 5-(pyridine-2-yl-ethynyl)-thiophene-2-carbaldehyde, 7.0 g (50.0 mmol) (2,4,4-trimethylpentane-2-yl)-isocyanide and 1.0 ml of a 70% aq. perchloric acid in chloroform (25 ml) was heated to 50 C while being stirred for 5 d. Dilution with DCM was subsequently performed and a 1 molar aq. Na2CO3 sol. was added. After 10 min of stirring at RT, the phases were separated. The aqueous phase was extracted with DCM. The collected organic phases were dried over Na2SO4, filtered and concentrated in a vacuum. 11.86 g (27.3 mmol, 55%) 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained by multiple crystallisation of the residue from AE.
Example 11: N-tert-butyl-2-methyl-6-(4-(pyridine-2-ylethynyl)phenyl)imidazo[2,1-b]thiazole-5-amine The synthesis of Example 11 was performed in accordance with the method described for Example 10.
Example 12: Synthesis of N-tert-butyi-6-(5-(pyridine-2-ylethynyl)furan-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 380 mg (3.8 mmol) 2-amino-thiazole, 749 mg (3.8 mmol) 5-(pyridine-2-yl-ethynyl)-furan-2-carbaldehyde, 378 mg (3.8 mmol) tert.butyl-isonitril and 73 pl of a 70% aq. perchloric acid in chloroform (2 ml) was heated to 45 C while being stirred for 16 h. Dilution with DCM was subsequently performed and a 1 molar aq.
Na2CO3 sol. was added. After 10 min of stirring at RT, the phases were separated. The aqueous phase was extracted with DCM. The collected organic phases were dried over Na2SO4, filtered and concentrated in a vacuum. 472 mg (1.3 mmol, 34%) N-tert-butyl-6-(5-(pyridine-2-ylethynyl)furan-2-yl)imidazo[2, 1 -b]thiazole-5-amine was obtained by CC (AE) with the residue.
Example 13: N-tert-butyl-3-methyl-6-(5-(phenylethynyl)thiophene-2-yl)im idazo[2,1-b]thiazole-5-amine The synthesis of Example 13 was performed in accordance with the method described for Example 12.
Example 14: Synthesis of 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine Trifluoroacetic acid (30 ml) was added to a solution of 2.5 g (5.75 mmol) 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine (Example 10) in DCM (30 ml) and the mixture was stirred for min at RT. Basification (pH > 12) was subsequently performed under cooling (ice bath) with a 12 molar aq. NaOH sol. The resultant residue was filtered off and dissolved in a mixture of AE (200 ml) and DCM (50 ml) and washed with water (15 ml) and dried over Na2SO4. After removal of the solvent in a vacuum, 773 mg (2.40 mmol, 42%) 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine was obtained.
Example 16: N-tert-butyl-6-(5-((3-fluoropyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine a) Synthesis of 6-(5-bromothiophene-2-yl)-N-tert-butylimidazo[2,1-b]thiazole-5-amine 22.9 g(119.9 mmol) 5-bromo-thiophene-2-carbaldehyde and 11.0 g (131.9 mmol) tert.-butyl-isonitrile were added to a solution of 12.0 g (119.9 mmol) 2-amino-thiazole in chloroform (60 ml). A 1 molar perchloric acid (2.3 ml) was added to the reaction solution and heated to 50 C while being stirred for 5 d. After cooling to RT, dilution ,,...._~.. ... _. . __.._.. .
with DCM was performed and a 1 molar aq. Na2CO3 sol. added. After 10 min of stirring at RT, the phases were separated. The organic phase was dried over Na2SO4, filtered and concentrated in a vacuum. 6.6 g (18.5 mmol, 15%) 6-(5-bromothiophene-2-yl)-N-tert-butylimidazo[2,1-b]thiazole-5-amine ([MH+] 356.0) was obtained by crystallisation of the residue from AE.
b) Synthesis of N-tert-butyl-6-(5-((trimethylsilyl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine 4.1 g (3.5 mmol) tetrakis(triphenyl)phosphine-palladium(0), 17.2 g (175.4 mmol) trimethyl-silylacetylene and 7.9 g (70.2 mmol) 1,4-diazabicyclo[2.2.2]octane were consecutively added to a suspension of 12.5 g (35.1 mmol) 6-(5-bromothiophene-yl)-N-tert-butylimidazo[2,1-b]thiazole-5-amine in acetonitrile (150 ml). The reaction solution was heated for 72 h under reflux and subsequently concentated in a vacuum. 3.0 g (7.9 mmol, 23%) N-tert-butyl-6-(5-((trimethylsilyl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine ([MH+] 374.1) was obtained by CC (DCM/AE
95:5).
c) Synthesis of N-tert-butyl-6-(5-ethynylthiophene-2-yl)imidazo[2,1-b]thiazole-amine A suspension of 3.0 g (7.9 mmol) N-tert-butyl-6-(5-((trimethylsilyl)-ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine in a mixture of DCM (12 ml) and methanol (58 ml) was heated to 35 C and 108 mg (0.79 mmol) potassium carbonate was added.
After 100 min of stirring at RT, water and DCM were added. The phases were separated and the aqueous phase was extracted with DCM. The collected organic phases were washed with water, dried over Na2SO4, filtered and concentrated in a vacuum. The obtained 2.17 g (7.2 mmol, 91%) of raw product of N-tert-butyl-6-(5-ethynylthiophene-2-yl)imidazo[2,1-b]thiazole-5-amine ([MH+] 302.1) was converted in the next step without further purification.
d) Synthesis of N-tert-butyl-6-(5-((3-fluoropyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine A solution of 450 mg (1.49 mmol) N-tert-butyl-6-(5-ethynylthiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, 333 mg (1.90 mmol) 3-fluoro-2-iodo-pyridine, 38 mg (0.06 mmol) bis(triphenylphosphine)-palladium-(II)-chloride, 19 mg (0.07 mmol) copper-(I)-iodide and 389 pI (2.80 mmol) NEt3 in AE (21 ml) was heated to 50 C while being stirred for ,.._.. . _ . ..
...,., ._~._~_ 20 h. Concentration in a vacuum was subsequently performed and a CC (AE) carried out with the residue, whereby 456 mg (1.15 mmol, 77%) N-tert-butyl-6-(5-((3-fl uoropyridi ne-2-yl)ethynyl)thiophene-2-yl)i mid azo[2, 1 -b]thiazole-5-amine was obtained.
Example 15: N-tert-butyl-6-(5-(pyrimidine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazoie-5-amine Example 17: N-tert-butyl-6-(5-((2-fluoropyridine-4-yl)ethynyl)thiophene-2-yl)im idazo[2,1-b]thiazole-5-amine Example 18: N-tert-butyl-6-(5-(thiophene-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine Example 19: N-tert-butyl-6-(5-(thiazole-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine Example 20: 3-((5-(5-(tert-butylamino)imidazo[2,1-b]thiazole-6-yl)thiophene-2-yl)ethynyl)phenol Example 21: 3-((5-(5-(tert-butylamino)imidazo[2,1-b]thiazole-6-yl)thiophene-2-yl)ethynyl)benzonitrile Example 23 N-tert-butyl-6-(5-((3-methylpyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine The synthesis of Examples 15, 17, 18, 19, 20, 21 and 23 was performed in accordance with the method described for Example 16.
Example 25: Synthesis of N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)benzamide . r_.._ .._.._.~r.... _,. _ _ _ _ 59 pI (0.52 mmol) benzoylchloride was dropped into a solution of 185 mg (0.57 mmol) 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine (Example 14) and 174 NI (1.26 mmol) NEt3 in DCM (3 ml) under cooling (ice bath).
After 16 h of stirring at RT, dilution with AE was performed. Washing was subsequently carried out consecutively with a saturated, aqueous sodium carbonate solution and with a saturated, aqueous sodium chloride solution. The organic phase was dried over Na2SO4, filtered and concentrated in a vacuum. A CC (AE) was performed with the residue, whereby 10 mg (0.02 mmol, 4%) N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)benzamide was obtained.
Example 22: N-ethyl-6-(6-(phenylethynyl)pyridine-3-yl)imidazo[2,1-b]thiazole-5-amine The synthesis of Example 22 was performed in accordance with the method described for Example 4.
Example 24: N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)acetamide The synthesis of Example 24 was performed in accordance with the method described for Example 25.
w_....,. __._. .
...~. ._...~~.,.,.~...~
The values obtained by means of mass spectrometry are listed in the following table.
Example Mass [MH+]
1 434.2 2 379.1 3 393.1 4 393.1 407.1 6 413.1 7 379.1 8 437.1 9 380.1 435.2 11 387.2 12 363.1 13 392.1 14 323.0 380.1 16 397.1 17 397.1 18 384.1 19 385.1 394.1 21 403.1 22 345.1 23 393.1 24 365.0 427.1 Pharmacological data:
1. The affinity of the substituted imidazo[2,1-b]thiazole compounds according to the invention of the general formula I to the mGluR5 receptor was determined as described above.
The substituted imidazo[2,1-b]thiazole compounds according to the invention exhibit an outstanding affinity to the mGluR5 receptor.
The pharmacological data for the substituted imidazo[2,1-b]thiazole compounds according to Examples 1 to 4 is reproduced in the following table 1:
Table 1:
Ex. ICso ['H]-MPEP bond mGIuR5 receptor (pig) ED50 formaline test mGIuR5 receptor (pig) (10 NM) (rat) i.v.
INMI inhibition (%) Img/kgl 1 2.1800 2 0.0063 0.47 3 0.0120 4 0.0055 0.0170 6 0.0099 7 0.0030 8 0.1600 0.1000 11 0.0200 12 0.0870 14 0.1400 0.0100 16 0.0130 17 0.0180 18 0.0450 19 0.0240 0.1700 21 0.0260 23 0.2300 2. The substituted imidazo[2,1-b]thiazole compounds according to the invention also exhibit an outstanding effect in the formaline test on rats as is reproduced in the following table 2.
Table 2:
Ex. ED50 formaline test Formaline test (rat) i.v. (rat) p.o.
[mg/kg] Reduction in the nociceptive behaviour over controls at 10 mg/kg [%]
2 0.47 66 3. The substituted imidazo[2,1-b]thiazole compounds according to the invention exhibit an outstanding affinity to the human mGluR5 receptor (Table 3.) Table 3.
Ex. K; mGluR5 receptor (human) CaZ+-influx [pM]
4 0.00031 7 0.00026 .., .w ~.......~..,.... _,-. . ... .. _.... .~...,...,_....~.-..
Claims (34)
1. Substituted imidazo[2,1-b]thiazole compounds of the general formula I, in which R1 and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NR6R7; -NH-C(=O)-R8; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR10; -C(=O)-NR11R12; -C(=O)-OR13; -(CH2),-C(=O)-OR14 with m = 1, 2, 3, 4 or 5; -O-C(=O)-R15; -(CH2)n-O-C(=O)-R16 with n = 1,
2,
3, 4 or 5; -OR"; -(CH2)o O-R18 with o = 1, 2, 3; 4 or 5; -SR19; -(CH2)p-S(=O)t-R20 with p = 1, 2, 3, 4 or 5 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NR29R30; -SF5; -(CH2)n-O-S(=O)2-R31 with u = 1, 2, 3, 4 or 5; -(CH2)v-O-S(=O)2-O-R32 with v = 1, 2, 3, 4 or 5; -(CH2)w-O-P(=O)(OR33)(OR34) with w = 1, 2, 3,
4 or 5;
a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic residue optionally having at least one heteroatom as a ring member, which cycloaliphatic residue is bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system; or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2, 3, 4 or 5; -C(=O)-O-R23; -(CH2)r-C(=O)-O-R24 with r = 1, 2, 3, 4 or 5; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2, 3, 4 or 5; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic residue optionally having at least one heteroatom as a ring member, which cycloaliphatic residue can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system; or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated, unsubstituted or at least monosubstituted heterocycloaliphatic residue optionally having at least one further heteroatom as a ring member, which heterocycloaliphatic residue can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R5, R6, R7, R8, R10, R11, R12, R15 and R16, in each case mutually independently, denote a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R9, R13, R14, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
M1 denotes an aryl or heteroaryl residue, which can be substituted with at least one further substituent and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
and M2 denotes an aryl or heteroaryl residue, which can be unsubstituted or at least monosubstituted and can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
in each case in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
2. Compounds according to Claim 1, characterised in that R' and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO21 -CN; -NH2; -NHR5; -NR6R7; -NH-C(=O)-R8; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR10; -C(=O)-NR11R12; -C(=O)-OR13; -(CH2)m-C(=O)-OR14 with m = 1, 2, 3, 4 or 5; -O-C(=O)-R15; -(CH2)n-O-C(=O)-R16 with n = 1, 2, 3, 4 or 5; -OR17; -(CH2)o-O-R18 with o = 1, 2, 3; 4 or 5; -SR19; -(CH2)p-S(=O)t-R20 with p = 1, 2, 3, 4 or 5 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NR29R30; -SF5; -(CH2)u-O-S(=O)2-R31 with u = 1, 2, 3, 4 or 5; -(CH2)v-O-S(=O)2-O-R32 with v = 1, 2, 3, 4 or 5; -(CH2)w-O-P(=O)(OR33)(OR34) with w = 1, 2, 3, or 5; a linear or branched, unsubstituted or at least monosubstituted C1-10-alkyl residue, C2-6-alkenyl residue or C2-6-alkynyl residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic C3-8 residue optionally having at least one heteroatom as a ring member, which residue can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group;
or an unsubstituted or at least monosubstituted 5- or 6-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2, 3, 4 or 5; -C(=O)-O-R23; -(CH2)r-C(=O)-O-R24 with r = 1, 2, 3, 4 or 5; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2, 3, 4 or 5; a linear or branched, unsubstituted or at least monosubstituted C1-10-alkyl residue, C2-6-alkenyl residue or C2-6-alkynyl residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic C3-8 residue optionally having at least one heteroatom as a ring member, which residue can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group; or an unsubstituted or at least monosubstituted 5- or 6-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered, or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated, unsubstituted or at least monosubstituted heterocycloaliphatic C4-10 residue optionally having at least one further heteroatom as a ring member, which residue can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R5, R6, R7, R8, R10, R11, R12, R15 and R16, in each case mutually independently, denote a linear or branched, unsubstituted or at least monosubstituted C1-10-alkyl residue, C2-6-alkenyl residue or C2-6-alkynyl residue; or an unsubstituted or at least monosubstituted 5- to 14-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R9, R13, R14, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a linear or branched, unsubstituted or at least monosubstituted C1-10-alkyl residue, C2-6-alkenyl residue or C2-6-alkynyl residue; or an unsubstituted or at least monosubstituted 5- to 14-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
M1 denotes a 5- or 6-membered aryl or heteroaryl residue, which can be substituted with at least one further substituent and can be condensed with an unsubstituted or at least monosubstituted mono- or bicyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered, and and M2 denotes a 5- or 6-membered aryl or heteroaryl residue, which can be unsubstituted or at least monosubstituted and can be condensed with an unsubstituted or at least monosubstituted mono- or bicyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
whereby the above-mentioned cycloaliphatic residues can optionally have 1, 2, 3, 4 or
a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic residue optionally having at least one heteroatom as a ring member, which cycloaliphatic residue is bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system; or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2, 3, 4 or 5; -C(=O)-O-R23; -(CH2)r-C(=O)-O-R24 with r = 1, 2, 3, 4 or 5; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2, 3, 4 or 5; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic residue optionally having at least one heteroatom as a ring member, which cycloaliphatic residue can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system; or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated, unsubstituted or at least monosubstituted heterocycloaliphatic residue optionally having at least one further heteroatom as a ring member, which heterocycloaliphatic residue can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R5, R6, R7, R8, R10, R11, R12, R15 and R16, in each case mutually independently, denote a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
R9, R13, R14, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic residue or an unsubstituted or at least monosubstituted aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
M1 denotes an aryl or heteroaryl residue, which can be substituted with at least one further substituent and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
and M2 denotes an aryl or heteroaryl residue, which can be unsubstituted or at least monosubstituted and can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system;
in each case in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
2. Compounds according to Claim 1, characterised in that R' and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO21 -CN; -NH2; -NHR5; -NR6R7; -NH-C(=O)-R8; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR10; -C(=O)-NR11R12; -C(=O)-OR13; -(CH2)m-C(=O)-OR14 with m = 1, 2, 3, 4 or 5; -O-C(=O)-R15; -(CH2)n-O-C(=O)-R16 with n = 1, 2, 3, 4 or 5; -OR17; -(CH2)o-O-R18 with o = 1, 2, 3; 4 or 5; -SR19; -(CH2)p-S(=O)t-R20 with p = 1, 2, 3, 4 or 5 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NR29R30; -SF5; -(CH2)u-O-S(=O)2-R31 with u = 1, 2, 3, 4 or 5; -(CH2)v-O-S(=O)2-O-R32 with v = 1, 2, 3, 4 or 5; -(CH2)w-O-P(=O)(OR33)(OR34) with w = 1, 2, 3, or 5; a linear or branched, unsubstituted or at least monosubstituted C1-10-alkyl residue, C2-6-alkenyl residue or C2-6-alkynyl residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic C3-8 residue optionally having at least one heteroatom as a ring member, which residue can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group;
or an unsubstituted or at least monosubstituted 5- or 6-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2, 3, 4 or 5; -C(=O)-O-R23; -(CH2)r-C(=O)-O-R24 with r = 1, 2, 3, 4 or 5; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2, 3, 4 or 5; a linear or branched, unsubstituted or at least monosubstituted C1-10-alkyl residue, C2-6-alkenyl residue or C2-6-alkynyl residue;
a saturated or unsaturated, unsubstituted or at least monosubstituted cycloaliphatic C3-8 residue optionally having at least one heteroatom as a ring member, which residue can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group; or an unsubstituted or at least monosubstituted 5- or 6-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered, or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a saturated or unsaturated, unsubstituted or at least monosubstituted heterocycloaliphatic C4-10 residue optionally having at least one further heteroatom as a ring member, which residue can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R5, R6, R7, R8, R10, R11, R12, R15 and R16, in each case mutually independently, denote a linear or branched, unsubstituted or at least monosubstituted C1-10-alkyl residue, C2-6-alkenyl residue or C2-6-alkynyl residue; or an unsubstituted or at least monosubstituted 5- to 14-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
R9, R13, R14, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a linear or branched, unsubstituted or at least monosubstituted C1-10-alkyl residue, C2-6-alkenyl residue or C2-6-alkynyl residue; or an unsubstituted or at least monosubstituted 5- to 14-membered aryl or heteroaryl residue, which can be bound via a linear or branched, unsubstituted or at least monosubstituted C1-5-alkylene group and/or can be condensed with an unsubstituted or at least monosubstituted mono- or polycyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
M1 denotes a 5- or 6-membered aryl or heteroaryl residue, which can be substituted with at least one further substituent and can be condensed with an unsubstituted or at least monosubstituted mono- or bicyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered, and and M2 denotes a 5- or 6-membered aryl or heteroaryl residue, which can be unsubstituted or at least monosubstituted and can be condensed with an unsubstituted or at least monosubstituted mono- or bicyclic ring system, whereby the rings of the ring system are in each case 5-, 6- or 7-membered;
whereby the above-mentioned cycloaliphatic residues can optionally have 1, 2, 3, 4 or
5 heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur, the above-mentioned heterocycloaliphatic residues can optionally have further 1, 2, 3, 4 or 5 heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising nitrogen, oxygen and sulphur, the rings of the mono- or polycyclic ring system have in each case optionally 0, 1, 2 or 3 heteroatom(s) as (the) ring member(s) which are mutually independently selected from the group comprising oxygen, nitrogen and sulphur;
and the above-mentioned heteroaryl residues can optionally have 1, 2, 3, 4 or 5 heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising oxygen, sulphur and nitrogen.
3. Compounds according to Claim 1 or 2, characterised in that R1 and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NR6R7; -NH-C(=O)-R8; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR10; -C(=O)-NR11R12; -C(=O)-OR13; -(CH2)m-C(=O)-OR14 with m = 1, 2 or 3; -O-C(=O)-R15; -(CH2)n-O-C(=O)-R16 with n = 1, 2 or 3;
-OR17 ; -(CH2)o-O-R18 with o = 1, 2 or 3; -SR19; -(CH2)p-S(=O)t-R20 with p =
1, 2 or 3 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NR29R30; -SF5; -(CH2)u-O-S(=O)2-R31 with u = 1, 2 or 3; -(CH2)v-O-S(=O)2-O-R32 with v = 1, 2 or 3; -(CH2)w-O-P(=O)(OR33)(OR34) with w = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, diazepanyl, azocanyl and dithiolanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, oxo (=O), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl;
or a residue selected from the group comprising phenyl, benzyl, phenethyl, (3-phenyl)-prop-1-yl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl.
4. Compounds according to one or more of Claims 1 to 3, characterised in that R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2 or 3; -C(=O)-O-R23; -(CH2)r-C(=O)-O-R24 with r = 1, 2 or 3; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2 or 3;
a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, diazepanyl, azocanyl and dithiolanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, oxo (=O), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl and/or can be bound via a linear or branched C1-3-alkylene group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl and/or can be bound via a linear or branched C1-3-alkylene group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -OH, oxo, thioxo, -O-CH3, -O-C2H5, -O-C3H7, -(CH2)-O-CH3, -(CH2)-O-C2H5, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NO2, -CF3, -O-CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -NH-S(=O)2-CH3, -C(=O)-OH, -C(=O)-H; -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3 and phenyl.
5. Compounds according to one or more of Claims 1 to 4, characterised in that R5, R6, R7, R8, R10, R11, R12, R15 and R16, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-NH-CH3, -(CH2)-N(CH3)2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3), -(CH2)-(CH2)-(CH2)-OH, -(CH2)-C(=O)-OH, -(CH2)-C(=O)-O-CH3, -(CH2)-C(=O)-O-C2H5, -(CH2)-(CH2)-C(=O)-OH, -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
and the above-mentioned heteroaryl residues can optionally have 1, 2, 3, 4 or 5 heteroatom(s) as (the) ring member(s) which can in each case mutually independently be selected from the group comprising oxygen, sulphur and nitrogen.
3. Compounds according to Claim 1 or 2, characterised in that R1 and R2, mutually independently, in each case denote a hydrogen residue; a halogen residue; -NO2; -CN; -NH2; -NHR5; -NR6R7; -NH-C(=O)-R8; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR10; -C(=O)-NR11R12; -C(=O)-OR13; -(CH2)m-C(=O)-OR14 with m = 1, 2 or 3; -O-C(=O)-R15; -(CH2)n-O-C(=O)-R16 with n = 1, 2 or 3;
-OR17 ; -(CH2)o-O-R18 with o = 1, 2 or 3; -SR19; -(CH2)p-S(=O)t-R20 with p =
1, 2 or 3 and t = 0, 1 or 2; -NH-S(=O)2-NR27R28; -S(=O)2-NR29R30; -SF5; -(CH2)u-O-S(=O)2-R31 with u = 1, 2 or 3; -(CH2)v-O-S(=O)2-O-R32 with v = 1, 2 or 3; -(CH2)w-O-P(=O)(OR33)(OR34) with w = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, diazepanyl, azocanyl and dithiolanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, oxo (=O), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl;
or a residue selected from the group comprising phenyl, benzyl, phenethyl, (3-phenyl)-prop-1-yl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl.
4. Compounds according to one or more of Claims 1 to 3, characterised in that R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2 or 3; -C(=O)-O-R23; -(CH2)r-C(=O)-O-R24 with r = 1, 2 or 3; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2 or 3;
a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3) and -(CH2)-(CH2)-(CH2)-OH; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, imidazolidinyl, tetrahydrofuranyl (tetrahydrofuryl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, thiomorpholinyl, dioxolanyl, azepanyl, diazepanyl, azocanyl and dithiolanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, oxo (=O), thioxo (=S), -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl and/or can be bound via a linear or branched C1-3-alkylene group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl and/or can be bound via a linear or branched C1-3-alkylene group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -OH, oxo, thioxo, -O-CH3, -O-C2H5, -O-C3H7, -(CH2)-O-CH3, -(CH2)-O-C2H5, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NO2, -CF3, -O-CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -NH-S(=O)2-CH3, -C(=O)-OH, -C(=O)-H; -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3 and phenyl.
5. Compounds according to one or more of Claims 1 to 4, characterised in that R5, R6, R7, R8, R10, R11, R12, R15 and R16, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-NH-CH3, -(CH2)-N(CH3)2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3), -(CH2)-(CH2)-(CH2)-OH, -(CH2)-C(=O)-OH, -(CH2)-C(=O)-O-CH3, -(CH2)-C(=O)-O-C2H5, -(CH2)-(CH2)-C(=O)-OH, -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
6. Compounds according to one or more of Claims 1 to 5, characterised in that R9, R13, R14, R17, R18, R19, R10, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-OH, -(CH2)-NH2, -(CH2)-NH-CH3, -(CH2)-N(CH3)2, -(CH2)-CN, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), -(CH2)-(CH2)-OH, -(CH2)-(CH2)-NH2, -(CH2)-(CH2)-CN, -(CF2)-(CF3), -(CH2)-(CH2)-(CF3), -(CH2)-(CH2)-(CH2)-OH, -(CH2)-C(=O)-OH, -(CH2)-C(=O)-O-CH3, -(CH2)-C(=O)-O-C2H5, -(CH2)-(CH2)-C(=O)-OH, -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, purinyl, dithiazolyl, pentazolyl, indolyl, isoindolyl, benzo[b]furanyl, isobenzo[b]furanyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzo[b]thiophenyl and isobenzo[b]thiophenyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
7. Compounds according to one or more of Claims 1 to 6, characterised in that M1 denotes a residue selected from the group comprising phenyl, furanyl, thiophenyl (thienyl), pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxadiazolyl, triazolyl, diazinyl, triazinyl, tetrazinyl and tetrazolyl, which can in each case be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F.
8. Compounds according to Claim 7, characterised in that M1 denotes a residue selected from the group comprising residues 1 to 38, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond.
9. Compounds according to one or more of Claims 1 to 8, characterised in that M2 denotes a residue selected from the group comprising phenyl, furanyl, thiophenyl (thienyl), pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, oxadiazolyl, triazolyl, diazinyl, triazinyl, tetrazinyl, tetrazolyl, pentazolyl, imidazolyl, quinolinyl, isoquinolinyl, naphthyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl and isobenzothiophenyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -C.ident.C-Si(CH3)3, -C.ident.C-Si(C2H5)3, -CH2-O-CH3, -CH2-O-C2H5, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -S(=O)2-phenyl, pyrazolyl, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -CH2-O-C(=O)-phenyl, -NH-S(=O)2-CH3, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -NH-C(=O)-CH3, -NH-C(=O)-C2H5, -O-C(=O)-phenyl, -C(=O)-NH2, -C(=O)-NH-CH3, -C(=O)-N(CH3)2, -Si(phenyl)2[C(CH3)3], -CH2-NH2, pyrrolyl, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -NH-C(=NH)-NH2, -NH-S(=O)2-OH, -S(=O)2-N(CH3)2, (1,3)-dioxolanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl (furanyl), thiadiazolyl, thiophenyl (thienyl) and benzyl.
10. Compounds according to Claim 9, characterised in that M2 denotes a residue selected from the group comprising residues 1 to 36, which in each case can be linked via the position marked by a wavy line with the carbon atom of the triple bond and can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2.
11. Compounds according to one or more of Claims 1 to 10, characterised in that R1 and R2, mutually independently, in each case denote a hydrogen residue; -F; -Cl; -Br; -I; -NO2; -CN; -NH2; -NHR5; -NR6R7; -C(=O)-R9, -C(=O)-NH2; -C(=O)-NHR10; -C(=O)-NR11R12; -C(=O)-OR13; -(CH2)m-C(=O)-OR14 with m = 1, 2 or 3; -O-C(=O)-R15; -OR17; -(CH2)o-O-R18 with o = 1, 2 or 3; -S(=O)2-NH2; -SF5; -(CH2)u-O-S(=O)2-R31 with u = 1, 2 or 3; -(CH2)v-O-S(=O)2-O-R32 with v =
1, 2 or 3; -(CH2)w-O-P(=O)(OR33)(OR34) with w = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, oxo (=O), thioxo (=S), -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F;
or a residue selected from the group comprising phenyl, benzyl, phenethyl, (3-phenyl)-prop-1-yl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2 or 3; -C(=O)-O-R23; -(CH2)r-C(=O)-O-R24 with r = 1, 2 or 3; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2 or 3;
a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, oxo (=O), thioxo (=S), -O-CH3, -O-C2H5, -O-C3H7 and -O-C(CH3)3 and/or can be bound via a linear or branched C1-3-alkylene group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, cyclopropyl, cyclobutyl and cyclopentyl and/or can be bound via a linear or branched C1-3-alkylene group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, -OH, oxo, thioxo, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NO2, -CF3, -O-CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3 and phenyl;
R5, R6, R7, R10, R11, R12 and R15, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CHF2), -(CH2)-(CH2F), -(CF2)-(CF3), -(CH2)-(CH2)-C(=O)-OH, -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F
and -C(=O)-CF3;
R9, R13, R14, R17, R18, R21, R22, R23, R24, R25, R16, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F and -C(=O)-CF3;
M1 denotes a residue selected from the group comprising residues 1 to 9, 11, 21, 22 and 36 to 38, which in each case can be unsubstituted or substituted with optionally 1 or 2 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising residues 1 to 36, which in each case can be linked via the position marked by a wavy line with the carbon atom of the triple bond and can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
1, 2 or 3; -(CH2)w-O-P(=O)(OR33)(OR34) with w = 1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, oxo (=O), thioxo (=S), -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F;
or a residue selected from the group comprising phenyl, benzyl, phenethyl, (3-phenyl)-prop-1-yl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2 or 3; -C(=O)-O-R23; -(CH2)r-C(=O)-O-R24 with r = 1, 2 or 3; -C(=O)-NHR25; -(CH2)s-C(=O)-NHR26 with s = 1, 2 or 3;
a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3 or 4 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, oxo (=O), thioxo (=S), -O-CH3, -O-C2H5, -O-C3H7 and -O-C(CH3)3 and/or can be bound via a linear or branched C1-3-alkylene group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2, -S-CH2F, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, cyclopropyl, cyclobutyl and cyclopentyl and/or can be bound via a linear or branched C1-3-alkylene group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, azepanyl, diazepanyl and azocanyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, -OH, oxo, thioxo, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -N(C2H5)2, -NH-CH3, -NH-C2H5, -NO2, -CF3, -O-CF3, -S-CF3, -SH, -SF5, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-C(CH3)3 and phenyl;
R5, R6, R7, R10, R11, R12 and R15, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CHF2), -(CH2)-(CH2F), -(CF2)-(CF3), -(CH2)-(CH2)-C(=O)-OH, -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F
and -C(=O)-CF3;
R9, R13, R14, R17, R18, R21, R22, R23, R24, R25, R16, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); or a residue selected from the group comprising phenyl, benzyl, phenethyl, furyl (furanyl), thienyl (thiophenyl), pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F and -C(=O)-CF3;
M1 denotes a residue selected from the group comprising residues 1 to 9, 11, 21, 22 and 36 to 38, which in each case can be unsubstituted or substituted with optionally 1 or 2 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, ethenyl, allyl, ethynyl, propynyl, -OH, -SH, -SF5, -NH2, -C(=O)-OH, -S-CH3, -S-C2H5, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2, -O-CH2F, -C(=O)-CF3, -S-CF3, -S-CHF2 and -S-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising residues 1 to 36, which in each case can be linked via the position marked by a wavy line with the carbon atom of the triple bond and can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
12. Compounds according to one or more of Claims 1 to 11, characterised in that R1 and R2, mutually independently, in each case denote a hydrogen residue; -F; -Cl; -Br; -I; -NO2; -CN; -NHR5; -NR6R7; -C(=O)-R9, -C(=O)-OR13; -(CH2)-O-C(=O)-R16; -OR17; -(CH2)-O-S(=O)2-R31; -(CH2)-O-S(=O)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR34); -SF5; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
or a residue selected from the group comprising phenyl, benzyl, phenethyl and (3-phenyl)-prop-1-yl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2 or 3; -(CH2)r-C(=O)-O-R24 with r =
1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which can be bound via a -(CH2)-, -(CH2)2-, -(CH(CH3))- or -(CH2)3 group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F and/or can be bound via a-(CH2)-, -(CH2)2-, -(CH(CH3))- or -(CH2)3 group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -C(=O)-O-CH3, -C(=O)-O-C2H5 and -C(=O)-O-C(CH3)3;
R5, R6, R7 and R16, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CHF2), -(CH2)-(CH2F), -(CF2)-(CF3), -(CH2)-(CH2)-C(=O)-OH; -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl and phenethyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3 and -O-C2H5;
R9, R13, R17, R21, R22, R24, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); or a residue selected from the group comprising phenyl, benzyl and phenethyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl,-O-and -O-C2H5;
M1 denotes a residue selected from the group comprising residues 1 to 6, 21, 22, 36 and 37, which in each case can be unsubstituted or substituted with optionally 1 or 2 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -SF5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl and 8-quinolinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
or a residue selected from the group comprising phenyl, benzyl, phenethyl and (3-phenyl)-prop-1-yl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F;
R3 and R4, mutually independently, in each case denote a hydrogen residue;
-C(=O)-R21; -(CH2)q-C(=O)-R22 with q = 1, 2 or 3; -(CH2)r-C(=O)-O-R24 with r =
1, 2 or 3; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl; a residue selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which can be bound via a -(CH2)-, -(CH2)2-, -(CH(CH3))- or -(CH2)3 group;
or a residue selected from the group comprising phenyl, furyl (furanyl), thienyl (thiophenyl), pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F and/or can be bound via a-(CH2)-, -(CH2)2-, -(CH(CH3))- or -(CH2)3 group;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, -S(=O)-CH3, -S(=O)2-CH3, -S(=O)-C2H5, -S(=O)2-C2H5, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-N(CH3)2, -C(=O)-NH-CH3, -C(=O)-NH2, -C(=O)-O-CH3, -C(=O)-O-C2H5 and -C(=O)-O-C(CH3)3;
R5, R6, R7 and R16, in each case mutually independently, denote a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CHF2), -(CH2)-(CH2F), -(CF2)-(CF3), -(CH2)-(CH2)-C(=O)-OH; -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5; or a residue selected from the group comprising phenyl, benzyl and phenethyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, -O-CH3 and -O-C2H5;
R9, R13, R17, R21, R22, R24, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3); or a residue selected from the group comprising phenyl, benzyl and phenethyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl,-O-and -O-C2H5;
M1 denotes a residue selected from the group comprising residues 1 to 6, 21, 22, 36 and 37, which in each case can be unsubstituted or substituted with optionally 1 or 2 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -CH2-CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, neo-pentyl, -SF5, -O-CH3, -O-C2H5, -O-C3H7, -O-C(CH3)3, -CF3, -CHF2, -CH2F, -O-CF3, -O-CHF2 and -O-CH2F, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl and 8-quinolinyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of one of the pure stereoisomers thereof, in particular enantiomers or diastereomers, the racemates thereof or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or in each case in the form of corresponding salts or in each case in the form of corresponding solvates.
13. Compounds of the general formula Ia according to Claim 12, in which R1, R2, R3 and R4 have the meaning according to Claim 12, and R35 and R36, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
14. Compounds of the general formula Ib according to Claim 12, in which R1, R2, R3 and R4 have the meaning according to Claim 12, and R37 and R38, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
15. Compounds of the general formula Ic according to Claim 12, in which R1, R2, R3 and R4 have the meaning according to Claim 12, and R39 and R40, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
16. Compounds of the general formula Id according to Claim 12, in which R1, R2, R3 and R4 have the meaning according to Claim 12, and R41 and R42, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
17. Compounds of the general formula Ie according to Claim 12, in which R1, R2, R3 and R4 have the meaning according to Claim 12, and R43 and R44, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
18. Compounds of the general formula If according to Claim 12, in which R1, R2, R3 and R4 have the meaning according to Claim 12, and R45 and R46, mutually independently, in each case denote a residue selected from the group comprising H, F, Cl, Br, -CN, -CF3, -SF5, -S-CH3, -S-C2H5, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, ethenyl, propenyl, -OH, -O-CH3, -O-C2H5, -O-C3H7, -NH2, -N(CH3)2, -NH-CH3, -CH2-NH2, -N(C2H5)2, -NO2, -O-CF3, -S-CF3, -SH, -C(=O)-H, -C(=O)-O-CH3, -C(=O)-O-C2H5, phenyl, pyrrolyl, (1,3)-dioxolanyl, -Si(phenyl)2[C(CH3)3], -C(=O)-CH3, -C(=O)-C2H5, NH-S(=O)2-CH3, -NH-S(=O)2-C2H5, -S(=O)2-NH2, -S(=O)2-NH-CH3, -CH2-OH, -C(=O)-OH, -CH2-O-CH3, -C(=O)-NH2, -C(=O)-NH-CH3, -NH-C(=O)-CH3, -NH-C(=NH)-NH2, -NH-S(=O)2-OH and -S(=O)2-N(CH3)2;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
19. Compounds according to one or more of Claims 1 to 18, characterised in that R1 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -O-CH3; -C(=O)-R9, -C(=O)-OR13; -(CH2)-O-C(=O)-R16; -(CH2)-O-S(=O)2-R31; -(CH2)-O-S(=O)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR34); or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), and -(CF2)-(CF3);
R2 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -O-CH3; -C(=O)-R9, -C(=O)-OR13; -(CH2)-O-C(=O)-R16; -(CH2)-O-S(=O)2-R31; -(CH2)-O-S(=O)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR34); or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), and -(CF2)-(CF3);
R3 denotes a hydrogen residue or a residue selected from the group comprising methyl, ethyl and isopropyl;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising pyrrolidinyl, piperidinyl and morpholinyl;
R16 denotes a residue selected from the group comprising -(CH2)-(CH2)-C(=O)-OH; -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5;
R9, R13, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3);
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3) or a phenyl residue, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl,-O-CH3 and -O-C2H5;
M1 denotes a residue selected from the group comprising residues 1, 3, 5, 22, 36 and 37, which in each case is unsubstituted, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
M2 denotes a residue selected from the group comprising phenyl, 2-pyrimidinyl, 5-pyrimidinyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl and 4-thiazolyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -O-CH3, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
R2 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -O-CH3; -C(=O)-R9, -C(=O)-OR13; -(CH2)-O-C(=O)-R16; -(CH2)-O-S(=O)2-R31; -(CH2)-O-S(=O)2-O-R32; -(CH2)-O-P(=O)(OR33)(OR34); or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F), and -(CF2)-(CF3);
R3 denotes a hydrogen residue or a residue selected from the group comprising methyl, ethyl and isopropyl;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl and (2,4,4)-trimethyl-pent-2-yl;
or R3 and R4 together with the nitrogen atom connecting them together as a ring member form a residue selected from the group comprising pyrrolidinyl, piperidinyl and morpholinyl;
R16 denotes a residue selected from the group comprising -(CH2)-(CH2)-C(=O)-OH; -(CH2)-(CH2)-C(=O)-O-CH3 and -(CH2)-(CH2)-C(=O)-O-C2H5;
R9, R13, R31, R32, R33 and R34, in each case mutually independently, denote a hydrogen residue; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, pentyl, 3-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3);
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-heptyl, n-octyl, (2,4,4)-trimethyl-pent-2-yl, -CF3, -CF2H, -CFH2, -(CH2)-(CF3), -(CH2)-(CHF2), -(CH2)-(CH2F) and -(CF2)-(CF3) or a phenyl residue, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, I, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl,-O-CH3 and -O-C2H5;
M1 denotes a residue selected from the group comprising residues 1, 3, 5, 22, 36 and 37, which in each case is unsubstituted, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
M2 denotes a residue selected from the group comprising phenyl, 2-pyrimidinyl, 5-pyrimidinyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl and 4-thiazolyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -O-CH3, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case optionally in the form of corresponding solvates.
20. Compounds according to one or more of Claims 1 to 19, characterised in that R' denotes a hydrogen residue; -F; -Cl; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R2 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R3 denotes a hydrogen residue;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl;
R13 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, pentyl and (2,4,4)-trimethyl-pent-2-yl;
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl or a phenyl residue which in each case is unsubstituted;
M1 denotes a residue selected from the group comprising residues 1, 3, 5, 22 and 36, which in each case is unsubstituted, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising phenyl, 2-pyrimidinyl, 5-pyrimidinyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl and 4-thiazolyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -OH, -O-CH3, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case in the form of corresponding solvates.
R2 denotes a hydrogen residue; -F; -Cl; -Br; -CN; -C(=O)-OR13; or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl and n-pentyl;
R3 denotes a hydrogen residue;
R4 denotes a hydrogen residue; -C(=O)-R21 or a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl;
R13 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, pentyl and (2,4,4)-trimethyl-pent-2-yl;
R21 denotes a residue selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl and (2,4,4)-trimethyl-pent-2-yl or a phenyl residue which in each case is unsubstituted;
M1 denotes a residue selected from the group comprising residues 1, 3, 5, 22 and 36, which in each case is unsubstituted, and which in each case can be linked in any direction via the positions marked by a wavy line with the bicycle and the carbon atom of the triple bond;
and M2 denotes a residue selected from the group comprising phenyl, 2-pyrimidinyl, 5-pyrimidinyl, 2-thiophenyl (2-thienyl), 3-thiophenyl (3-thienyl), 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-thiazolyl and 4-thiazolyl, which in each case can be unsubstituted or substituted with optionally 1, 2, 3, 4 or 5 substituents mutually independently selected from the group comprising F, Cl, Br, -CN, -OH, -O-CH3, -OH, -CF3, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl;
in each case optionally in the form of corresponding salts, or in each case in the form of corresponding solvates.
21. Compounds according to one or more of Claims 1 to 20 selected from the group comprising [1] 6-(5-(phenylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)-imidazo[2,1-b]thiazole-5-amine, [2] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [3] N-tert-butyl-3-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [4] N-tert-butyl-2-methyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [5] N-tert-butyl-2,3-dimethyl-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [6] N-tert-butyl-2-chloro-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-5-amine, [7] N-tert-butyl-6-(5-(pyridine-4-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [8] 5-(tert-butylamino)-6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)-imidazo[2,1-b]thiazole-2-carboxylic acid methylester, [9] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)thiazole-2-yl)imidazo[2,1-b]thiazole-5-amine;
[10] 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine, [11] N-tert-butyl-2-methyl-6-(4-(pyridine-2-ylethynyl)phenyl)imidazo[2,1-b]thiazole-5-amine, [12] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)furan-2-yl)imidazo[2,1-b]thiazole-5-amine, [13] N-tert-butyl-3-methyl-6-(5-(phenylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [14] 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [15] N-tert-butyl-6-(5-(pyrimidine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [16] N-tert-butyl-6-(5-((3-fluoropyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [17] N-tert-butyl-6-(5-((2-fluoropyridine-4-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [18] N-tert-butyl-6-(5-(thiophene-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [19] N-tert-butyl-6-(5-(thiazole-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [20] 3-((5-(5-(tert-butylamino)imidazo[2,1-b]thiazole-6-yl)thiophene-2-yl)ethynyl)phenol, [21] 3-((5-(5-(tert-butylamino)imidazo[2,1-b]thiazole-6-yl)thiophene-2-yl)ethynyl)benzonitrile,
[10] 6-(5-pyridine-2-ylethynyl)thiophene-2-yl)-N-(2,4,4-trimethylpentane-2-yl)imidazo[2,1-b]thiazole-5-amine, [11] N-tert-butyl-2-methyl-6-(4-(pyridine-2-ylethynyl)phenyl)imidazo[2,1-b]thiazole-5-amine, [12] N-tert-butyl-6-(5-(pyridine-2-ylethynyl)furan-2-yl)imidazo[2,1-b]thiazole-5-amine, [13] N-tert-butyl-3-methyl-6-(5-(phenylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [14] 6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [15] N-tert-butyl-6-(5-(pyrimidine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [16] N-tert-butyl-6-(5-((3-fluoropyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [17] N-tert-butyl-6-(5-((2-fluoropyridine-4-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [18] N-tert-butyl-6-(5-(thiophene-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [19] N-tert-butyl-6-(5-(thiazole-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine, [20] 3-((5-(5-(tert-butylamino)imidazo[2,1-b]thiazole-6-yl)thiophene-2-yl)ethynyl)phenol, [21] 3-((5-(5-(tert-butylamino)imidazo[2,1-b]thiazole-6-yl)thiophene-2-yl)ethynyl)benzonitrile,
[22] N-ethyl-6-(6-(phenylethynyl)pyridine-3-yl)imidazo[2,1-b]thiazole-5-amine,
[23] N-tert-butyl-6-(5-((3-methylpyridine-2-yl)ethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-amine,
[24] N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)acetamide and
[25] N-(6-(5-(pyridine-2-ylethynyl)thiophene-2-yl)imidazo[2,1-b]thiazole-5-yl)benzamide;
in each case optionally in the form of corresponding salts, in particular the hydrochlorides, or in each case in the form of corresponding solvates.
22. Compounds according to one or more of Claims 1 to 21, characterised in that they, after 60 minutes of incubation in 450 µg protein from pig brain homogenate at a temperature between 20 °C and 25 °C in a concentration of less than 2500 nM, preferably of less than 1000 nM, particularly preferably of less than 700 nM, very particularly preferably of less than 100 nM, even more preferably of less than 70 nM, bring about a 50-percent displacement of [3H]-2-methyl-6-(3-methoxyphenyl)-ethynylpyridine which is present in a concentration of 5 nM.
23. Method for producing substituted imidazo[2,1-b]thiazole compounds of the general formula I according to one or more of Claims 1 to 22, characterised in that at least one compound of the general formula 11, in which R1 and R2 have the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one organic or inorganic acid or at least one transition metal salt, is converted with at least one isocyanide of the general formula III, R3-N.ident.C
III, in which R3 has the meaning according to one or more of Claims 1 to 22, and at least one aldehyde of the general formula IV, in which M1 and M2 have the meaning according to one or more of Claims 1 to 22, and the compound obtained in this manner of the general formula V, in which R1, R2, R3, M1 and M2 have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, or at least one compound of the general formula II, in which R1 and R2 have the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one organic or inorganic acid or at least one transition metal salt, is converted with at least one isocyanide of the general formula III, R3-N.ident.C
III, in which R3 has the meaning according to one or more of Claims 1 to 22, and at least one aldehyde of the general formula VI, in which M1 has the meaning according to one or more of Claims 1 to 22 and X
denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, and the compound obtained in this manner of the general formula VII, in which R1, R2, R3, M1 and X have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and by conversion with at least one acetylene of the general formula XI, in which R, mutually independently, in each case denotes a linear or branched alkyl residue or an unsubstituted phenyl residue, in a reaction medium, optionally in the presence of at least one suitable catalyst and optionally in the presence of at least one inorganic and/or organic base is transformed into a correspondingly substituted compound of the general formula XII, in which R1, R2, R3 and M1 have the above-mentioned meaning and R, mutually independently, in each case denotes a linear or branched alkyl residue or an unsubstituted phenyl residue, and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and at least one compound of the general formula XII is transformed in a reaction medium, optionally in the presence of at least one inorganic and/or organic base, optionally in the presence of at least one inorganic salt, and optionally in the presence of at least one ammonium salt, into a correspondingly substituted compound of the general formula XIII, in which R1, R2, R3 and M1 have the above-mentioned meaning, and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and at least one compound of the general formula XIII and/or at least one compound of the general formula XII is transformed by conversion with at least one compound of the general formula M2-X, in which M2 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one suitable catalyst, optionally in the presence of at least one inorganic and/or organic base, optionally in the presence of at least one inorganic salt and optionally in the presence of at least one ammonium salt into a correspondingly substituted compound of the general formula V, in which R1, R2, R3, M1 and M2 have the above-mentioned meaning and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, or a compound of the general formula VII is transformed by conversion with at least one acetylene of the general formula VIII, in which M2 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one suitable catalyst and optionally in the presence of at least one inorganic and/or organic base into a correspondingly substituted compound of the general formula V, in which R1, R2, R3, M1 and M2 have the above-mentioned meaning and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and optionally the compound of the general formula V is transformed by conversion with at least one compound of the general formula R4-X, in which R4 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, in a reaction medium, in the presence of at least one organic or inorganic base, preferably in the presence of at least one metal hydride salt, or by conversion with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or in the presence of at least one coupling agent, or by conversion with at least one compound of the general formula R21-C(=O)-X, in which R21 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one organic or inorganic base, or by conversion with at least one compound of the general formula R21-C(=O)-H, in which R21 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one reducing agent, into a compound of the general formula I, optionally in the form of a corresponding salt, in which R1, R2, R3, R4, M1 and M2 have the meaning according to one or more of Claims 1 to 22, and this is optionally purified and/or isolated.
24. Method for producing substituted imidazo[2,1-b]thiazole compounds of the general formula I according to one or more of Claims 1 to 22, characterised in that at least one compound of the general formula V is converted, in which R1, R2, R3, M1 and M2 have the meaning according to one or more of Claims 1 to 22, optionally in a reaction medium in the presence of at least one organic or inorganic acid, and the compound obtained in this manner of the general formula IX, in which R1, R2, M1 and M2 have the meaning according to one or more of Claims 1 to 22, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated and this compound/this salt is transformed optionally by conversion in a reaction medium, in the presence of at least one inorganic or organic base, preferably in the presence of at least one metal hydride salt, with at least one compound of the general formula R3-X, in which R3 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, or in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or optionally in the presence of at least one coupling agent with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the meaning according to one or more of Claims 1 to 22, or in a reaction medium, optionally in the presence of at least one organic or inorganic base with at least one compound of the general formula R21-C(=O)-X, in which R21 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, or in a reaction medium, optionally in the presence of at least one reducing agent with at least one compound of the general formula R21-C(=O)-H, in which R21 has the meaning according to one or more of Claims 1 to 22, into a corresponding compound of the general formula X, optionally in the form of a corresponding salt, in which R1, R2, R3, M1 and M2 have the meaning according to one or more of Claims 1 to 22, and this is optionally purified and/or isolated, and optionally the compound of the general formula X is transformed by conversion with at least one compound of the general formula R4-X, in which R4 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, in a reaction medium, in the presence of at least one organic or inorganic base, preferably in the presence of at least one metal hydride salt, or by conversion with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or in the presence of at least one coupling agent, or by conversion with at least one compound of the general formula R21-C(=O)-X, in which R21 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one organic or inorganic base, or by conversion with at least one compound of the general formula R21-C(=O)-H, in which R21 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one reducing agent, into a compound of the general formula I, optionally in the form of a corresponding salt, in which R1, R2, R3, R4, M1 and M2 have the meaning according to one or more of Claims 1 to 22, and this is optionally purified and/or isolated.
25. Drug containing at least one compound according to one or more of Claims 1 to 22 and optionally one or more physiologically acceptable auxiliary substances.
in each case optionally in the form of corresponding salts, in particular the hydrochlorides, or in each case in the form of corresponding solvates.
22. Compounds according to one or more of Claims 1 to 21, characterised in that they, after 60 minutes of incubation in 450 µg protein from pig brain homogenate at a temperature between 20 °C and 25 °C in a concentration of less than 2500 nM, preferably of less than 1000 nM, particularly preferably of less than 700 nM, very particularly preferably of less than 100 nM, even more preferably of less than 70 nM, bring about a 50-percent displacement of [3H]-2-methyl-6-(3-methoxyphenyl)-ethynylpyridine which is present in a concentration of 5 nM.
23. Method for producing substituted imidazo[2,1-b]thiazole compounds of the general formula I according to one or more of Claims 1 to 22, characterised in that at least one compound of the general formula 11, in which R1 and R2 have the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one organic or inorganic acid or at least one transition metal salt, is converted with at least one isocyanide of the general formula III, R3-N.ident.C
III, in which R3 has the meaning according to one or more of Claims 1 to 22, and at least one aldehyde of the general formula IV, in which M1 and M2 have the meaning according to one or more of Claims 1 to 22, and the compound obtained in this manner of the general formula V, in which R1, R2, R3, M1 and M2 have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, or at least one compound of the general formula II, in which R1 and R2 have the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one organic or inorganic acid or at least one transition metal salt, is converted with at least one isocyanide of the general formula III, R3-N.ident.C
III, in which R3 has the meaning according to one or more of Claims 1 to 22, and at least one aldehyde of the general formula VI, in which M1 has the meaning according to one or more of Claims 1 to 22 and X
denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, and the compound obtained in this manner of the general formula VII, in which R1, R2, R3, M1 and X have the above-mentioned meaning, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and by conversion with at least one acetylene of the general formula XI, in which R, mutually independently, in each case denotes a linear or branched alkyl residue or an unsubstituted phenyl residue, in a reaction medium, optionally in the presence of at least one suitable catalyst and optionally in the presence of at least one inorganic and/or organic base is transformed into a correspondingly substituted compound of the general formula XII, in which R1, R2, R3 and M1 have the above-mentioned meaning and R, mutually independently, in each case denotes a linear or branched alkyl residue or an unsubstituted phenyl residue, and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and at least one compound of the general formula XII is transformed in a reaction medium, optionally in the presence of at least one inorganic and/or organic base, optionally in the presence of at least one inorganic salt, and optionally in the presence of at least one ammonium salt, into a correspondingly substituted compound of the general formula XIII, in which R1, R2, R3 and M1 have the above-mentioned meaning, and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and at least one compound of the general formula XIII and/or at least one compound of the general formula XII is transformed by conversion with at least one compound of the general formula M2-X, in which M2 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one suitable catalyst, optionally in the presence of at least one inorganic and/or organic base, optionally in the presence of at least one inorganic salt and optionally in the presence of at least one ammonium salt into a correspondingly substituted compound of the general formula V, in which R1, R2, R3, M1 and M2 have the above-mentioned meaning and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, or a compound of the general formula VII is transformed by conversion with at least one acetylene of the general formula VIII, in which M2 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one suitable catalyst and optionally in the presence of at least one inorganic and/or organic base into a correspondingly substituted compound of the general formula V, in which R1, R2, R3, M1 and M2 have the above-mentioned meaning and is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated, and optionally the compound of the general formula V is transformed by conversion with at least one compound of the general formula R4-X, in which R4 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, in a reaction medium, in the presence of at least one organic or inorganic base, preferably in the presence of at least one metal hydride salt, or by conversion with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or in the presence of at least one coupling agent, or by conversion with at least one compound of the general formula R21-C(=O)-X, in which R21 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one organic or inorganic base, or by conversion with at least one compound of the general formula R21-C(=O)-H, in which R21 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one reducing agent, into a compound of the general formula I, optionally in the form of a corresponding salt, in which R1, R2, R3, R4, M1 and M2 have the meaning according to one or more of Claims 1 to 22, and this is optionally purified and/or isolated.
24. Method for producing substituted imidazo[2,1-b]thiazole compounds of the general formula I according to one or more of Claims 1 to 22, characterised in that at least one compound of the general formula V is converted, in which R1, R2, R3, M1 and M2 have the meaning according to one or more of Claims 1 to 22, optionally in a reaction medium in the presence of at least one organic or inorganic acid, and the compound obtained in this manner of the general formula IX, in which R1, R2, M1 and M2 have the meaning according to one or more of Claims 1 to 22, is optionally purified and/or isolated, and optionally transformed into a corresponding salt and this is optionally purified and/or isolated and this compound/this salt is transformed optionally by conversion in a reaction medium, in the presence of at least one inorganic or organic base, preferably in the presence of at least one metal hydride salt, with at least one compound of the general formula R3-X, in which R3 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, or in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or optionally in the presence of at least one coupling agent with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the meaning according to one or more of Claims 1 to 22, or in a reaction medium, optionally in the presence of at least one organic or inorganic base with at least one compound of the general formula R21-C(=O)-X, in which R21 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, or in a reaction medium, optionally in the presence of at least one reducing agent with at least one compound of the general formula R21-C(=O)-H, in which R21 has the meaning according to one or more of Claims 1 to 22, into a corresponding compound of the general formula X, optionally in the form of a corresponding salt, in which R1, R2, R3, M1 and M2 have the meaning according to one or more of Claims 1 to 22, and this is optionally purified and/or isolated, and optionally the compound of the general formula X is transformed by conversion with at least one compound of the general formula R4-X, in which R4 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, in a reaction medium, in the presence of at least one organic or inorganic base, preferably in the presence of at least one metal hydride salt, or by conversion with at least one compound of the general formula R21-C(=O)-OH, in which R21 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one organic or inorganic base and/or in the presence of at least one coupling agent, or by conversion with at least one compound of the general formula R21-C(=O)-X, in which R21 has the meaning according to one or more of Claims 1 to 22 and X denotes a leaving group, preferably a halogen residue or a sulphonic acid ester, particularly preferably chlorine, bromine or trifluoromethanesulphonate, in a reaction medium, optionally in the presence of at least one organic or inorganic base, or by conversion with at least one compound of the general formula R21-C(=O)-H, in which R21 has the meaning according to one or more of Claims 1 to 22, in a reaction medium, optionally in the presence of at least one reducing agent, into a compound of the general formula I, optionally in the form of a corresponding salt, in which R1, R2, R3, R4, M1 and M2 have the meaning according to one or more of Claims 1 to 22, and this is optionally purified and/or isolated.
25. Drug containing at least one compound according to one or more of Claims 1 to 22 and optionally one or more physiologically acceptable auxiliary substances.
26. Drug according to Claim 24 for mGluR5 receptor regulation, in particular for inhibition of the mGluR5 receptor.
27. Drug according to Claim 25 or 26 for the prevention and/or treatment of disorders and/or illnesses which are at least partially mediated by mGluR5 receptors.
28. Drug according to one or more of Claims 25 to 27 for the treatment and/or prevention of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain; migraine; depression;
neurodegenerative diseases, preferably selected from the group comprising multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's chorea; cognitive dysfunction, preferably cognitive deficiency states, particularly preferably Attention Deficit Disorder (ADD); psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks; epilepsy; coughing; urinary incontinence; diarrhoea; pruritus;
schizophrenia; cerebral ischaemia; muscle spasms; cramps; lung illnesses, preferably selected from the group comprising asthma and pseudo-croup;
regurgitation (vomiting); listlessness; drowsiness; weariness; laryngitis;
disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on alcohol; dependency on medicines; dependency on drugs, preferably dependency on nicotine and/or cocaine; alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications, preferably to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux; irritable bowel syndrome; for diuresis; for antinatriuresis; for influencing the cardiovascular system; for increasing vigilance; for increasing libido;
for modulating locomotor activity or for local anaesthesia.
neurodegenerative diseases, preferably selected from the group comprising multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's chorea; cognitive dysfunction, preferably cognitive deficiency states, particularly preferably Attention Deficit Disorder (ADD); psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks; epilepsy; coughing; urinary incontinence; diarrhoea; pruritus;
schizophrenia; cerebral ischaemia; muscle spasms; cramps; lung illnesses, preferably selected from the group comprising asthma and pseudo-croup;
regurgitation (vomiting); listlessness; drowsiness; weariness; laryngitis;
disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on alcohol; dependency on medicines; dependency on drugs, preferably dependency on nicotine and/or cocaine; alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications, preferably to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux; irritable bowel syndrome; for diuresis; for antinatriuresis; for influencing the cardiovascular system; for increasing vigilance; for increasing libido;
for modulating locomotor activity or for local anaesthesia.
29. Use of at least one compound according to one or more of Claims 1 to 22 for the production of a drug for mGluR5 receptor regulation, preferably for inhibition of the mGluR5 receptor.
30. Use of at least one compound according to one or more of Claims 1 to 22 for the production of a drug for the prevention and/or treatment of disorders and/or illnesses which are at least partially mediated by mGluR5 receptors.
31. Use of at least one compound according to one or more of Claims 1 to 22 for the production of a drug for the treatment and/or prevention of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain; migraine; depression; neurodegenerative diseases, preferably selected from the group comprising multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's chorea; cognitive dysfunction, preferably cognitive deficiency states, particularly preferably Attention Deficit Disorder (ADD); psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks; epilepsy;
coughing; urinary incontinence; diarrhoea; pruritus; schizophrenia; cerebral ischaemia; muscle spasms; cramps; lung illnesses, preferably selected from the group comprising asthma and pseudo-croup; regurgitation (vomiting);
listlessness; drowsiness; weariness; laryngitis; disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on alcohol; dependency on medicines; dependency on drugs, preferably dependency on nicotine and/or cocaine; alcohol abuse;
abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse;
withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications, preferably to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux; irritable bowel syndrome; for diuresis; for antinatriuresis; for influencing the cardiovascular system; for increasing vigilance; for increasing libido; for modulating locomotor activity or for local anaesthesia.
coughing; urinary incontinence; diarrhoea; pruritus; schizophrenia; cerebral ischaemia; muscle spasms; cramps; lung illnesses, preferably selected from the group comprising asthma and pseudo-croup; regurgitation (vomiting);
listlessness; drowsiness; weariness; laryngitis; disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity; dependency on alcohol; dependency on medicines; dependency on drugs, preferably dependency on nicotine and/or cocaine; alcohol abuse;
abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse;
withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications, preferably to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux; irritable bowel syndrome; for diuresis; for antinatriuresis; for influencing the cardiovascular system; for increasing vigilance; for increasing libido; for modulating locomotor activity or for local anaesthesia.
32. Use according to Claim 31 for the production of a drug for the treatment and/or prevention of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain; psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks; dependency on alcohol; dependency on medicines; cognitive dysfunction, preferably cognitive deficiency states, particularly preferably Attention Deficit Disorder (ADD); disorders of food intake, preferably selected from the group comprising bulimia, cachexia, anorexia and obesity;
dependency on drugs, preferably dependency on nicotine and/or cocaine;
alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications and/or drugs, particularly to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux and irritable bowel syndrome.
dependency on drugs, preferably dependency on nicotine and/or cocaine;
alcohol abuse; abuse of medication; drug abuse; preferably nicotine and/or cocaine abuse; withdrawal symptoms associated with dependency on alcohol, medications and/or drugs (in particular nicotine and/or cocaine); development of tolerance to medications and/or drugs, particularly to natural or synthetic opioids; stomach-esophagus-reflux-syndrome; gastroesophagal reflux and irritable bowel syndrome.
33. Use according to Claim 31 or 32 for the production of a drug for the treatment and/or prevention of pain, preferably of pain selected from the group comprising acute pain, chronic pain, neuropathic pain and visceral pain.
34. Use according to Claim 31 or 32 for the production of a drug for the treatment and/or prevention of psychiatric disorders, preferably selected from the group comprising anxiety states and panic attacks.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006011574.0 | 2006-03-10 | ||
DE102006011574A DE102006011574A1 (en) | 2006-03-10 | 2006-03-10 | Substituted imidazo [2,1-b] thiazole compounds and their use for the preparation of medicaments |
PCT/EP2007/002067 WO2007104485A2 (en) | 2006-03-10 | 2007-03-09 | Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2643410A1 true CA2643410A1 (en) | 2007-09-20 |
Family
ID=38370833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002643410A Abandoned CA2643410A1 (en) | 2006-03-10 | 2007-03-09 | Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs |
Country Status (16)
Country | Link |
---|---|
US (1) | US7893069B2 (en) |
EP (1) | EP1996596B1 (en) |
JP (1) | JP2009529508A (en) |
KR (1) | KR20080108534A (en) |
CN (1) | CN101421281A (en) |
AU (1) | AU2007224678B2 (en) |
BR (1) | BRPI0708740A2 (en) |
CA (1) | CA2643410A1 (en) |
DE (1) | DE102006011574A1 (en) |
ES (1) | ES2549112T3 (en) |
MX (1) | MX2008011576A (en) |
NO (1) | NO20084177L (en) |
NZ (1) | NZ570710A (en) |
RU (1) | RU2450010C2 (en) |
WO (1) | WO2007104485A2 (en) |
ZA (1) | ZA200807321B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1884515A1 (en) * | 2006-07-31 | 2008-02-06 | Laboratorios del Dr. Esteve S.A. | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments |
US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
GB0800414D0 (en) * | 2008-01-10 | 2008-02-20 | Glaxo Group Ltd | Novel use |
CN102666551B (en) | 2009-12-18 | 2014-12-10 | 詹森药业有限公司 | Bicyclic thiazoles as allosteric modulators of MGLUR5 receptors |
KR20120097400A (en) | 2009-12-18 | 2012-09-03 | 얀센 파마슈티카 엔.브이. | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
GB201321731D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
KR101719321B1 (en) * | 2016-03-31 | 2017-03-23 | 충남대학교산학협력단 | Composition for treating obesity or depressive disorder comprising 3-(4-chlorophenyl)benzo[4,5]imidazo[2,1-b]thiazole-6-carboxylic acid |
CN115867547A (en) * | 2020-08-27 | 2023-03-28 | 上海和誉生物医药科技有限公司 | 1H-pyrazole-4-amide derivative, and preparation method and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE755204A (en) * | 1969-10-01 | 1971-02-01 | Chinoin Gyogyszer Es Vegyeszet | |
SU910636A1 (en) * | 1980-07-11 | 1982-03-07 | Институт Органической Химии Ан Усср | 2,3,5,6-tetrahydro-6-phenyl-7-phenacyclimidazo-[2,1-b thiazolium! bromide exhibiting immuno controlling activity |
DE19948434A1 (en) * | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substance library containing bicyclic imidazo-5-amines and / or bicyclic imidazo-3-amines |
JP2003511456A (en) * | 1999-10-08 | 2003-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Bicyclic imidazo-5-yl-amine derivatives |
HUP0400570A3 (en) * | 2000-12-04 | 2004-09-28 | Hoffmann La Roche | Phenylethenyl or phenylethinyl heteroaril derivatives as glutamate receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them |
US7105533B2 (en) * | 2002-09-13 | 2006-09-12 | Merck & Co., Inc. | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators |
TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
CN100462363C (en) * | 2003-06-12 | 2009-02-18 | 弗·哈夫曼-拉罗切有限公司 | Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists |
AU2005250101B2 (en) * | 2004-06-01 | 2011-08-25 | F. Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mGlu5 receptor antagonists |
DE102004044884A1 (en) * | 2004-09-14 | 2006-05-24 | Grünenthal GmbH | Substituted bicyclic imidazo-3-yl-amine compounds |
-
2006
- 2006-03-10 DE DE102006011574A patent/DE102006011574A1/en not_active Withdrawn
-
2007
- 2007-03-09 ES ES07711873.5T patent/ES2549112T3/en active Active
- 2007-03-09 AU AU2007224678A patent/AU2007224678B2/en not_active Ceased
- 2007-03-09 NZ NZ570710A patent/NZ570710A/en not_active IP Right Cessation
- 2007-03-09 KR KR1020087024772A patent/KR20080108534A/en not_active Application Discontinuation
- 2007-03-09 EP EP07711873.5A patent/EP1996596B1/en active Active
- 2007-03-09 MX MX2008011576A patent/MX2008011576A/en active IP Right Grant
- 2007-03-09 BR BRPI0708740-3A patent/BRPI0708740A2/en not_active Application Discontinuation
- 2007-03-09 CA CA002643410A patent/CA2643410A1/en not_active Abandoned
- 2007-03-09 WO PCT/EP2007/002067 patent/WO2007104485A2/en active Application Filing
- 2007-03-09 JP JP2008557671A patent/JP2009529508A/en active Pending
- 2007-03-09 CN CNA2007800135187A patent/CN101421281A/en active Pending
- 2007-03-09 RU RU2008140022/04A patent/RU2450010C2/en not_active IP Right Cessation
-
2008
- 2008-08-25 ZA ZA200807321A patent/ZA200807321B/en unknown
- 2008-09-09 US US12/207,307 patent/US7893069B2/en not_active Expired - Fee Related
- 2008-10-06 NO NO20084177A patent/NO20084177L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20080108534A (en) | 2008-12-15 |
US20090005399A1 (en) | 2009-01-01 |
MX2008011576A (en) | 2008-09-22 |
ES2549112T3 (en) | 2015-10-23 |
NO20084177L (en) | 2008-11-12 |
CN101421281A (en) | 2009-04-29 |
US7893069B2 (en) | 2011-02-22 |
WO2007104485A2 (en) | 2007-09-20 |
EP1996596B1 (en) | 2015-07-08 |
BRPI0708740A2 (en) | 2011-06-14 |
RU2008140022A (en) | 2010-05-10 |
RU2450010C2 (en) | 2012-05-10 |
DE102006011574A1 (en) | 2007-10-31 |
NZ570710A (en) | 2010-05-28 |
AU2007224678B2 (en) | 2012-08-16 |
ZA200807321B (en) | 2009-07-29 |
EP1996596A2 (en) | 2008-12-03 |
WO2007104485A3 (en) | 2007-11-08 |
AU2007224678A1 (en) | 2007-09-20 |
JP2009529508A (en) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2643410A1 (en) | Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs | |
US8318774B2 (en) | Compounds involving mGluR5 receptor regulation and methods of making the compounds | |
EP1765816B1 (en) | Substituted 1-propiolylpiperazines having an affinity for the mglur5 receptor in order to treat painful conditions | |
JP2009529557A (en) | Substituted 4-amino-quinazoline-derivatives as regulators of metabotropic glutamate receptors and their use in the manufacture of medicaments | |
JP5156011B2 (en) | 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxylic acid amide and use thereof for the manufacture of a medicament | |
CA2633722A1 (en) | Substituted propiolic acid amides and their use for producing drugs | |
CA2610373A1 (en) | Substituted n-benzo [d] isoxazol-3-ylamine derivatives as inhibitors of mglur5, serotonine (5-ht) and noradrenaline receptors, and the use thereof for producing medicaments | |
JP2009522222A (en) | Substituted thiazole and its use in the manufacture of a medicament | |
US8008304B2 (en) | Substituted propiolic acid amides and their use for producing drugs | |
CA2631360A1 (en) | Substituted bis(hetero)aromatic n-ethylpropiolamides and use thereof for production of medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20140311 |